

SCANNED, # 8

12 FEB 2002

FORM PTO-1390 (Modified)
(REV 5-93)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

**TRANSMITTAL LETTER TO THE UNITED STATES
DESIGNATED/ELECTED OFFICE (DO/EO/US)
CONCERNING A FILING UNDER 35 U.S.C. 371**

ATTORNEY'S DOCKET NUMBER

065691-0270

INTERNATIONAL APPLICATION NO.
PCT FR00/02319

INTERNATIONAL FILING DATE
08/11/2000

U.S. APPLICATION NO. (If known, see 37 CFR 1.52)
Unassigned
PRIORITY DATE CLAIMED
08/12/1999

107 049372

TITLE OF INVENTION


Odorant-Binding Human Proteins Fixing Hydrophobic Ligands: Polypeptides and Polynucleotides Coding for said polypeptides and Uses Thereof

APPLICANT(S) FOR DO/EO/US

Gilles PITIOT, Eric LACAZETTE and Francoise GACHON

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.
 2. ☐ This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.
 3. ☐ This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).
 4. ☒ A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.
 5. ☒ A copy of the International Application as filed (35 U.S.C. 371(c)(2))
 - ☐ is transmitted herewith (required only if not transmitted by the International Bureau).
 - ☒ has been transmitted by the International Bureau.
 - ☐ is not required, as the application was filed in the United States Receiving Office (RO/US)
 6. ☐ A translation of the International Application into English (35 U.S.C. 371(c)(2)).
 7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))
 - ☐ are transmitted herewith (required only if not transmitted by the International Bureau).
 - ☐ have been transmitted by the International Bureau.
 - ☐ have not been made; however, the time limit for making such amendments has NOT expired.
 - ☒ have not been made and will not be made.
 8. ☐ A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
 9. ☐ An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).
 10. ☐ A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).
 11. ☐ Applicant claims small entity status under 37 CFR 1.27.
- Items 12. to 17. below concern other document(s) or information included:
12. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
 13. ☐ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
 14. ☐ A FIRST preliminary amendment.
 - ☐ A SECOND or SUBSEQUENT preliminary amendment.
 15. ☐ A substitute specification.
 16. ☐ A change of power of attorney and/or address letter.
 17. ☒ Other items or information: Application Data Sheet, Paper Copy of Sequence Listing, and French Language Patent Application Specification

U.S. APPLICATION NO. (If known, see 37 CFR 1.50) Unassigned		INTERNATIONAL APPLICATION NO. PCT/FR00/02319		ATTORNEY'S DOCKET NUMBER 065691-0270	
18. <input checked="" type="checkbox"/> The following fees are submitted:				CALCULATIONS	
Basic National Fee (37 CFR 1.492(a)(1)-(5): Search Report has been prepared by the EPO or JPO.....				\$890.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482).....				\$710.00	
No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)).....				\$740.00	
Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO.....				\$1,040.00	
International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(2)-(4).....				\$100.00	
ENTER APPROPRIATE BASIC FEE AMOUNT =				\$890.00	
Surcharge of \$130.00 for furnishing the oath or declaration later than 20 Months from the earliest claimed priority date (37 CFR 1.492(e))					
Claims	Number Filed	Included in Basic Fee	Extra Claims	Rate	
Total Claims	51	- 20	= 31	x \$18.00	\$558.00
Independent Claims	5	- 3	= 2	x \$84.00	\$168.00
Multiple dependent claim(s) (if applicable)				\$280.00	\$280.00
TOTAL OF ABOVE CALCULATIONS =					\$1896.00
Reduction by 1/2 for filing by small entity, if applicable.					\$0.00
SUBTOTAL =					\$1896.00
Processing fee of \$130.00 for furnishing English translation later the 20 months from the earliest claimed priority date (37 CFR 1.492(f)).				+	
TOTAL NATIONAL FEE =					\$1896.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +					
TOTAL FEES ENCLOSED =					\$1896.00
				Amount to be:	
				refunded \$	
				charged \$	
a. <input checked="" type="checkbox"/> A check in the amount of \$1896.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. <u>19-0741</u> in the amount of \$0.00 to the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. <u>19-0741</u> . A duplicate copy of this sheet is enclosed.					
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.					
SEND ALL CORRESPONDENCE TO:					
Foley & Lardner Customer Number: 22428					
 22428					
PATENT TRADEMARK OFFICE					
SIGNATURE <u>Stephen B. Maebius</u> NAME STEPHEN B. MAEBIUS REGISTRATION NUMBER 35,264					

PTO/PGT Rec'd

15 AUG 2002

11/11/02 11:11:11

#6

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Atty. Docket No: 065691/0270

In re patent application of

PITTIOT, GILLES et al.

Serial No. 10/049,372

Filed: February 12, 2002

For: HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC LIGANDS:
POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES, AND USES
THEREOF

STATEMENT TO SUPPORT FILING AND SUBMISSION IN
ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

Assistant Commissioner for Patents
Washington, D.C. 20231
Box SEQUENCE

Sir:

In connection with a Sequence Listing submitted concurrently
herewith, the undersigned hereby states that:

1. the submission, filed herewith in accordance with 37
C.F.R. § 1.821(g), does not include new matter;

2. the content of the attached paper copy and the
attached computer readable copy of the Sequence Listing, submitted in
accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same;
and


3. all statements made herein of their own knowledge are
true and that all statements made on information and belief are believed to
be true; and further, that these statements were made with the knowledge
that willful false statements and the like so made are punishable by fine
or imprisonment, or both, under Section 1001 of Title 18 of the United

Serial No. 10/049,372

States Code and that such willful false statements may jeopardize the validity of the application or any patent resulting therefrom.

Respectfully submitted,

August 6, 2002
Date


James A. Coburn

HARBOR CONSULTING
Intellectual Property Services
1500A Lafayette Road
Suite 262
Portsmouth, N.H.
800-318-3021

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No. :

U.S. National Serial No. :

Filed :

PCT International Application No. : PCT/FR00/02319

VERIFICATION OF A TRANSLATION

I, the below named translator, hereby declare that:


My name and post office address are as stated below;

That I am knowledgeable in the French language in which the below identified international application was filed, and that, to the best of my knowledge and belief, the English translation of the amended sheets of the international application No. PCT/FR00/02319 is a true and complete translation of the amended sheets of the above identified international application as filed.

I hereby declare that all the statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the patent application issued thereon.

Date: February 28, 2002

Full name of the translator :



Elaine Patricia PARRISH

For and on behalf of RWS Group plc

Post Office Address :

Europa House, Marsham Way,
Gerrards Cross, Buckinghamshire,
England.

15 AUG 2002

#6

Atty. Dkt. No. 065691/0270

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Gilles PITIOT et al.

Title: HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC LIGANDS:
POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES,
AND USES THEREOF

Appl. No. 10/049,372

Filing Date: 08/15/2002

Examiner: Unassigned

Art Unit: Unassigned

AMENDMENT IN RESPONSE TO NOTICE UNDER 37 CFR §§1.821-825Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Notice to Comply With Requirements for Applications Containing Sequence Disclosures mailed April 16, 2002, please amend the application as follows:

In the Specification:

Please amend the specification as shown:

Please delete the paragraph on page 6, lines 28-30, and replace it with the following paragraph:

The polypeptides according to the invention are characterized in that they preferably comprise the Gly-Thr-Trp-Tyr (SEQ ID NO: 25) domain.

Please delete the paragraph on page 33, lines 6-15, and replace it with the following paragraph:

The upper lines represent the hOBPIIa sequences (SEQ ID NOS 17-19, 21-24) and the lower lines represent the hOBPIIb sequence (SEQ ID NO: 20) for which only the different nucleotides are represented; a dash indicates the absence of corresponding sequences. The shaded capitals are the exon sequences and the lower case letters are the intron sequences. The sizes indicated on the left are indicated in bp. The TATA box is in bold characters and the polyadenylation signal is underlined. The boxes indicate the splice acceptor sites for exons 5, 5b and 5c.

Please delete the paragraph on page 33, lines 35-39 thru page 34 lines 1-4, and replace it with the following paragraph:

FIGURE 5: Alignment of the protein sequences derived from the two human genes hOBPIIa and hOBPIIb (hOBPIIa α = OBP2aaHOMSA (SEQ ID NO: 2), hOBPIIb α = OBP2baHOMSA (SEQ ID NO: 10), hOBPIIb β = OBP2bbHOMSA (residues 15-179 of SEQ ID NO: 12), hOBPIIa γ = OBP2agHOMSA (SEQ ID NO: 6), hOBPIIa β = OBP2abHOMSA (SEQ ID NO: 4)), of human tear lipocalins (LCN1_HOMSA) (SEQ ID NO: 46), of rat OBPII (OBP2_RATNO) (SEQ ID NO: 47), of bovine lactoglobulin BLG (LACB_BOSTA) (SEQ ID NO: 48), of mouse MUP (MUP6_MUSMU) (SEQ ID NO: 49), of human RBP (RBP_HOMSA) (SEQ ID NO: 50), of bovine OBP (OBP_BOSTA) (SEQ ID NO: 51), of rat MUP (MUP_RATNO) (SEQ ID NO: 52) and of porcine OBP (OBP_SUSSC) (SEQ ID NO: 53).

Please delete the paragraph on page 34, lines 6-16 and replace it with the following paragraph:

The residues in the dark grey boxes are identical and those in the light gray boxes are similar. The elements of secondary structure predicted with the DSC program are underlined and the amino acid residues are in italics. The β -sheets and the α -helices are

numbered for hOBPIIa and b. The anticipated signal peptide cleavage site is indicated with an arrow (AAA₁LS) at position 15. Nonaligned sequences of very divergent forms of spliced genes, hOBPa6 (OPB2adHOMSA) (SEQ ID NO: 8) and hOBPby (OBP2bgHOMSA) (SEQ ID NO: 14) have been added at the bottom of the alignment after the analysis.

Please delete the paragraph on page 39, lines 30-38 thru page 40, lines 1-2, and replace it with the following paragraph:

A Lambda gt11 human testes cDNA library (Clontech) (10⁷ p.f.u.) was amplified by 30 polymerase chain reaction (PCR) cycles (94°C 45 sec, 54°C 45 sec, 72°C 1 min 30 sec) with the primer oliEST58 CCTGCAGGTACATGAGCTTCC (SEQ ID NO: 26) and 5' or 3' screening amplimers for inserts located on the arms of the lambda gt11 vectors. A nested PCR was then carried out with oliEST26 CGCTGTATTTGCCAGGCTCC (SEQ ID NO: 27) and oligonucleotides specific for the arm of the vector. The PCR products were subcloned into the pGEM-T (r) vector, which made it possible to obtain the 5' end of the hOBPII gene cDNAs.

Please delete the paragraph on page 40, lines 20-39 thru page 41, lines 1-5, and replace it with the following paragraph:

Tissue samples were collected from 45 to 55 year old Caucasian individuals, in agreement with the French regulations in force. The total RNA is extracted according to a single-step method using the RNA NOW[®] reagent, according to the manufacturer's (Biogentex) instructions. 5 µg of total RNA were reversed-transcribed in a final volume of 20 µl using 0.5 ng of oligonucleotide GACTCGAGTCGACATCGATTTTTTTTTTTTTTTTTT (SEQ ID NO: 28) with the Superscript[®] preamplification system (Gibco BRL). Three µl of these reactions were then used for the following PCRs. The expression of the specific mRNAs was determined by PCR using: the primers TL: CCTCTCCAGCCCCAGCAAG (SEQ ID NO: 29) and AP: GACTCGAGTCGACATCG (SEQ

ID NO: 30) for the LCN1-type genes (LCN1, LCN1b, LCN1c) and, for the hOBPII-type genes, the primers DE: CGCCAGTGACCTGCCGAGGTC (SEQ ID NO: 31), and FI: CTTTATTTGGAGTCAGGTGGGTG (SEQ ID NO: 32). As a quality control for the RNA's the primers G3PDH1: CTCTGCCCCCTCTGCTGATG (SEQ ID NO: 33) and G3PDH2: CCTGCTTACCACCTTCTTG (SEQ ID NO: 34) for the G3PDH gene were used; the G3PDH gene is considered to be constitutively expressed in all cell types. 32 PCR cycles (94°C 45 sec, 54°C 45 sec, 72°C 2 min 30 sec) were performed and the amplification products were separated on 1% agarose gel. The DNA was transferred onto a Hybond N+® membrane.

Please delete the paragraph on page 41, lines 7-16, and replace it with the following paragraph:

For the detection of the expression of the various genes, several oligonucleotides specific for the respective genes were synthesized:

- oLCN1: GACTCAGACTCCGGAGATGA (SEQ ID NO: 35),
- oLCN1b: AACTCAGACACCAGAGATGA (SEQ ID NO: 36),
- oLCN1c: GACTCAGATCCCGGAGATGA (SEQ ID NO: 37),
- oI5: CCAGGAGGGGACCACTACA (SEQ ID NO: 38) specific for the hOBPIIb gene,
- oI4: CCGGGACGGGACGACTACG (SEQ ID NO: 39) specific for the hOBPIIa gene,
- G3PDH3: CTCATGACCACAGTCCATGC (SEQ ID NO: 40).

Please delete the paragraph on page 41, lines 30-39 thru page 42, lines 1-7, and replace it with the following paragraph:

The genotyping is carried out with PCR reactions using 100 ng of genomic DNA originating from 8 CEPH reference families, and using the oligonucleotides oli9 TGTTCGGGAACGCAGCTT (SEQ ID NO: 41) and

Atty. Dkt. No. 065691/0270

oli10a TGCCGCTGTCCCCACGTCGG (SEQ ID NO: 42). The thermocycler parameters consist of an initial cycle at 94°C for 10 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec and 70°C for 45 sec, and then a final elongation step of 10 min at 70°C. The PCR products are then analyzed on a 3% agarose gel. The information regarding the markers for chromosome 9 may be obtained at the following internet address (<http://galton.ucl.ac.uk>); the analyses were carried out using the linkage study tools previously described in Lacazette *et al.* (1997). The haplotypes are reconstructed manually according to the recombination events previously described in family 1362 (Attwood *et al.*, 1994).

Please delete the paragraph on page 52, lines 34-39 thru page 54, lines 1-11, and replace it with the following paragraph:

In the case of the hOBPIIb gene, in addition to the hOBPIIb mRNA previously described, a 106 bp super-numerary exon (exon 3b) between the previous exons 3 and 4 was identified (figure 3). This longer mRNA (782 nucleotides) encodes a 165 amino acid protein hOBPIIb β . From a protein structure point of view, hOBPIIb β is identical to hOBPIIb α up to the 5th putative β -sheet and then differs due to a reading frame shift. The predictions from the computer programs indicate that the motif ALWEALAIIDTRLK (SEQ ID NO: 43) is an α -helix which is just behind the fifth β -sheet. Two additional β -sheets may be present in the long C-terminal portion.

Please delete the paragraph on page 58, lines 36-39 thru page 59, lines 1-23, and replace it with the following paragraph:

A PCR on the plasmid DNA of an hOBPIIb α clone using the primers BIla/b (5' GTC GGA TCC CTG TCC TTC ACC CTG GAG G 3') (SEQ ID NO: 44), a sense oligonucleotide beginning 45 bases after the protein-initiating ATG, and XIb (5; GTC CTC GAG GTG TTC GGG AAC GCA GCT TC 3') (SEQ ID NO: 45), an antisense oligonucleotide preceding the stop

codon of the hOBPIIb α protein, made it possible to amplify all of the DNA encoding the secreted hOBPIIb α protein. The BanH I and Xho I enzymatic restriction sites located at the ends of the two oligonucleotides (bases underlined) were used for directional cloning into a plasmid expression vector pGEX-6P1, followed by transformation by electroporation (1800 V, 200 Ω , 25 μ F) into bacterial strain BL21. Synthesis of the recombinant protein is obtained by adding IPTG, at 5 mM final for 3 h, to 250 ml of culture of the strain in LB medium containing 100 μ g/ml of ampicillin pre-incubated at 37°C for 2 h. The centrifuged cultures are taken up in 25 ml of TENG buffer. The lysate is sonicated and recentrifuged. The fusion protein is then purified using 4 ml of beads bearing covalently attached insoluble glutathione (Sigma) per 25 ml of supernatant. After incubation for 4 h, they are washed with 3 volumes of 1M NaCl and then with 10 volumes of 1 X PBS. The elution is obtained by bringing the beads into contact with a glutathione solution (10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0) for 10 min.

REMARKS

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date August 14, 2002

By 

FOLEY & LARDNER
Customer Number: 22428

Stephen Maebius
Attorney for Applicants
Registration No. 35,264



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5407
Facsimile: (202) 672-5399

Should additional fees be necessary in connection with the filing of this paper, or if a petition for extension of time is required for timely acceptance of same, the Commissioner is hereby authorized to charge Deposit Account No.19-0741 for any such fees; and applicant(s) hereby petition for any needed extension of time.

MARKED UP VERSION ATTACHED TO AMENDMENT IN

SERIAL NO. 10/049,372

Marked up version of the paragraph on page 6, lines 28-30 is below:

The polypeptides according to the invention are characterized in that they preferably comprise the Gly-Thr-Trp-Tyr (SEQ ID NO: 25) domain.

Marked up version of the paragraph on page 33, lines 6-15, is below:

The upper lines represent the hOBPIIa sequences (SEQ ID NOS 17-19, 21-24) and the lower lines represent the hOBPIIb sequence (SEQ ID NO: 20) for which only the different nucleotides are represented; a dash indicates the absence of corresponding sequences. The shaded capitals are the exon sequences and the lower case letters are the intron sequences. The sizes indicated on the left are indicated in bp. The TATA box is in bold characters and the polyadenylation signal is underlined. The boxes indicate the splice acceptor sites for exons 5, 5b and 5c.

Marked up version of the paragraph on page 33, lines 35-39 thru page 34 lines 1-4, is below:

FIGURE 5: Alignment of the protein sequences derived from the two human genes hOBPIIa and hOBPIIb (hOBPIIa α = OBP2aaHOMSA (SEQ ID NO: 2), hOBPIIb α = OBP2baHOMSA (SEQ ID NO: 10), hOBPIIb β = OBP2bbHOMSA (residues 15-179 of SEQ ID NO: 12), hOBPIIa γ = OBP2agHOMSA (SEQ ID NO: 6), hOBPIIa β = OBP2abHOMSA (SEQ ID NO: 4)), of human tear lipocalins (LCN1_HOMSA) (SEQ ID NO: 46), of rat OBPII (OBP2_RATNO) (SEQ ID NO: 47), of bovine lactoglobulin BLG (LACB_BOSTA) (SEQ ID NO: 48), of mouse MUP (MUP6_MUSMU) (SEQ ID NO: 49), of human RBP (RBP_HOMSA) (SEQ ID NO: 50), of bovine OBP (OBP_BOSTA) (SEQ ID NO: 51), of rat MUP (MUP_RATNO) (SEQ ID NO: 52) and of porcine OBP (OBP_SUSSC) (SEQ ID NO: 53).

Marked up version of the paragraph on page 34, lines 6-16, is below:

The residues in the dark grey boxes are identical and those in the light gray boxes are similar. The elements of secondary structure predicted with the DSC program are underlined and the amino acid residues are in italics. The β -sheets and the α -helices are numbered for hOBPIIa and b. The anticipated signal peptide cleavage site is indicated with an arrow (AAA;LS) at position 15. Nonaligned sequences of very divergent forms of spliced genes, hOPBa6 (OPB2adHOMSA) (SEQ ID NO: 8) and hOBPby (OBP2bgHOMSA) (SEQ ID NO: 14) have been added at the bottom of the alignment after the analysis.

Marked up version of the paragraph on page 39, lines 30-38 thru page 40, lines 1-2, is below:

A Lambda gt11 human testes cDNA library (Clontech) (10^7 p.f.u.) was amplified by 30 polymerase chain reaction (PCR) cycles (94°C 45 sec, 54°C 45 sec, 72°C 1 min 30 sec) with the primer oliEST58 CCTGCAGGTACATGAGCTTCC (SEQ ID NO: 26) and 5' or 3' screening amplimers for inserts located on the arms of the lambda gt11 vectors. A nested PCR was then carried out with oliEST26 CGCTGTATTGGCCAGGCTCC (SEQ ID NO: 27) and oligonucleotides specific for the arm of the vector. The PCR products were subcloned into the pGEM-T (r) vector, which made it possible to obtain the 5' end of the hOBPII gene cDNAs.

Marked up version of the paragraph on page 40, lines 20-39 thru page 41, lines 1-5, is below:

Tissue samples were collected from 45 to 55 year old Caucasian individuals, in agreement with the French regulations in force. The total RNA is extracted according to a single-step method using the

RNA NOW[®] reagent, according to the manufacturer's (Biogentex) instructions. 5 µg of total RNA were reversed-transcribed in a final volume of 20 µl using 0.5 ng of oligonucleotide GACTCGAGTCGACATCGATTTTTTTTTTTTTTTT (SEQ ID NO: 28) with the Superscript[®] preamplification system (Gibco BRL). Three µl of these reactions were then used for the following PCRs. The expression of the specific mRNAs was determined by PCR using: the primers TL: CCTCTCCCAGCCCCAGCAAG (SEQ ID NO: 29) and AP: GACTCGAGTCGACATCG (SEQ ID NO: 30) for the LCN1-type genes (LCN1, LCN1b, LCN1c) and, for the hOBPII-type genes, the primers DE: CGCCAGTGACCTGCCGAGGTC (SEQ ID NO: 31), and FI: CTTTATTTGGAGTCAGGTGGGTG (SEQ ID NO: 32). As a quality control for the RNA's the primers G3PDH1: CTCTGCCCCCTCTGCTGATG (SEQ ID NO: 33) and G3PDH2: CCTGCTTCACCACCTTCTTG (SEQ ID NO: 34) for the G3PDH gene were used; the G3PDH gene is considered to be constitutively expressed in all cell types. 32 PCR cycles (94°C 45 sec, 54°C 45 sec, 72°C 2 min 30 sec) were performed and the amplification products were separated on 1% agarose gel. The DNA was transferred onto a Hybond N+[®] membrane.

Marked up version of the paragraph on page 41, lines 6-16, is below:

For the detection of the expression of the various genes, several oligonucleotides specific for the respective genes were synthesized:

- olLCN1 : GACTCAGACTCCGGAGATGA (SEQ ID NO: 35),
- olLCN1b: AACTCAGACACCAGAGATGA (SEQ ID NO: 36),
- olLCN1c: GACTCAGATCCCGGAGATGA (SEQ ID NO: 37),
- ol5: CCAGGAGGGACCACTACA (SEQ ID NO: 38) specific for the hOBPIIb gene,
- ol4: CCGGGACGGACGACTACG (SEQ ID NO: 39) specific for the hOBPIIa gene,

- G3PDH3: CTCATGACCACAGTCCATGC (SEQ ID NO: 40).

Marked up version of the paragraph on page 41, lines 30-39 thru page 42, lines 1-7, is below:

The genotyping is carried out with PCR reactions using 100 ng of genomic DNA originating from 8 CEPH reference families, and using the oligonucleotides oli9 TGTCGGGAACGCAGCTT (SEQ ID NO: 41) and oli10a TGCCGCTGTCCCCACGTCGG (SEQ ID NO: 42). The thermocycler parameters consist of an initial cycle at 94°C for 10 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec and 70°C for 45 sec, and then a final elongation step of 10 min at 70°C. The PCR products are then analyzed on a 3% agarose gel. The information regarding the markers for chromosome 9 may be obtained at the following internet address (<http://galton.ucl.ac.uk>); the analyses were carried out using the linkage study tools previously described in Lacazette *et al.* (1997). The haplotypes are reconstructed manually according to the recombination events previously described in family 1362 (Attwood *et al.*, 1994).

Marked up version of the paragraph on page 52, lines 34-39 thru page 54, lines 1-11, is below:

In the case of the hOBPIIb gene, in addition to the hOBPIIb α mRNA previously described, a 106 bp super-numerary exon (exon 3b) between the previous exons 3 and 4 was identified (figure 3). This longer mRNA (782 nucleotides) encodes a 165 amino acid protein hOBPIIb β . From a protein structure point of view, hOBPIIb β is identical to hOBPIIb α up to the 5th putative β -sheet and then differs due to a reading frame shift. The predictions from the computer programs indicate that the motif ALWEALAI DTRLK (SEQ ID NO: 43) is an α -helix which is just behind the fifth β -sheet. Two additional β -sheets may be present in the long C-terminal portion.

Marked up version of the paragraph on page 58, lines 36-39 thru page 59, lines 1-23, is below:

A PCR on the plasmid DNA of an hOBPIIb α clone using the primers BIIa/b (5' GTC GGA TCC CTG TCC TTC ACC CTG GAG G 3') (SEQ ID NO: 44), a sense oligonucleotide beginning 45 bases after the protein-initiating ATG, and XIIb (5; GTC CTC GAG GTG TTC GGG AAC GCA GCT TC 3') (SEQ ID NO: 45), an antisense oligonucleotide preceding the stop codon of the hOBPIIb α protein, made it possible to amplify all of the DNA encoding the secreted hOBPIIb α protein. The BanH I and Xho I enzymatic restriction sites located at the ends of the two oligonucleotides (bases underlined) were used for directional cloning into a plasmid expression vector pGEX-6Pl, followed by transformation by electroporation (1800 V, 200 Ω , 25 μ F) into bacterial strain BL21. Synthesis of the recombinant protein is obtained by adding IPTG, at 5 mM final for 3 h, to 250 ml of culture of the strain in LB medium containing 100 μ g/ml of ampicillin pre-incubated at 37°C for 2 h. The centrifuged cultures are taken up in 25 ml of TENG buffer. The lysate is sonicated and recentrifuged. The fusion protein is then purified using 4 ml of beads bearing covalently attached insoluble glutathione (Sigma) per 25 ml of supernatant. After incubation for 4 h, they are washed with 3 volumes of 1M NaCl and then with 10 volumes of 1 X PBS. The elution is obtained by bringing the beads into contact with a glutathione solution (10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0) for 10 min.

CLAIMS

1. An isolated polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequences SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14.
2. An isolated polypeptide, characterized in that it comprises a polypeptide chosen from:
 - a) a polypeptide of sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14;
 - b) a polypeptide which is a variant of a polypeptide of amino acid sequences defined in a);
 - c) a polypeptide homologous to the polypeptide defined in a) or b) and comprising at least 90% identity with said polypeptide of a);
 - d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);
 - e) a biologically active fragment of a polypeptide defined in a), b) or c).
3. An isolated polypeptide selected from a polypeptide corresponding to the sequence SEQ ID No. 2 and named OBPII_{αα}, to the sequence SEQ ID No. 4 and named OBPII_{αβ}, to the sequence SEQ ID No. 6 and named OBPII_{αγ}, and to the sequence SEQ ID No. 12 and named OBPII_{ββ}.
4. The polypeptide as claimed in any one of claims 1 to 3, characterized in that it comprises at least the Gly-Thr-Trp-Tyr domain.

- 68 -

5. An isolated polynucleotide, characterized in that it encodes a polypeptide as claimed in any one of claims 1 to 4.
6. The polynucleotide as claimed in claim 5, of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13.
7. An isolated polynucleotide, characterized in that it comprises a polynucleotide chosen from:
 - a) a polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13, or the sequence of which is that of the RNA corresponding to the sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13;
 - b) a polynucleotide, the sequence of which is complementary to the sequence of a polynucleotide defined in a),
 - c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or b),
 - d) a fragment of at least 15 consecutive nucleotides, in preference 21 consecutive nucleotides, and preferably 30 consecutive nucleotides, of a polynucleotide defined in a), b), c) or d).
8. The polynucleotide as claimed in claim 7, characterized in that it is labeled directly or indirectly with a radioactive compound or a nonradioactive compound.
9. The use of a polynucleotide as claimed in claim 8, as a probe for detecting nucleic acid sequences.

10. The use of a polynucleotide as claimed in any one of claims 5 to 8, as a primer for amplifying or polymerizing nucleic acid sequences.
- 5 11. The use of a polynucleotide as claimed in claim 8, as a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product.
- 10 12. A recombinant vector for cloning a polynucleotide as claimed in one of claims 5 to 8 and/or for expressing a polypeptide as claimed in one of claims 1 to 4, characterized in that it contains a polynucleotide as claimed in any one of claims 5 to 8.
- 15 13. The vector as claimed in claim 12, characterized in that it comprises the elements which allow the expression, optionally the secretion, of said polypeptide in a host cell.
- 20 14. The vector as claimed in any one of claims 12 to 13, characterized in that the elements which allow the expression of said polypeptide are chosen from:
 - 25 a) the isolated polynucleotide of sequence SEQ ID No. 15 and SEQ ID No. 16;
 - b) a polynucleotide, the sequence of which is complementary to the sequence of the polynucleotide defined in a);
 - 30 c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or in b);
 - 35 d) a polynucleotide which hybridizes, under conditions of high stringency, with a sequence of the polynucleotide defined in a), b) or c).

15. The vector as claimed in claims 13 and 14, for expression in eukaryotic cells, selected from viral DNA and naked DNA.

5

16. A host cell, characterized in that it is transformed with a vector as claimed in one of claims 12 to 15.

10 17. A process for preparing a recombinant polypeptide, characterized in that a host cell as claimed in claim 16 is cultured under conditions which allow the expression and, optionally, the secretion of said recombinant polypeptide, and in that said recombinant
15 polypeptide is recovered.

18. A recombinant polypeptide which can be obtained using a process as claimed in claim 17.

20 19. The use of a polypeptide chosen from a polypeptide as claimed in any one of claims 1 to 4 and 18, or a fragment thereof, as a protein which binds to a hydrophobic ligand, preferably an odorous molecule.

25 20. The use of a polypeptide as claimed in any one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}, a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at
30 least 90% identity with said polypeptide hOBPII_{ba} or a fragment thereof, as a competitive inhibitor, as an agonist or as an antagonist of the cellular receptors for lipocalins.

35 21. A monoclonal or polyclonal antibody, and fragments thereof, characterized in that it is specifically against an isolated polypeptide as claimed in one of claims 1 to 4 and 18.

22. The use of an antibody as claimed in claim 21, for demonstrating the presence of a polypeptide as claimed in one of claims 1 to 4 and 18 in a biological sample.
23. A process for detecting an antibody against hOBPII in human serum from an allergic and/or asthmatic patient, using an hOBPII polypeptide.
24. A process for controlling the volatilization of an odorant, characterized in that it comprises a step of binding of said odorant with a polypeptide as claimed in any one of claims 1 to 4 and 18, or with the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.
25. The process as claimed in claim 24, characterized in that the polypeptide is bound to a solid support.
26. The process as claimed in claim 24, characterized in that the polypeptide is in a liquid composition.
27. The process as claimed in claim 26, characterized in that said composition is a fragranced composition for the skin.
28. A process for screening a molecule, preferably odorants or flavors, which comprises passing the molecule over a substrate which comprises a polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, bound to said substrate, said polypeptide

- 72 -

binding said odorant or flavor, and recovering said odorant or flavor from the polypeptide if necessary.

29. The process as claimed in claim 28, characterized in that the molecules are human pheromones.

30. A process for solubilizing lipophilic molecules, characterized in that it comprises binding said molecule to a polypeptide as claimed in any one of claims 1 to 4 and 18, or to the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.

31. The application of the polypeptides as claimed in one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, of a polypeptide which is a variant of said polypeptide hOBPII_{ba} or of a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, in combination with dietary fatty acids, as a food supplement.

32. The application as claimed in claim 31, for preparing a medicinal product intended for the treatment of hyperlipidemias and obesity.

33. The application as claimed in claim 31, for supplementing nonmaternal milks.

34. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as an agent for targeting a pharmaceutical compound.

35. The polypeptide as claimed in claim 34, characterized in that said polypeptide is expressed in the form of a protein from fusion with a protein which
5 allows specific cellular addressing.

36. The polypeptide as claimed in claim 35, characterized in that said protein which allows specific cellular addressing is chosen from the group composed
10 of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

37. The polypeptide as claimed in claim 34, characterized in that said polypeptide is combined with a
15 molecule which allows specific cellular addressing.

38. The polypeptide as claimed in claim 37, characterized in that said molecule which allows specific cellular addressing is chosen from the group composed
20 of steroids, of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

39. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{bx} of sequence SEQ ID No. 10, a polypeptide which is a variant of said
25 polypeptide hOBPII_{bx} or a polypeptide homologous to said polypeptide hOBPII_{bx} comprising at least 90% identity
30 with said polypeptide hOBPII_{bx}, as a pharmaceutical compound transporter.

40. A pharmaceutical composition comprising a pharmaceutical compound bound at least to a polypeptide as
35 claimed in one of claims 34 to 39, and a pharmaceutically acceptable vehicle.

41. The pharmaceutical composition as claimed in

claim 40, characterized in that the pharmaceutical compound is chosen from the group of anticancer agents.

42. The pharmaceutical composition as claimed in claim 41, characterized in that said anticancer agent is a radioactive isotope chosen from the group: iodine¹³¹, yttrium⁹⁰, gold¹⁹⁹, palladium¹⁰⁰, copper⁶⁷, bismuth²¹⁷ and antimony²¹¹.
43. The pharmaceutical composition as claimed in any one of claims 40 to 42, characterized in that said polypeptide as claimed in any one of claims 34 to 39 constitutes a delayed form of delivery of said pharmaceutical compound in the body.
44. A pharmaceutical composition comprising an expression vector as claimed in claim 12 or 13, and a pharmaceutically acceptable vehicle.
45. The pharmaceutical composition as claimed in any one of claims 40 to 44, for treating cancer preferably chosen from breast cancer, uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell carcinoma.
46. The use of a polypeptide chosen from the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} and a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the treatment of uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell cancer.
47. The use of the polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, or a polypeptide which is a

variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the transport of a compound across the placental barrier.

48. The use as claimed in claim 47, characterized in that said transport is carried out from the gestating mother to the fetus, and in that said compound is chosen from hormones, essential fatty acids, lipophilic medicinal products and vitamins.

49. The use as claimed in claim 47, characterized in that said transport is carried out from the fetus to the mother and is intended for the detoxification of the fetus.

50. The polypeptide as claimed in claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a pregnancy marker.

51. The polypeptide as claimed in claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a marker for a fetoplacental pathological condition

SEQUENCE LISTING

<110> PITIOT, GILLES
LACAZETTE, ERIC
GACHON, FRANCOISE

<120> HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC
LIGANDS; POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID
POLYPEPTIDES, AND USES THEREOF

<130> 065691/0270

<140> 10/049,372

<141> 2002-02-12

<150> PCT/FR00/02319

<151> 2000-08-11

<150> FR 99 10439

<151> 1999-08-12

<160> 53

<170> PatentIn Ver. 2.1

<210> 1

<211> 676

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (43)..(552)

<220>

<223> cDNA396 (676) /gl (hOBPIIa-alpha)

<400> 1

```
cgcccaagtga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
Met Lys Thr Leu
1
ttc ctg ggt gtc acg ctc gcc ctg gcc gct gcc ctg tcc ttc acc ctg 102
Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
5 10 15 20
gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
25 30 35
gat aag gac ttt cag gag gac agg agg ccc agg aag gtg tcc cca gtg 198
Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
40 45 50
aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
55 60 65
```

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr
70 75 80

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctc ata tac 342
Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
85 90 95 100

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
105 110 115

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg ggt agg aat 438
Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Gly Arg Asn
120 125 130

cct aat acc aac ctg gag gcc ctg gaa gaa ttt aag aaa ttg gtg cag 486
Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln
135 140 145

cac aag gga ctc tgc gag gag gac att ttc atg ccc ctg cag acg gga 534
His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly
150 155 160

agc tgc gtt ctc gaa cac taggcagccc ccgggtctgc acctccagag 582
Ser Cys Val Leu Glu His
165 170

ccaccctac caccagacac agagcccgga ccacctggac ctaccctcca gccatgaccc 642

tccctgctc caccacact gactccaaat aaag 676

<210> 2
<211> 170
<212> PRT
<213> Homo sapiens

<400> 2
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
1 5 10 15

Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
20 25 30

Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
35 40 45

Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala
50 55 60

Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
65 70 75 80

Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
85 90 95

Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
100 105 110

Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
115 120 125

Val Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys
130 135 140

Lys Leu Val Gln His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro
145 150 155 160

Leu Gln Thr Gly Ser Cys Val Leu Glu His
165 170

<210> 3

<211> 725

<212> DNA

<213> Homo sapiens

 $\langle 220 \rangle$

<221> CDS

<222> (43) . . (480)

<220>

<223> cDNA396 (725) /SM12 (hOBPIIa-beta)

<400> 3

cgcccagtga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
Met Lys Thr Leu
1

ttc	ctg	ggg	gtc	acg	ctc	ggc	ctg	gcc	gct	gcc	ctg	tcc	ttc	acc	ctg	102
Phe	Leu	Gly	Val	Thr	Leu	Gly	Leu	Ala	Ala	Ala	Leu	Ser	Phe	Thr	Leu	
5					10					15					20	

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
25 30 35

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
40 45 50

aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
55 60 65

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr
70 75 80

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctc ata tac 342
Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
85 90 95 100

4

```

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
      105      110      115

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg ggg ccg tgc 438
Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Gly Pro Cys
      120      125      130

cgc tgt ccc cac gtc ggc tca cct ggc cac ctc acc tgc agg 480
Arg Cys Pro His Val Gly Ser Pro Gly His Leu Thr Cys Arg
      135      140      145

taggaatcct aataccaacc tggaggccct ggaagaattt aagaaattgg tgcagcacia 540

gggactctcg gaggaggaca ttttcatgcc cctgcagacg ggaagctcgg ttctcgaaca 600

ctaggcagcc cccgggtctg cactccaga gccacccta ccaccagaca cagagcccg 660

accacctgga cctaccctcc agccatgacc ctccctgct cccaccacc tgactccaaa 720

taaag 725

<210> 4
<211> 146
<212> PRT
<213> Homo sapiens

<400> 4
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
  1          5          10          15

Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
      20      25      30

Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
      35      40      45

Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala
      50      55      60

Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
      65      70      75      80

Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
      85      90      95

Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
      100      105      110

Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
      115      120      125

Val Gly Pro Cys Arg Cys Pro His Val Gly Ser Pro Gly His Leu Thr
      130      135      140

Cys Arg
145

```


Pro Trp Lys Asn Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg
 165 170 175
 Arg Thr Phe Ser Cys Pro Cys Arg Arg Glu Ala Ala Phe Ser Asn Thr
 180 185 190
 Arg Gln Pro Pro Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr
 195 200 205
 Gln Ser Pro Asp His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu
 210 215 220
 Leu Pro Pro Thr
 225

<210> 7
 <211> 607
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43)..(483)
 <220>
 <223> cDNA396 (607) - short form (hOBPIIa-delta)

<400> 7
 cgccacagtga cctgcccagg tcggcagcac agagctctgg ag atg aag acc ctg 54
 Met Lys Thr Leu
 1
 ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
 Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
 5 10 15 20
 gag gag gag gat gag gga gaa tcg gtg cat cca gaa gaa aat cct gat 150
 Glu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu Glu Asn Pro Asp
 25 30 35
 gcg gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa 198
 Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
 40 45 50
 gct cat ata cct gca gga gct gcc cgg gac gga cga cta cgt ctt tta 246
 Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg Leu Arg Leu Leu
 55 60 65
 ctg caa aga cca gcg ccg tgg ggg cct gcg cta cat ggg aaa gct tgt 294
 Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His Gly Lys Ala Cys
 70 75 80
 ggc atc tgc tcc ctg cag gcc cgt gcc gct gtc ccc acc ttg gct cac 342
 Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro Thr Leu Ala His
 85 90 95 100

8

ctg gcc acc tca cct gca ggt agg aat cct aat acc aac ctg gag gcc 390
 Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala 115
 105
 ctg gaa gaa ttt aag aaa ttg gtg cag cgc aag gga ctc tgc gag gag 438
 Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly Leu Ser Glu Glu 130
 120 125
 gac att ttc atg ccc ctg cag acg gga agc tgc gtt ctc gaa cac 483
 Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val Leu Glu His 145
 135 140
 taggcagccc cgggtctgc acctccagag ccaccctac caccagacac agagcccgga 543
 ccacctggac ctacctcca gccatgaccc ttcctgctc ccaccacct gactccaaat 603
 aaag 607

<210> 8
 <211> 147
 <212> PRT
 <213> Homo sapiens

<400> 8
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15
 Ser Phe Thr Leu Glu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu
 20 25 30
 Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
 35 40 45
 Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg
 50 55 60
 Leu Arg Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His
 65 70 75 80
 Gly Lys Ala Cys Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro
 85 90 95
 Thr Leu Ala His Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr
 100 105 110
 Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly
 115 120 125
 Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val
 130 135 140
 Leu Glu His
 145

10

agc tgc gtt ccc gaa cac taggcagccc cggggtctgc acctccagag 582
 Ser Cys Val Pro Glu His
 165 170

ccacacctac caccagacac agagcccggga ccacctggac ctacctcca gccatgaccc 642
 ttccctgctc ccaccacact gactccaaat aaag 676

<210> 10
 <211> 170
 <212> PRT
 <213> Homo sapiens

<400> 10
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu
 1 5 10 15
 Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30
 Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
 35 40 45
 Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala
 50 55 60
 Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
 65 70 75 80
 Met Arg Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Tyr Gly Gly Arg
 85 90 95
 Lys Leu Met Tyr Leu Gln Glu Leu Pro Arg Arg Asp His Tyr Ile Phe
 100 105 110
 Tyr Cys Lys Asp Gln His His Gly Gly Leu Leu His Met Gly Lys Leu
 115 120 125
 Val Gly Arg Asn Ser Asp Thr Asn Arg Glu Ala Leu Glu Glu Phe Lys
 130 135 140
 Lys Leu Val Gln Arg Lys Gly Leu Ser Glu Glu Asp Ile Phe Thr Pro
 145 150 155 160
 Leu Gln Thr Gly Ser Cys Val Pro Glu His
 165 170

<210> 11
 <211> 782
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (1)..(537)

<220>

<223> cDNA2098 (782) - long form (hOBPIIb-beta)

<400> 11

cgc cca gtg acc tgc cga ggt cgg cag cac aga gct ctg gag atg aag 48
Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys
1 5 10 15

acc ctg ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc 96
Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe
20 25 30

acc ctg gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg 144
Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met
35 40 45

gtg gtc gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc 192
Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser
50 55 60

cca gtg aag gtg aca gcc ctg ggc ggt ggg aag ttg gaa gcc acg ttc 240
Pro Val Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala Thr Phe
65 70 75 80

acc ttc atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg 288
Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg
85 90 95

aag acg gag gag cct ggc aaa tac agc gcc tgc ttg tcc gca gtc gag 336
Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu
100 105 110

atg gac cag atc acg cct gcc ctc tgg gag gcc cta gcc att gac aca 384
Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr
115 120 125

ttg agg aag ctg agg att ggg aca agg agg cca agg att aga tgg ggg 432
Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Arg Ile Arg Trp Gly
130 135 140

cag gaa gct cat gta cct gca gga gct gcc cag gag gga cca cta cat 480
Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His
145 150 155 160

ctt tta ctg caa aga cca gca cca tgg ggg cct gct cca cat ggg aaa 528
Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys
165 170 175

gct tgt ggg taggaattct gataccaacc gggaggccct ggaagaattt 577
Ala Cys Gly

aagaaattgg tgcagcgcaa gggactctcg gaggaggaca ttttcacgcc cctgcagacg 637

qgaagctgcg ttcccgaaca ctaqqcagcc cccqqgtctg cacctccaga qcccacccta 697

ccaccagaca cagagcccgg accacctgga cctaccctcc agccatgacc cttccctgct 757

cccacccacc tgactccaaa taaag 782

<210> 12
 <211> 179
 <212> PRT
 <213> Homo sapiens

<400> 12
 Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys
 1 5 10 15
 Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe
 20 25 30
 Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met
 35 40 45
 Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser
 50 55 60
 Pro Val Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala Thr Phe
 65 70 75 80
 Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg
 85 90 95
 Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu
 100 105 110
 Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr
 115 120 125
 Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Arg Ile Arg Trp Gly
 130 135 140
 Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His
 145 150 155 160
 Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys
 165 170 175
 Ala Cys Gly

<210> 13
 <211> 542
 <212> DNA
 <213> Homo sapiens

<220>
 <221> CDS
 <222> (43) .. (297)
 <220>
 <223> cDNA2098 (542) - short form (OBPIIb-gamma)

<400> 13
cgccccagtga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
Met Lys Thr Leu
1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
5 10 15 20

gag gag gag gat gag gga gga tgc gtg cat cca gaa gaa aat cct gat 150
Glu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu Glu Asn Pro Asp
25 30 35

gcg gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa 198
Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
40 45 50

gct cat ata cct gca gga gct gcc cag gag gga cca cta cat ctt tta 246
Ala His Ile Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His Leu Leu
55 60 65

ctg caa aga cca gca cca tgg ggg cct gct cca cat ggg aaa gct tgt 294
Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys Ala Cys
70 75 80

ggg taggaattct gataccaacc gggaggccct ggaagaattt aagaattgg 347
Gly
85

tcgacgcgcaa gggactctcg gaggaggaca ttttcacgcc cctgcagacg ggaagctgcg 407

ttcccgaaaca ctaggcagcc cccgggtctg cacctccaga gccaccacct caccagaca 467

cagagcccg accacctgga cctaccctcc agccatgacc cttccctgct cccaccacc 527

tgactccaaa taaag 542

<210> 14
<211> 85
<212> PRT
<213> Homo sapiens

<400> 14
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
1 5 10 15

Ser Phe Thr Leu Glu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu
20 25 30

Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
35 40 45

Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Gln Glu Gly Pro
50 55 60

Leu His Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His
65 70 75 80

Gly Lys Ala Cys Gly
85

<210> 15

<211> 10664

<212> DNA

<213> Homo sapiens

<220>

<223> hOBPIIa Gene

<220>

<221> modified_base

<222> (8507)

<223> a, t, c, g, other or unknown

<220>

<221> modified_base

<222> (10635)

<223> a, t, c, g, other or unknown

<220>

<221> modified_base

<222> (10643)

<223> a, t, c, g, other or unknown

<400> 15

```

ctctgctctt atattgggcc tccaaatctg tgcctaatgc agcaactgga gtgacccctt 60
aaatacgtaa gtcacagcctt gcctttgtca gagctatcca ggggtcttca ctcagagcag 120
aagctgaagt cctcggtggg gtccttaatc cctacatggc cgttccaccc actccccagc 180
ctcatgtgtg gccggtctcc ctggatcatt tgcctgtggc gctctgccgt gtgttccccg 240
aaactgccag cgttctccca cctctgggct ggcactggat gctcctgcc a cctggactcc 300
tcttccagct gacgagctca tggcttgctt cctcatgtc ttaaatctcg gtgttgaaatg 360
ccaacttggc gaggctgttc ctcatcaatt catgtaaagg acaaatcaac cctgtctggg 420
ccaactcctgt ccaacttgct cactttgctt tttccatagc actgatcacc atttaaaata 480
atgtatgaac cagtgaacca tcagtgacca gagacagtag attgaacagg attgctgtgc 540
acagtgaaca atcagctcta gaggtttaa gaagaaccaca aagaatggct caggatttga 600
cgagggcagt taaggaagaa ataaacaggg gtggggatcc ttccacaag tgtgggttca 660
gaccgcatgg gagaagggtg ggttctccca agggaaagctg gagaagtttg ctgggttgtc 720
ccagccacag ctggccacag gtcagggcag agggcagcag gcagggaat gtaggctggg 780
tctggcaagc aggaagcctc tcttcccccg caaggcaggt gggctggggc tgggaagcct 840
acaagagtca ctgggaaccc acaggtgcag atgccactga atctcaatag gaagccatct 900
gggggggttc cctgaattca atgtggtgtg tgccgcagca cgtccccaac tbtgtccact 960
gccatttata caggaagaga aagaaaaagg aagaatatga agcatctgga accagtcac 1020
ctggacccat gctaggaggt gcttccccct acgctccac caacaaagct tagcatttga 1080
ccaggtgcac aagagaagcg cctgctggct ccagctccat tgcctcgga accagtcac 1140
agggctgcgt tggagctgga ggcaagacat tgatagctgg cactgcaatt cacttattta 1200
ttaaagtccc ttaagtccc ctgcacctag aatataagcc cccaagcac aggcatttg 1260
ttttatgatg cgtgtatttc cttgtgcccc aaagaatgag aggcattctag aaagtctgca 1320
aaaaacaac ataaaaatga accctttatc agtcattgtt attttgatg atatttgagg 1380
catttccaag atttgttaag acaattgaa ccttctctct ggttcatgtg tgggagtgta 1440
ctgttcaaaa tgatgcttct gagtggagtt gctgagtctt tggtctcagg tttttttttt 1500
ttaagcattt atgctcattg tggtttttaa attaaacatt taacctgag acactgtaga 1560
ttccatcgca attgtaaaaa gccacacaga gctatcatgt gtatcttcac ctggtctgct 1620
ccagccccaa ccccgcaat gacagacctg ttctccactc ctgcaatctg ctcattgcaa 1680

```


gaatgtcgtc	tattgcaatc	ataaaattgt	gggattggct	ttttttttcc	tgtgcagcat	1740
cattctctcg	agattcatcc	tattgttgca	tttatcaata	gtttattcca	ttttacttct	1800
gagtagtgct	ctatgggtatg	gatgtaccac	agtcgtgtta	accattcacc	ttttggaggga	1860
agtcgtcttg	tatagatttg	ggcatatgaca	catgtatagg	ttttgtctcg	gacatcagtt	1920
ttcattttccc	ttgggacaaag	gccccagggtg	tctattgctg	gattctatgc	ttgttacagc	1980
gctcattttg	gtttgttttg	ctttgtttta	ttttgttttt	aacctgtcaac	gccattttcc	2040
agatccagtt	tcocatgcatc	ctcaccaggcc	ttcagtatga	tcactatgat	cttatctcag	2100
ccaccttaat	aggtagtgcac	tgatatataca	tggtcttttat	gttcatttca	ctgatgacta	2160
atgggtgttga	gcactcttttc	atgtgtttat	ttgccatctg	tatatctctt	ctagtcaagt	2220
gtccctctcat	gtctttttgtt	tacgtttctat	ttttgaaact	gttgagtttt	gaaaaattct	2280
ttataaaagta	tagaaaactaa	ttctttgttg	aatalgtagt	ttgtcaaat	ttttcttcag	2340
tcctttggctt	gtcttttttat	tcgtttaaca	gggtctctta	cagagcaaaa	gtgtttttat	2400
ttgatgaagt	ctatttttaac	aatttttctt	tttatggatc	atatttttgg	caacaaactc	2460
aaaaactcct	gaccaggctc	catatgtcaa	agattttctt	gtttctaaa	agtttttatag	2520
ttttaagttt	tatgttgaag	tcctatgtcc	attttgagtt	aattttcata	cagggtgtga	2580
gaccaaggtt	gtggttcttc	tttttctttg	gtggttttgt	ctgtggatgt	ccagttgtct	2640
cagccactct	gtctacaaaag	ctactttctc	tcactgtgaat	tacttttgca	ttcttgtaaa	2700
aatgttaattg	gggtgtatttg	tacaggctcg	tttgaggatt	ctctattgtc	tgtccacttg	2760
atctatgcat	gtgtcccatgt	gctagctata	taagtcctga	aaagggtagcc	taaggctgtg	2820
tgtggtggcg	agagcctcta	atccagctga	ttcgggaagt	ggagccaggga	gaatcgattg	2880
aaocccaggag	gtggagggtg	cagtgagctca	agatcgtgcc	actgcactcc	agccctgggtg	2940
acagagtgaa	ctctcataaa	aaaaataaaa	acaaaaataa	agtagcgtga	ttcttcccac	3000
cttattcttt	tttaaaaaag	ttttagctat	tcagattctc	ttgctcttcc	tataaaattc	3060
tagaataatc	ttgtctaat	ctaccacaa	ttcttcttga	attttgatag	aaatttttgt	3120
acactcttat	attattttgag	agaaatgata	tttttactat	gttgagtctt	ctaatccctg	3180
gatataaagt	ctctccattt	gtttagatct	ttcttgattt	attttataat	catgtgactg	3240
ttttcagact	acaaaaccag	catatggggt	gtgtagactta	tgctaggcca	ctcatctttt	3300
ttagccatta	taaatagtac	tgtgttttta	agtttagggt	ccattactag	tatgtagaca	3360
cacaattgat	ctttgtatat	ttatcttgtg	tcctgcaacc	ttgtctgaact	cactttactag	3420
ttctaggagg	tgtattgttt	ttctttgttt	tgtttttcaa	ttttctggga	ttttctacag	3480
agataataat	gtcatctgca	gatgcagttt	ttctctctcc	tttccaatct	gtatgtcttt	3540
aat ttctctt	ttaaaaaac	tattttactc	tgactagaac	ttctgtact	atgttaaat	3600
caagtgttag	agtggtacatc	cttgccttgt	ccctgatgtt	aaagagaaa	cattttgaac	3660
tgagtatccc	agccctcaaaa	tgtgcttaaa	aacttttttc	ctttcttgct	ttcagccttg	3720
aaacatactt	cgaaactctt	tattttctcc	tttcccacca	ggcacttcgc	tgagcagtcg	3780
tcgcttatct	aattatgtgc	ttacttagaa	attccagggt	ccaattttga	aaacaaaccag	3840
gcagagagac	ccagctgcag	aatcctccct	cttaggggga	gttacaggta	gcttaccact	3900
ttccggctga	aatcaggatg	acgcaaacca	gaacctccga	cagacagctt	atgactcaca	3960
ataacatcca	gaacacagtg	cagaccaaca	tcctcctgca	ccattcccac	attttcccca	4020
caactttttc	tccttaaaac	ccttcgctca	gtccagaaaa	ttctgaatggt	ctttttaaagg	4080
catgggtctg	gccatctccc	aactgccagt	atttgaataa	agctccttcc	tttttaccac	4140
acctcacttc	tcactgccttg	acttctgagc	agcgagcagc	tgagcttgag	ccagttaacac	4200
atcagttctt	caccattaga	aataatgtag	ccataggttt	tttttctctg	gatgttcttt	4260
ttcaggttaa	agaagttctc	ttctattctt	atttttctga	gaggtgttat	ccggaatgag	4320
tgttgaattt	tgttaataac	ttttaacaac	ccaacaggaa	ccaccatcat	aaagccatga	4380
gagaaaagca	cacggccaca	aagcactggg	ggccagggtg	cttgcctctg	ctgtctcgca	4440
tggtgtgacc	ccagcctccc	aaacctacca	tcacctgacg	gtgctctgag	cagttgaacc	4500
caaccagcat	ctaaaagaac	acagtttggt	aacgagactg	ggacacaggg	caagtaggggt	4560
ggagatcagg	aggtcctctg	agagcacccg	taccagcgag	catagaattc	atgggggtga	4620
ctctgtctct	gaagcatctg	cgcgtgtgtt	tcagcatttt	ttctcaaggga	ttgagccagg	4680
agcacagctg	tcactacggtg	cttaaatcaa	tgatttccag	ccaaccaaag	aaatacaagg	4740
ttccgggtcg	gcgcggtggc	tcacgcctgt	aatccacga	ctttgggagg	ccgagggcgg	4800
cggatcacga	gttcaggaga	tcgagacat	ccgggtctaa	acgggtgaaac	ccgtctctca	4860
ctaaaaatc	aaaaaaaatt	agccgggctg	agtgccggcg	gcctgtagtc	ccagctactt	4920
gggaggtctg	ggcagagaaa	ttggcgtgaac	ccgggagggc	gagcttgacg	tgagcccaaga	4980
ttccgcctac	gcactccagc	ctggggcgaca	gagcgagact	ccgtctctaa	aaaaaaaaaa	5040
aaaaaaaaaa	aaaaaaaata	caaggtgcct	ggggtacagg	gagcaaaaaa	ggggaaacga	5100
gaaattcttc	cgttgaggta	gagactccag	cctgtttgct	catctctggt	cctgaagagc	5160

ccagtcceccg ccctaaggat ggggtttctg ctccggcagca ctgcccgtga gagggggtgag 5220
gcactgggtc acgccagccc ttcttttata gcccccaggg ttattatagag tgtgcattag 5280
tattatttag caagcacttg aggggtgtctg atcttggggc agagaggcac aagaagtgtg 5340
tggggccagg acctgctcgt agagcgtggg tcagccttgg gtcccaaggg agatgacgca 5400
ggcccgggaa ctacagggtc caggagggag aaggcaaatg tctggctcag gttgggtggg 5460
gtgagggcca gcggagccag gtgcccaagg gactcagcc acaaatctag agcacaggct 5520
ggcaggtggc tcttgatgct catgccacc atttatctaa agggatgaga ttcaaggcct 5580
gtctctgttg ctggggggcg tgaagctga cgagagagg gtgttagatg gaatgtatat 5640
tccactctac cacttgtatt taacagggag atggatgatg aacacgtgca ggaggaaaca 5700
ggcaggacaa tccagagaga tcacgtgttc tgaggacagc acagccaggc tccgtatcgg 5760
agtgaagcgg ggtggggcag gcggcggggt cccctcatat gcccgaggag gccgtatat 5820
tactgacctt aggcacaca atagtgcct tctctgccc taggaagctc gactgcaggg 5880
tccaggtggg gaaaatcaat gcagagtggg tcccagagt ggccgaagct tgggctctg 5940
ggcgtgggg acctcagctg cagcagcccc acatctctat ggttctaaag cccagtcctat 6000
ttctgctcag caggggagat gccagttccc cagaggactt gccagggtc cccgctcgg 6060
ccctggggag gctcaggggt gagggaaggga gaattccgag ccgtggggcc tccctctgtg 6120
gctcgggggt gcagactgca ctacctgcc ctgtcctctg gactcctccg gactcatcca 6180
agtggggcca ttgggtgca aacctggag agcatcgtgt gtcttttctt ctctggctgg 6240
cactgaattg ctgttccaca gatgccagca atgaggacac tccccctccc ggaatcagga 6300
ctgggttgcca ccatggggag ggggtccacc tgccactgct tcccaggaca ctggccaggg 6360
ggctataaag aacatctcga gaggagccag cacagccttg ttcagacgcc cagtgcactg 6420
ccgaggtcgg cagcacagag ctctggagat gaagaccctg ttctgggtg tccagctcgg 6480
ctgtgcgcct gccctgtcct tcacctctgg ggaggaggat gtgagctggg tgaggctggg 6540
cggatggagg agccaggtgg actccttggg agggggcagc gccagggggc ctgctttagg 6600
agggttcaat taagctcgtg gtggtgggtg aggggtccta ttgttctctc agcacacaat 6660
gtcctccatg agggccagg ccggagcagg ctcggtcag gggttcctgc tgcactgacg 6720
cctgaagccc gaaggtctcg cagggttggg cctgtggag ggagggctca ctgggtgctg 6780
gggcccgggg gtccatggg tgcagacatg cctcctctcc actgggggct gggagccctg 6840
agcagggggc tggctctaac tcactccage tgagctctaa ctaagggtgca ggaaccaggc 6900
ctgcctttag ggggtggcag cgggcacat ggggtgctgg ttatagctgc aggcctgagt 6960
gccaggttca gagtgaatc tgggcccacc caggcctct caecgtctcca 7020
gatcacaggg acctggtacg tgaaggccat ggtggtcgat aaggacttcc cggaggacag 7080
gaggcccagg aaggtgtccc cagtgaaggt gacagccctg gccggtggga acttggaaagc 7140
cacgttccac ttcatgtgag tgttcccacc tgcagggccc ctacggccac ttctgctccc 7200
cgcccaggag ccactgggt cccattgcc ccatccacat tccgggtgtg ggaagatgca 7260
ccccctgctc tggagggaaa cagccagggc atcctgaagc tgggtggggg gggggggcag 7320
tggaaatttc aggttgccgg gtccaggcca tgcaccaggt gagctgagga tgggcagggt 7380
gtgtctctgg agcccgctgc cgcgtgtctc ctgttttcca ggaggggaga tccgtgcatc 7440
cagaagaaaa tcttgatgca gaagacggag gagcctggca aatacagcgc ctgtgagccc 7500
ctccccagcc ccccaactcc catgcccaac cccggatgca ccagcccccac tgcagtgga 7560
gagtgccag gccacacttc tggcagggtc cagccctcga ccaactccaa agcagctgct 7620
gcctctcct cctggggggc tgggtggcct gacatcagac accaggtgtg acagggttgt 7680
ccacagtaca gatggaccag atcaagcctg cctctggga gccctagctc attgacaact 7740
tgaggaaatc gagtgttag gaccaggagg ccaggggtta gggatgggaa gcccaaggct 7800
agggtttggg atcaggaatc cgagggttag ggcacaggaa gtggggcagg agcagctgct 7860
ggagctggga aggcgggact ctagtctggg acgtgctctg gccttgtggc tccattactt 7920
gcaltgggag gcttccgag gaggctcctg cctcctgtc cgggtccatg ctgtgctggag 7980
cagccacagg ttgctcagg gtgccaggc acctgggtga ccaactgaaac cctctgagt 8040
gttcttcgt gttctctga gtgctctctc cgggaatgag ggcactgaga atccatcttc 8100
ctgtcatctc acagatgggg gcaggaaagt catatacctg caggagctgc cggggacgga 8160
acactacgtc ttttaetgca aagaccagcg ccgtgggggc ctgcgtctca ttggaaagct 8220
tgtgggtgag gggcccgctg gggccctgat gtctcgtccc atggtctctg cctccaggaa 8280
ccagtgaaac caccatcac acgccctggc acggggggaa aaggaaagccc ctccgcggg 8340
ccttcgtgtg ctaggcacca agcgtctccc tggatggctg gtccaagtc ctgaagtggg 8400
agtgggtggg gccaggcagg gacagacag gccctcgggt acgtgaacct ccaaggggcc 8460
gcttctgggg tctcaggtgt aggggcctca ccttaagggg gaggtaacct cttaacagag 8520
ctcttcagtg ggcagggact ctccagggag gcagtcctct caggacacag 8580
gtccctccag gtaggggttg tgacctgca gagtggcttt gggagctgcc caggtcccc 8640

tgggggttgct	gagtggtctg	gaccctgcca	ctgtcccctt	tcctggggac	ctctcacctg	8700
ggcggtggcc	gtctcccttg	tcceccagtc	caccctcgag	ctctgttcca	ttctcaaggcc	8760
tcctctcccc	cttgccctgt	gctggagact	tgccatctct	ctctgtccca	gccccaccoc	8820
tgagctctga	tccactctcg	ggcctctccc	cgcctctgat	gctggggcgt	gtctgtctcc	8880
ttttagcatc	tgctccctgc	aggggccctg	cgtctgtccc	acgtcggtcc	acctggccac	8940
ctcacctgca	cagggaatc	ctaataccaa	cctggaggcc	ctggagaat	taagaiaatt	9000
gggtcgagca	aagggaatc	cggaggagga	caattttcac	cccttgacga	cgggtgagga	9060
cggctgtgac	caagtaacct	tgctcccttg	tgctctgtgt	tgatctccag	tgctccatga	9120
ccctctgtgc	ctcccatctc	cccgcctctc	cccatgtgct	ccgagttctc	tgcagggggc	9180
ctctggggcct	gcttagcatc	ctcgtctgtg	gagggtctgc	actctgggtg	gcgatggggt	9240
ctggggctcc	gcgctctggg	ctcgatgctg	gtctggggct	ccgcgctctg	gggtcgcatg	9300
gggtctcggt	ctccgcgtct	tgggctgcga	tgggtctctg	ggctccgcgc	ctctgggtcg	9360
gatgggggtct	ggggctccgc	gctctgggct	gcgatggggt	ctggggctcc	gcgctctggg	9420
ctgcgatggg	gtctggggct	ccgcgctctg	ggctcgcatg	gggtctgggg	ctccgcgtctc	9480
tgggctgcga	tggggctctg	ggctccgcgc	ctctgggctg	gatgggggtct	ggggctctga	9540
gctctgggct	gcgatggggt	ctgggcccctg	gtctaggggc	ctctctaate	ctctgggtttt	9600
tcttggtctc	tgccaggaag	tgctgtctctg	aaactatagg	tgagtggagcc	tttagggggc	9660
cactgcgaca	gcccagagtc	ctgggttccc	gggggttcag	ggtacatctc	ctctggagct	9720
tcacatccca	cacaggcagg	gagacccccc	cagggtcagg	ctcagaggtg	gcacctcaga	9780
gtctgcccaa	ccaaaattcc	tggaacattc	gggaagtcct	ttgttttaac	attcctgcac	9840
ctgcagagcc	gagtgagggt	ctcctctggg	ctttccacag	cgaaggctcc	ctccgcgtcc	9900
ctcaggtgtc	agctcggccc	atcgcccctc	gcacctgtcc	ccactcggtc	tactcccccc	9960
caaccactca	ccaagatgct	tcagaggcct	gccagtgcat	tggaggagct	gaggctgtctc	10020
tggagccccg	aggctgccca	gcagtgggcg	atgtgggaag	tcagagagct	ggggagggag	10080
cttggggctc	ggcctctgct	ctacccctga	gcctccctga	ctctgtctcc	ttctccccgc	10140
acagacagccc	ccgggtctgc	acctccagag	ccacccctac	caccagacac	agagcccagg	10200
ccacctggac	ctacctccca	gccatgacct	ttccctgtct	ccacccacct	gaactccaaa	10260
aaagagcttc	tcccccagct	ctgggacagg	ctatctgtgtg	ggagcggagg	gctcgacagg	10320
gtccctctgg	aggcctgtct	ggagggggag	ccacaaggga	agctggggag	atgtgtggac	10380
tagcaagggtc	caaaaccaaa	gaggcacgat	gtccaacagg	ctgtggggct	gcgtgatgtc	10440
ctggaggggg	ctccggaaga	gcgcgcctcg	gatctcaggc	tcagcttggt	accgggcagg	10500
ctctggggcag	gagcactctg	gaagccactg	ggagggccgg	agtggggaca	cggcgtcaga	10560
ctcgatcagc	tggtgtccac	acagggctcc	cgcgccgggg	gtctcagttg	gatcctccga	10620
gggggtccac	tttancatcc	tgnctcagtt	ggcatcactg	gata		10664

<210> 16
 <211> 11851
 <212> DNA
 <213> Homo sapiens
 <220>
 <223> hOBPIIb Gene

<400> 16						
tctctgtcttc	tatatctggc	ctccaaatct	gtgctcaatg	cagcaactgg	agtgaccocct	60
taaatacgta	agtcacagct	tgccctttgtc	agagctctcc	agggtctcttc	actcagagca	120
gaagctgaag	tcctctgtgt	ggctccttaat	ccctacatgg	cagttccacc	cactccccag	180
ctctcatgtg	ggccggtctc	ctcggtatcat	ttgtgtgtgg	tgctctgtgt	ttgtgtcccg	240
gaaactcgcca	gcattctctcc	acctccaggg	tgccacttga	tgctcctgtg	acctggagtc	300
ctctctccag	tgacgaagtc	atggcttgct	tccttcattg	cttaattctg	gtgtttgaat	360
gcacactcttg	cgggggtgtt	ctcctaatat	tcattttaag	gacaaataac	cccttgtctct	420
gacactctgt	tccaacttgt	ccactttgct	ttttccatag	cactgatcac	catttaaaat	480
aacgtatgaa	ccagtgaacc	atcaggatcc	agagacaata	gattgaacag	ggatgtgttg	540
cacaatgaac	aatcagctct	agaggttttaa	agagaaccac	aaagaatggc	ttaggaattgc	600
acgagggcag	tttaggaaga	aataaacagg	gggtggggatc	ctttccacaa	gtctgggttc	660
agacctcagc	ggagaagggt	tggtctctcc	aagggaagct	ggagaagttg	gctgggttgt	720
ccagccca	gctggccac	ggtcagggca	gaggccagca	ggcagggaaa	tgtaggtgtg	780

gtctggcgaag	caggaagcct	ctctccccac	ccaaggcagg	tgggctgggg	ctgggaagcc	840
tgaagagatc	actgagaacc	cacaggtgca	gatgccactg	aactcaca	ggaagccatc	900
tggggggcgt	ccctcgaa	caatgtggtg	tgtgcccgca	gacgtccccc	actgtgacca	960
ctgcacattg	catagggaaga	gaaagaaaaa	ggaagaaatg	gaagcatctg	gaaccagctca	1020
tccctggacc	atgctaggag	gcgctctccc	ctacgcctca	accaacaaag	cttagcattg	1080
caccagggtg	acaagagaag	cgctctgctg	ctccagctcc	attgcctcgg	aaccggccat	1140
gaagggtacg	tgtgagctg	gagggaagac	attgatagct	ggcactgcga	tccacttatt	1200
tattgtgttc	atttttaagt	ccctgcacct	agaatataag	ccccccagc	acaggacatt	1260
tgttttcatt	atcgatgat	tccttgtgcc	ccaagaatg	agaggcatct	agaaagtctg	1320
caaaaatcaa	acataaaaat	gaacctttat	tcagtcattg	ttattttgat	ggaaaattga	1380
ggcatttcca	agatttgtaa	gtaacaattg	aacctctctg	ctgggttcag	tgtgggaattg	1440
tatctgttga	aatgatgctt	ctgagtgagg	tgtctgagtc	ttggctctga	gggttttttt	1500
ttttaagcat	ttatgcttat	tgtggttttt	aaattaaaac	tttaaccctg	agacacttgt	1560
gattcccatg	cagttgtaaa	aagccacaca	gagctatcat	gtgatctctc	acctggcctg	1620
ctccagcccc	aaccccagca	atgacagacc	tgttctccac	tccgtgaatc	tgctcattgc	1680
aagaatgctg	tctattgcaa	tcataaaaat	gtgggagtgg	cttttttttt	tccctgtgag	1740
catcatctct	tggagattca	tcccatgtgt	gcatttatca	atagtttatt	ccattttact	1800
tctgagtagt	gcctgatggt	atggatgtac	cacagctctg	ttaaactatt	tccctgttga	1860
ggatgtctgt	gtttatagat	ttgggtctatg	acacatgtac	aggtttttgc	atggacatca	1920
gtttctattt	tcttgggaca	aaggccaggg	gggtctattg	cggggttcta	tgcttgtgtc	1980
aggggttttt	tttttaaac	tgtcaagcca	ttttccagaa	actgtccagt	ttccatgcat	2040
ccctcacagg	ctctagatgt	atcacatgat	tcttatctca	ggcaccttaa	taggtatgta	2100
ctgatatact	atggccttta	tttgcaattc	actgatga	aatgggtgtg	agcatctttt	2160
catgtgttta	ttttgcactt	gtatatcttc	tctagtcaag	tgcccttcca	tgctttttgt	2220
ttacatttcta	tttttgaac	tgttgaattt	tgaaaaaatc	tttataaagt	atagaaatca	2280
attcttttgt	gaatgatgat	tttgtcaata	ttttcttcca	gtctttgggt	tgtcttttta	2340
ttctgttaac	agggctctct	acagagcaaa	aggtttttat	tttgatgaag	tcatttttaa	2400
caatttttcc	ttttatggat	catatttttg	gtgacacatc	taaaatctcc	tgacccagct	2460
ccatatccca	aagattttct	ttctgttttc	taaaagcttt	atagttttta	gttttatgtt	2520
taagtctatg	atccattttg	agtttaattt	cttgcaaggt	gtgagaccaa	gggtgtgggt	2580
cttctttttg	tttgtgtgtt	ttgtctgtgg	atgtccagtt	aatccagccc	atttgtctaca	2640
aaagctatct	tccattgaa	tgcttttgca	cttttgttaa	aacttaactg	gggatattgc	2700
tgcaggctct	tttgaggatt	ctttattgtc	tgccccattg	atcatgcat	ctgtccatct	2760
gtcagctata	taatgagctt	tgaagggtta	gcctgtagct	gggtatgggt	gtgtgcatct	2820
gtaatccaga	ctacttggga	ggcgaggcca	ggagaatcac	ttgaatctgg	gaggtggagtc	2880
tgtcaatgag	tcgagattgt	gtcactgcac	tccagcctgg	gtgacagagc	aagactctgt	2940
ctctaaaaaa	aagaaagaag	aagaaaagga	aagaaaggtg	agcctgattc	ctccccactt	3000
attcttaaaa	aaaaaagttt	tagttattct	agttctcttg	cccttccata	taaatgttag	3060
ataaatcttt	tttgattctta	caaaaattcc	ttctggaatt	tgtatagaaa	tgttgtttaa	3120
tctttatatt	atttgagaga	aatgacgctt	ttattatggt	gagtcctcta	atccatggat	3180
atagacacat	tctcactttg	tttagatttt	ctttgattta	ttttataatc	atttgcatat	3240
tttcagcata	caaatccagc	atatgggttg	ttaaacttat	gcctaggtat	ctcttttttt	3300
tagccacat	aagttagatt	gtgtttttta	gtttagggtc	cgttactagt	acttagagac	3360
acaattgac	ttgttatatt	tatcttgtat	cttgcaacct	tgctgaacct	gcttaatagt	3420
tctaggaggt	tctttgtttt	cttttgtgtt	gttttccagt	tctttggagt	ttctaacaga	3480
gacaaatcat	tcatctgcag	atgcagacag	ttttcttctc	tcccttccaa	tttgtatgtc	3540
tttaatttcc	tttttaaaaa	acctttatgt	ctctgactag	aactttctgt	acttagttaa	3600
atacaagtgg	tgaaggatga	catccttgcc	ttgtccctga	tgttaaggag	aaagcgtttg	3660
taactgagta	tccagccttc	aaaatgtgct	taaaaaactt	ttcctttctt	tgctttcagc	3720
cttgaacact	actctgaaac	tctttatttc	tccctttccc	accaggcaact	tctgtgagca	3780
gtgctgcctt	attctaattt	gtgcttactt	agaaattcca	ggggccaaat	ttgaaacaaa	3840
caggcgagag	agacccagct	gcagaatcct	ccctcttagg	gggagttaca	ggtagcctac	3900
cacttccggg	ctcaaatcag	gatgactcaa	accagacctc	tgagacagat	attaagtact	3960
catgataacc	attgggaaca	gatgcagacc	aacatctctc	tgacacatct	ccacatattt	4020
ccccacactt	tctcctctta	aaccctcttg	ctcagtcacg	aaagtgtgaa	tgtcttttta	4080
aaggctatggg	gccttgccat	ctctctactg	ctagcatgtg	ataatgtctg	cttccctttc	4140
accacacttc	actctctatg	ccttgacttc	tgagcagcga	gcagctggag	ttagccaggt	4200
tacacatcag	tctttcacca	tgaagaatga	tgttagccat	aggttttttt	tagatgctct	4260

ttgtcaaggt	aaggaggttc	tctctctatc	ctactttttc	gagagttggt	ttcctgaagt	4320
cgtagtgat	ttagtcaagt	actttttctg	cattgatcga	tatgatcatg	taattttttc	4380
tcttaacata	ttaatatggt	tgatttttga	gtatgtgacc	aggtttccat	ccctcggaata	4440
aactgctttt	ggatcatggt	tagaattaat	tttatatatt	attattttgt	aatattttgt	4500
aaaggatttc	tgatctcata	ttcatggagt	atattgtctc	gcagctttcc	tttttttggt	4560
gtcaggtttt	gggtgggaga	tattctctca	tctcttgaga	tattgcagcat	ttgtgtttat	4620
ttattttttt	aatggttggt	agaattttct	aatgaaacca	tatggacatg	aaagaattat	4680
ttttggaagt	ttttaaata	aaatgttaac	tttaagtgtc	atagagctat	taatttttat	4740
tatctcttat	tgccattgtg	ttttttgaga	aatgtgttca	tttcacctat	gttgtcaaat	4800
atatgtggga	aggtctcttc	gtagtattcc	cttattatcc	tttgatgctc	gcagggtctg	4860
tagtgatagt	ctctgttttg	ttccagatgt	tggttatttg	tgctttttct	tctttttttg	4920
tttgtcagtc	ttttcagaac	tgctccaatt	tttattaatt	ttccagagaa	ccaacctctg	4980
tttcattggt	tttctctggt	gtttttctgc	tttcgatttt	ttctgctttc	tgctttttgt	5040
tttattaatt	ctgctcttat	ctttgttatt	tcttttcttc	ttgctttggg	tttattttgc	5100
tcttcttttt	ctagggtctt	gaagtgggag	cttagatagt	tgatttttgg	cttctctttt	5160
ctaataatg	catltaatgc	ctctcagcac	tgattttagct	gtgtctcaca	aattttgata	5220
ttgtttttgt	tgttttgttt	tgaggttagag	tctcgtctgt	latcccgagg	tggaagtgcg	5280
tggtcactat	tggtctcact	gcaacctcca	ctcctcgggt	tgcaagcaat	ctcctcgtct	5340
agcccccctaa	gtagctggga	ttcacagtat	acgccaccat	gctgtccagg	ttattttatt	5400
attttttttt	gtatttttag	tagagatgag	gtttttgtcat	gctgtccagg	ctgggtctcga	5460
actctcgacc	ccaagtgtat	tgcccaagtg	gggtcccaaa	ccactgagat	tataggcata	5520
agccactgtg	cccgagctgt	ttttgtttct	tttgagatgg	agctctgtctc	tgatcaccca	5580
gctgtgagtg	agtgccatga	tagccccact	caacctccgc	ctccccgggt	caagtgaatc	5640
tttgtcctca	gctccccgat	tagctgggag	tacaggcgctg	caccaccaca	ctcagctagt	5700
ttttgcatll	tggttagaga	tggtgttttc	ccatgtttgc	caggctggctg	tcgaattctc	5760
gatcccaagt	gatccaccgt	ccctgggctc	ccaaaagtgt	ggaatttatag	gcacaagcca	5820
ttcagccagc	ctgatatggt	glatttttat	tttcatccag	cttagtatat	ttttaaattt	5880
accctcaggg	ttctctcttg	acctgtggat	tattcacagg	tggtgttggt	ccaagcatct	5940
gaagaagaat	tttccattat	ctttctggca	ttgatttata	gttagattcc	atgtgttcag	6000
agactaccct	ctatatctat	taaattttta	aaaatttctt	gaggtctcatt	tttctcatca	6060
ggatatggtc	tatcttggtt	tatatctggg	tgcaactgaa	aagaatgtgt	gtagtgtctg	6120
tgccagggtg	tggtgtctac	aaatgtcaat	tcgattatgt	taattgatgg	gtggccgagt	6180
tctttgatgt	ccctgctggt	tttctgtcta	gttgctctga	gagaagggtg	ttgaagtctc	6240
caactataat	tggtgctttt	taaatltctc	ctttcagtcg	tgttttgctt	acatatgtct	6300
gcagctcaat	tttggtgcac	acacgtttag	gattactatg	ttctctttgc	ttttttggcc	6360
acttattatt	gtataatgct	ctctctgtgt	aattagtctt	tgttctaaag	tctattttac	6420
ctgttattga	aataatgctt	ctgctttctt	ttgattaatg	tttatataat	ttttttctatg	6480
tttttacttt	caacctgtct	ctattgttacc	atttgaagta	agtttctctg	agacggcata	6540
tttggtgata	atggtcttta	attcaacttg	ccaatcactg	tcatttaata	tttaaaccat	6600
ttacatttaa	tataatttatt	aactatgtag	agtttgtatt	atttttatag	gggtgtctata	6660
acaaaactac	accaactggg	tggtctagaa	caaaaattta	ttttctcaca	tttctggtag	6720
cagaagctctg	agatccaagt	agatttgtaa	ggtagaaaaa	ccaacaaat	atgttaatga	6780
tgtaaccatt	gtgggcaact	gggactcagt	ctctctgagg	ccatctctgag	aaatagggtg	6840
gaacacattt	tgattgttcc	acttagaagg	aagagtccag	accattttat	ccatcagtta	6900
ctatccctac	agactgagga	tgctgattca	cttgccatct	tggtgttctat	cagtgtcagg	6960
ggaagcacag	aagaaaaggt	gcaggcactt	aaggtgggaa	gctgtgaaat	cgctccgtga	7020
gggtctcagg	cgctgcggga	ctcagctggc	agcagcccca	gtctctctctg	gtctcaaaag	7080
ccagctcatt	cttgctccagc	aggagagatg	ccagttcccc	agaggcactg	cccagggtcc	7140
cagccgtggt	ctcgggaggg	tgccgggggt	ggtgagggag	tatcccgagg	tgcttggccc	7200
tgctctctgt	gctctggggtg	cagatggaca	ccacctctgc	ctgtctctctg	gagtcctctg	7260
ggctcatctg	agtgggcgcg	ttcgggtggt	gcaaaactctg	gtatgctctt	tgctctcttt	7320
ctctctctgc	tgccactgtac	ttgctgttca	ccagatgccca	gcaatgagga	cactccccct	7380
cccgatggca	ggactgggtg	ccaccatggg	gagggggtga	ccgtgccacg	tgctccagg	7440
acactgtgcca	gggggctata	aagaacatct	cgaggaggagc	cagcacagcc	ttgttcagac	7500
gccactggcc	ctgcaggagt	cggcagcaca	gagctctgga	gatgaagacc	ctgttctctg	7560
gtgtcacgct	cgccctggcc	gctgccctgt	cttccacctg	ggaggaggag	gatgtgagct	7620
gggttggcgt	ggcggatggg	aggagccagg	cggactccctg	ggcagggggc	agtgccaggg	7680
gcctctgctt	aggaggtgtc	actgaaggct	ggctctgac	ccctgtctcc	cagcctgggg	7740

tgggtgggtgga	ggggctctat	tgttctctcca	gcagacacagg	ccccccgagg	cccagggccc	7800
gagcaggctgc	gtctcagggg	tctctgctgc	actgaacgct	gaagcccgaa	ggctctcgag	7860
gggttggggccc	gttggggagg	gggctcacct	gggtgctgggg	ccccgggggtc	ctctgggggtc	7920
agacatcgact	tctctccact	gggggctggg	agccctgagc	agggggctggg	ccttaacctca	7980
ctccagctgga	gtcttaacta	aggtgcagga	acacagcctg	ctcttaagggg	cagagccggcg	8040
gcacacatgga	tgtctgggta	tagctgcagg	ccctgaagtgc	aggggtcagag	tagaactctgg	8100
gcaccccatgg	gtgggctcac	ggccttggcc	tgtctccagat	cacaggggacc	tggtaactgta	8160
agggcactggg	ggctcgataag	gaactttccg	aggacaggag	ggccaggaaag	gtgtccccag	8220
tgaagggtgac	agccctgggc	gggtgggaagt	tggaaagccac	gttccaccttc	atgtgaggtgt	8280
tggccactgc	agggccccctc	agggccacttt	cgctccccctc	cccagacccca	ccctgggtccc	8340
attgccccat	ccacgtttctg	gggtgttggga	agagtcaccc	ccctgctctgg	aggggaaacc	8400
ccctgggcatc	ctgaagctcg	gtgggggtggg	ggacagtgga	attttcagggt	tgcggggctca	8460
ggggccatgca	ccagggtgagc	tgaaggatggg	ccatgggtgtg	ccctggggagcc	gctgccccgg	8520
tgtctcctgt	tttctcaggag	ggaggatcgg	tgcattccaga	agaaaaactct	gatgcgggaag	8580
accggaggagc	ctggcacaata	cagcgctcgt	gagccccctcc	cccactcccca	ccccccacctc	8640
ccccccaccgc	caacccccagt	gcaccagcct	ccacaggtag	agagtgcccca	ggctgccccct	8700
tgtccagggg	cccagctctg	cccacctcca	aggaggggct	ggcctctcct	tgctggggggg	8760
ctgggtggccc	tcagactcaga	caccggggtgt	gacagggtctg	tccgcagctct	agatgggacca	8820
gatcacgcctc	gccctctcggg	agggcctcagc	cattgacaca	ttgagggaagc	tgaaggattgg	8880
gacagcaggag	ccaaggatta	ggtaacgggga	ggctgagggt	taggggatggg	gaagctgagg	8940
gttaaggatg	gggaagctga	gggttaaggga	tggggaggctc	gaggggtagg	taagggggggc	9000
aaagggttagg	gatctgggaag	ctgagggtta	gggataggga	ggccgagggtt	taggggatggg	9060
ggggccaggag	gttactgtctg	cgggaagctga	ggattagaga	tggggaggctc	taagggggaag	9120
atagggggtta	ggggcaggga	agtggggcag	gacagactgc	tggagctctgg	aaggccgggac	9180
tctagtctctc	gaactgtctct	ggccttctgtg	ctccattact	tgcatttggga	cccttctctag	9240
agagggtctcc	tggctccgtg	tccgggtcca	cactgtgcgg	agcagccagg	ccctgggtcag	9300
gctgtccagg	gcacctgggt	gaocgctgaa	acattcccgga	gtgtttcttc	atgtggcccc	9360
gagtggtcttc	tctgggaaatg	accatttttcc	tctgtcatct	acagatgggg	gcagggaaagct	9420
catgtacctg	caggagctgc	ccaggaggga	ccactacatc	ttttactgca	aagaccagca	9480
ccatggggggc	ctgctccaca	tgggaaagct	tgtgggtgag	gggcttgcctg	gggtcttcgtt	9540
gctctgcccc	acggtctctg	ccctcggaag	ccggtggaaac	cagcaccacc	atgccctgggc	9600
atgggggaaaa	aggaagcccc	ctgtgcocgg	tttcatgtgc	cgggcaccgc	tggggcagccg	9660
gtggccattgg	ctgaagtggtg	aatgggatgg	gccaggcagg	gacagacatg	ccctcactgt	9720
acatgaacct	gccaaaggcc	acttctgggg	tctcgggtgt	aggagggttca	cccttaagggg	9780
gaggggtcacc	ttaagcgtcc	taagagagct	cttcatgggg	cagggaacctc	ccagggcgagg	9840
aggggtggccg	gtgcctctgg	gagacaaagt	ccctccaggt	gagggctgtgt	accctgcagg	9900
gtggccattgg	gagctgcccc	ggctccctgg	gggtgcgcag	tggcttggag	agtcccccgc	9960
actgtcccc	tctctggggga	ccctctcatct	gggcagtgac	tgtctctctc	gtccccagtc	10020
caacccttga	gctctctacc	attctcaagt	ctctctctct	gtgtgtccgg	tgtgtctcgt	10080
tggccactctc	tcttgtccccc	ggccccacccc	cagagctctg	gtccactctc	ggggtctctcc	10140
cccttctctct	gtgcttgggca	gtggccatct	ccctctgtccc	cagcccccaac	cccgagctctc	10200
gattccactct	caggcctctc	ccctctgtctc	gggtgtgggc	cgtgtgtctg	tcccttccgc	10260
atctctcccc	tgcaggcccg	tgcgcgtgtc	cccaactcgg	ctcaactctgc	ccctcactct	10320
gcaggtaggga	attctgatac	caaccgggag	gcccctggaa	aatttaagaa	atgggtgcag	10380
cgcacaaggag	ggacatlttcc	gtgctgatac	agcaggggtgc	agcaggggtgc	ggatctgtgt	10440
gcacagctccc	ctgtgtccct	ctgctgtgtc	tgtctgctat	ctccagtgctc	ccagtgacccc	10500
catgtctctcc	catgtccccc	gcattccccca	tgtgccccga	gtgtcctcgc	ccagggctccc	10560
gggcccctggt	tacgctctcc	ctcatttggag	gctctgtgct	ctggggctcgc	atgggggtctg	10620
gggctcccgcg	ctctgggctg	cgatggggctc	tggggctccg	cactctgggg	ggctgatggg	10680
tctggggctct	cgcgctctgg	gctgcgattg	gctctggggc	tctgagctct	gggctgtgat	10740
gggggtctggg	cccttgtctga	ggggcgccttc	taatccctgt	gttttctctg	gtctctgag	10800
gaagctcgct	tcccgaaac	taggggtgagt	gagcctttag	gagggcactgc	gaccacacca	10860
gagtcctggg	tccccgggtt	tccagggttac	atctgctctg	gcccctccca	ctccacacag	10920
ccaggggagac	ccccccagg	tcaggcacga	gggtggcacc	tcagagtctc	ccccaccaca	10980
gtctctggga	catctgggaa	gtcctttgttt	ttatcatctc	tgcaactgcc	agcccagtg	11040
agggctctcc	tccggcttcc	cacagcgagg	ctccctcccg	gtccctcag	gtctcagctc	11100
agccctacgc	ccccctcacc	tgtccccacg	cgttccacac	ccacacaaag	accctccaaag	11160
gatgtctcaga	ggcctgcccc	gtcatttggag	gagctgaggt	cgctctggag	ccccgaggtt	11220

21

```

gccagcagct ggcgatgtg ggggctgcag agcctgggga gggagctctg gccctggcct 11280
ctgccctacc ctgcagcctc cctgacctct cctcctcttc ccagcacagc agcccccggg 11340
ctgcacacct cagagccacc cctaccacca gacacagagc ccggaccacc tggacctacc 11400
ctccagccat gacctctcc tgetccacc cacctgactc caaataaagt ccttctcccc 11460
cagctctggg caggcctatc tgtggggaca gaggggcttg caccgcctcc ctggggaggtc 11520
tgctgggggg gggagccaca aggaaagctg gggagatgtt ggacctagca agggccaaaac 11580
cacaagaggg acgatgtcca acaggcctga ggggctcgct gatgtcctgg aggggcctcc 11640
ggaaagagcc ccctcaggtc tcagggttcag cttaggacag gcagggccct gggcaggagc 11700
gtttggaaa gacatgggga ggacaggagc ggggacacgg cgtcagggct gcagcagctg 11760
ggccaccgca gggctccgc ctcagggggtc tcagagggat cctccaagct ccccccattt 11820
agcagcctgg gctcagtggc agcactggag a 11851

```

<210> 17
 <211> 253
 <212> DNA
 <213> Homo sapiens

```

<400> 17
cactccccct cccgatgtga ggaactggtg ccacatggg ggggggtgca ccgtgccacg 60
tgctccacgg acatgggcca gggggctata aagaacatct ccagaggagc cagcacagcc 120
ttgttcagag gccagtgac ctgccagagt cggcagcaca gagctctgga gatgaagacc 180
ctgtctctgg gtgtcacgct cggcctggcc gctgccctgt ccttcacct ggaggaggag 240
gatgtgagct ggg 253

```

<210> 18
 <211> 154
 <212> DNA
 <213> Homo sapiens

```

<400> 18
cctgctccag atcacaggga cctgggtacgt gaaggccatg gtggtcgata aggactttcc 60
ggaggacagc agggcccagg aggtgtcccc agtgaaggtg acagccctgg gcggtgggaa 120
cttgaagacc acgttcacct tcatgtgagt gttg 154

```

<210> 19
 <211> 91
 <212> DNA
 <213> Homo sapiens

```

<400> 19
tgttttccag gaggggagat cggtgcatcc agaagaaaat cctgatgcgg aagacggagg 60
agcctggcaa atacagcgcc tgtgagcccc t 91

```

<210> 20
 <211> 126
 <212> DNA
 <213> Homo sapiens

```

<400> 20
gtgtgtgacag gcttgtccgc agtcgagatg gaccagatca cgcctgcct ctggggaggcc 60
ctagccattg acacattgag gaagctgagg attgggacaa ggaggccaag gattaggtac 120
ggggag 126

```

22

<210> 21
<211> 131
<212> DNA
<213> Homo sapiens

<400> 21
tcattctacag atgggggagc gaagctcata tacctgcagg agctgcccg gacggacgac 60
tacgtctttt actgcaaaga ccagcgccgt gggggcctgc gctacatggg aaagcttggtg 120
ggtgaggggc c 131

<210> 22
<211> 188
<212> DNA
<213> Homo sapiens

<400> 22
ctccttttag catctgctcc ctgcagggcc gtgcgcgtgt cccacgctcg gctcacctgg 60
ccacctcacc tgcaggtagg aatcctaata ccaacctgga ggccctggaa gaatttaaga 120
aattggtgca gcacaaggga ctctcggagg aggacatttt cagccccctg cagacggggtg 180
aggatcgg 188

<210> 23
<211> 44
<212> DNA
<213> Homo sapiens

<400> 23
gtctctgcag gaagctgcgt tctcgaacac tagggtagt gacg 44

<210> 24
<211> 130
<212> DNA
<213> Homo sapiens

<400> 24
ccagcacag cagcccccg gtctgcacct ccagagccca cctaccacc agacacagag 60
ccggaccac ctggacctac cctccagcca tgacccttcc ctgctccca ccaectgact 120
ccaaataaag 130

<210> 25
<211> 4
<212> PRT
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Synthetic peptide

<400> 25
Gly Thr Trp Tyr
1

<210> 26
 <211> 21
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 26
 cctgcaggta catgagcttc c 21

 <210> 27
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 27
 cgctgtattt gccaggctcc 20

 <210> 28
 <211> 35
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

 <400> 28
 gactcgagtc gacatcgatt tttttttttt ttttt 35

 <210> 29
 <211> 20
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

 <400> 29
 cctctcccag ccccagcaag 20

 <210> 30
 <211> 17
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Description of Artificial Sequence: Primer

<400> 30
gactcgagtc gacatcg 17

<210> 31
<211> 22
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 31
cgcccagtg cctgccgagg tc 22

<210> 32
<211> 23
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 32
ctttatttgg agtcaggtgg gtc 23

<210> 33
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 33
ctctgcccc tctgctgatg 20

<210> 34
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: Primer

<400> 34
cctgcttcac caccttcttg 20

<210> 35
<211> 20
<212> DNA
<213> Artificial Sequence

<210> 40
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 40
 ctcatgacca cagtccatgc 20

<210> 41
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 41
 tgttcgggaa cgcagctt 18

<210> 42
 <211> 20
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 oligonucleotide

<400> 42
 tgccgctgtc cccacgtcgg 20

<210> 43
 <211> 13
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: Synthetic
 motif

<400> 43
 Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr Arg Leu Lys
 1 5 10

<210> 44
 <211> 28

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 44

gtcggatccc tgcctctcac cctggagg

28

<210> 45

<211> 29

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Primer

<400> 45

gtctctgagg tgttcgggaa cgcagcttc

29

<210> 46

<211> 176

<212> PRT

<213> Homo sapiens

<400> 46

Met Lys Pro Leu Leu Leu Ala Val Ser Leu Gly Leu Ile Ala Ala Leu
1 5 10 15

Gln Ala His His Leu Leu Ala Ser Asp Glu Glu Ile Gln Asp Val Ser
20 25 30

Gly Thr Trp Tyr Leu Lys Ala Met Thr Val Asp Arg Glu Phe Pro Glu
35 40 45

Met Asn Leu Glu Ser Val Thr Pro Met Thr Leu Thr Thr Leu Glu Gly
50 55 60

Gly Asn Leu Glu Ala Lys Val Thr Met Leu Ile Ser Gly Arg Cys Gln
65 70 75 80

Glu Val Lys Ala Val Leu Glu Lys Thr Asp Glu Pro Gly Lys Tyr Thr
85 90 95

Ala Asp Gly Gly Lys His Val Ala Tyr Ile Ile Arg Ser His Val Lys
100 105 110

Asp His Tyr Ile Phe Tyr Cys Glu Gly Glu Leu His Gly Lys Pro Val
115 120 125

Arg Gly Val Lys Leu Val Gly Arg Asp Pro Lys Asn Asn Leu Glu Ala
130 135 140

Leu Glu Asp Phe Glu Lys Ala Ala Gly Ala Arg Gly Leu Ser Thr Glu
145 150 155 160

Ser Ile Leu Ile Pro Arg Gln Ser Glu Thr Cys Ser Pro Gly Ser Asp
 165 170 175

<210> 47
 <211> 176
 <212> PRT
 <213> Rattus sp.

<400> 47
 Met Lys Ser Arg Leu Leu Thr Val Leu Leu Leu Gly Leu Met Ala Val
 1 5 10 15
 Leu Lys Ala Gln Glu Ala Pro Pro Asp Asp Gln Glu Asp Phe Ser Gly
 20 25 30
 Lys Trp Tyr Thr Lys Ala Thr Val Cys Asp Arg Asn His Thr Asp Gly
 35 40 45
 Lys Arg Pro Met Lys Val Phe Pro Met Thr Val Thr Ala Leu Glu Gly
 50 55 60
 Gly Asp Leu Glu Val Arg Ile Thr Phe Arg Gly Lys Gly His Cys His
 65 70 75 80
 Leu Arg Arg Ile Thr Met His Lys Thr Asp Glu Pro Gly Lys Tyr Thr
 85 90 95
 Thr Phe Lys Gly Lys Lys Thr Phe Tyr Thr Lys Glu Ile Pro Val Lys
 100 105 110
 Asp His Tyr Ile Phe Tyr Ile Lys Gly Gln Arg His Gly Lys Ser Tyr
 115 120 125
 Leu Lys Gly Lys Leu Val Gly Arg Asp Ser Lys Asp Asn Pro Glu Ala
 130 135 140
 Met Glu Glu Phe Lys Lys Phe Val Lys Ser Lys Gly Phe Arg Glu Glu
 145 150 155 160
 Asn Ile Thr Val Pro Glu Leu Leu Asp Glu Cys Val Pro Gly Ser Asp
 165 170 175

<210> 48
 <211> 178
 <212> PRT
 <213> Bovine sp.

<400> 48
 Met Lys Cys Leu Leu Leu Ala Leu Ala Leu Thr Cys Gly Ala Gln Ala
 1 5 10 15
 Leu Ile Val Thr Gln Thr Met Lys Gly Leu Asp Ile Gln Lys Val Ala
 20 25 30

30

Thr Asp Tyr Asp Asn Phe Leu Met Ala His Leu Ile Asn Glu Lys Asp
 115 120 125
 Gly Glu Thr Phe Gln Leu Met Gly Leu Tyr Gly Arg Glu Pro Asp Leu
 130 135 140
 Met Ser Asp Ile Lys Glu Arg Phe Ala Gln Leu Cys Glu Glu His Gly
 145 150 155 160
 Ile Leu Arg Glu Asn Ile Ile Asp Leu Ser Asn Ala Asn Arg Cys Leu
 165 170 175
 Gln Ala Arg Glu
 180

<210> 50
 <211> 199
 <212> PRT
 <213> Homo sapiens

<400> 50
 Met Lys Trp Val Trp Ala Leu Leu Leu Ala Ala Trp Ala Ala Ala
 1 5 10 15
 Glu Arg Asp Cys Arg Val Ser Ser Phe Arg Val Lys Glu Asn Phe Asp
 20 25 30
 Lys Ala Arg Phe Ser Gly Thr Trp Tyr Ala Met Ala Lys Lys Asp Pro
 35 40 45
 Glu Gly Leu Phe Leu Gln Asp Asn Ile Val Ala Glu Phe Ser Val Asp
 50 55 60
 Glu Thr Gly Gln Met Ser Ala Thr Ala Lys Gly Arg Val Arg Leu Leu
 65 70 75 80
 Asn Asn Trp Asp Val Cys Ala Asp Met Val Gly Thr Phe Thr Asp Thr
 85 90 95
 Glu Asp Pro Ala Lys Phe Lys Met Lys Tyr Trp Gly Val Ala Ser Phe
 100 105 110
 Leu Gln Lys Gly Asn Asp Asp His Trp Ile Val Asp Thr Asp Tyr Asp
 115 120 125
 Thr Tyr Ala Val Gln Tyr Ser Cys Arg Leu Leu Asn Leu Asp Gly Thr
 130 135 140
 Cys Ala Asp Ser Tyr Ser Phe Val Phe Ser Arg Asp Pro Asn Gly Leu
 145 150 155 160
 Pro Pro Glu Ala Gln Lys Ile Val Arg Gln Arg Gln Glu Glu Leu Cys
 165 170 175
 Leu Ala Arg Gln Tyr Arg Leu Ile Val His Asn Gly Tyr Cys Asp Gly
 180 185 190

Arg Ser Glu Arg Asn Leu Leu
195

<210> 51
<211> 159
<212> PRT
<213> Bovine sp.

<400> 51
Ala Gln Glu Glu Glu Ala Glu Gln Asn Leu Ser Glu Leu Ser Gly Pro
1 5 10 15
Trp Arg Thr Val Tyr Ile Gly Ser Thr Asn Pro Glu Lys Ile Gln Glu
20 25 30
Asn Gly Pro Phe Arg Thr Tyr Phe Arg Glu Leu Val Phe Asp Asp Glu
35 40 45
Lys Gly Thr Val Asp Phe Tyr Phe Ser Val Lys Arg Asp Gly Lys Trp
50 55 60
Lys Asn Val His Val Lys Ala Thr Lys Gln Asp Asp Gly Thr Tyr Val
65 70 75 80
Ala Asp Tyr Glu Gly Gln Asn Val Phe Lys Ile Val Ser Leu Ser Arg
85 90 95
Thr His Leu Val Ala His Asn Ile Asn Val Asp Lys His Gly Gln Thr
100 105 110
Thr Glu Leu Thr Glu Leu Phe Val Lys Leu Asn Val Glu Asp Glu Asp
115 120 125
Leu Glu Lys Phe Trp Lys Leu Thr Glu Asp Lys Gly Ile Asp Lys Lys
130 135 140
Asn Val Val Asn Phe Leu Glu Asn Glu Asp His Pro His Pro Glu
145 150 155

<210> 52
<211> 181
<212> PRT
<213> Rattus sp.

<400> 52
Met Lys Leu Leu Leu Leu Leu Cys Leu Gly Leu Thr Leu Val Cys
1 5 10 15
Gly His Ala Glu Glu Ala Ser Ser Thr Arg Gly Asn Leu Asp Val Ala
20 25 30
Lys Leu Asn Gly Asp Trp Phe Ser Ile Val Val Ala Ser Asn Lys Arg
35 40 45
Glu Lys Ile Glu Glu Asn Gly Ser Met Arg Val Phe Met Gln His Ile
50 55 60

Asp Val Leu Glu Asn Ser Leu Gly Phe Lys Phe Arg Ile Lys Glu Asn
65 70 75 80

Gly Glu Cys Arg Glu Leu Tyr Leu Val Ala Tyr Lys Thr Pro Glu Asp
85 90 95

Gly Glu Tyr Phe Val Glu Tyr Asp Gly Gly Asn Thr Phe Thr Ile Leu
100 105 110

Lys Thr Asp Tyr Asp Arg Tyr Val Met Phe His Leu Ile Asn Phe Lys
115 120 125

Asn Gly Glu Thr Phe Gln Leu Met Val Leu Tyr Gly Arg Thr Lys Asp
130 135 140

Leu Ser Ser Asp Ile Lys Glu Lys Phe Ala Lys Leu Cys Glu Ala His
145 150 155 160

Gly Ile Thr Arg Asp Asn Ile Ile Asp Leu Thr Lys Thr Asp Arg Cys
165 170 175

Leu Gln Ala Arg Gly
180

<210> 53
<211> 157
<212> PRT
<213> Sus scrofa

<400> 53
Gln Glu Pro Gln Pro Glu Gln Asp Pro Phe Glu Leu Ser Gly Lys Trp
1 5 10 15

Ile Thr Ser Tyr Ile Gly Ser Ser Asp Leu Glu Lys Ile Gly Glu Asn
20 25 30

Ala Pro Phe Gln Val Phe Met Arg Ser Ile Glu Phe Asp Asp Lys Glu
35 40 45

Ser Lys Val Tyr Leu Asn Phe Phe Ser Lys Glu Asn Gly Ile Cys Glu
50 55 60

Glu Phe Ser Leu Ile Gly Thr Lys Gln Glu Gly Asn Thr Tyr Asp Val
65 70 75 80

Asn Tyr Ala Gly Asn Asn Lys Phe Val Val Ser Tyr Ala Ser Glu Thr
85 90 95

Ala Leu Ile Ile Ser Asn Ile Asn Val Asp Glu Glu Gly Asp Lys Thr
100 105 110

Ile Met Thr Gly Leu Leu Gly Lys Gly Thr Asp Ile Glu Asp Gln Asp
115 120 125

Leu	Glu	Lys	Phe	Lys	Glu	Val	Thr	Arg	Glu	Asn	Gly	Ile	Pro	Glu	Glu
	130					135					140				
Asn	Ile	Val	Asn	Ile	Ile	Glu	Arg	Asp	Asp	Cys	Pro	Ala			
145					150					155					

HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC
LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING
SAID POLYPEPTIDES, AND APPLICATIONS THEREOF

- 5 The present invention relates to the demonstration of novel human odorant-binding proteins, hereafter named "OBPs", and also to the applications thereof, both therapeutically and non-therapeutically.
- 10 The present invention is based on the identification of a family of lipocalin genes, composed of three genes and two pseudogenes, on human chromosome 9q34; the three genes correspond to the LCN1 gene which has already been described and to two novel genes which are
- 15 the subject of the present invention and are called hOBPIIa and hOBPIIb. In addition, the invention is based on the attribution of novel functions to already known human lipocalins, through the demonstration of new areas of expression.
- 20 Although a certain number of OBPs have already been demonstrated (Pelosi *et al.*, 1996), such as the rat OBP for example (see in particular patent EP-0 335 654), the OBPs according to the present invention are human
- 25 OBPs which have a very large number of advantages, as will emerge from the remainder of the text, compared to the murine proteins.

- These OBP proteins of the lipocalin family have, as far
- 30 as some of them are concerned, been mentioned indirectly in patent WO 99/07740, but their OBP function has never been described to date; the same is also true of the proteins LCN1, retinol-binding protein (RBP) and apolipoprotein D (ApoD), as will be more fully explained
- 35 hereinafter.

Historically, the lipocalin family (Pervaiz and Brew, 1987), has been defined based on the human retinol-

binding protein (RBP) and on 3 other proteins: bovine β -lactoglobulin, rat $\alpha 2\mu$ -globulin and human $\alpha 1$ -microglobulin. From these reference proteins, and using sequence homologies, the lipocalin family has increased in size so as to now incorporate a large number of proteins, more than about 100, both in eukaryotes and in prokaryotes (Flower et al., 1995, 1996). This family consists of small proteins (160-190 amino acids) which contain a hydrophobic pocket and are generally secreted (Bocskei et al., 1992; Senoo et al., 1990, Zeng et al., 1996; Miller, 1998), although, in certain cases, they are proteins which remain associated with the membrane (Nagata et al., 1991). In vertebrates, the sequence identities between the various lipocalins are in the region of 20%; however, the sequence identities are greater for the orthologous proteins, and also for the recent paralogous genes described (Igarashi et al., 1992; Dewald et al., 1992).

The present invention relates to the isolated OBPII polypeptides encoded by the two new isolated human genes, OBPIIa and OBPIIb, located at the 9q34 locus; the invention also relates to the corresponding polynucleotide sequences, the corresponding mRNAs and also the regulatory promoter sequences which determine the expression profile in the various tissues and in particular in the secretory tissues. These two genes encode at least seven different polypeptides given the existence of alternative splicing of the transcripts.

The OBPIIa gene encodes at least 4 different polypeptides, named OBPII $\alpha\alpha$, OBPII $\alpha\beta$, OBPII $\alpha\gamma$ and OBPII $\alpha\delta$, and the OBPIIb gene encodes three different polypeptides, named OBPII $\beta\alpha$, OBPII $\beta\beta$ and OBPII $\beta\delta$. Even though one gene is mainly expressed, all the messenger forms are found in the nasal structure.

The subject of the present invention is therefore an isolated polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid

sequences SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14, and LCN1, ApoD and RBP.

- 5 It should be understood that the invention relates to the polypeptides obtained by purification from natural sources or obtained using recombinant techniques, as will be described subsequently; the invention also relates to the polypeptides obtained by chemical
- 10 synthesis, which may then comprise unnatural amino acids. In the present description, the term "polypeptide" will be used to denote equally a protein or a peptide.
- 15 The expression "percentage identity between the sequences" is intended to denote the percentage of amino acids which are identical between the sequences, obtained with the best possible sequence alignment, this percentage being purely statistical and the
- 20 differences between the polypeptides being distributed randomly and over the entire length.

The present invention also relates to an isolated polypeptide, characterized in that it comprises a polypeptide chosen from:

- 25 a) a polypeptide of sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14;
- 30 b) a polypeptide which is a variant of a polypeptide of amino acid sequences defined in a);
- 35 c) a polypeptide homologous to the polypeptide defined in a) or b) and comprising at least 90% identity with said polypeptide of a);
- d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);

e) a biologically active fragment of a polypeptide defined in a), b) or c).

- 5 The term "variant polypeptide" will be intended to mean all the mutated polypeptides which may exist naturally, in particular in humans, and which correspond in particular to truncations, substitutions, deletions and/or additions of amino acid residues. The variant
10 polypeptides according to the invention conserve at least one hydrophobic ligand-binding domain.

The term "homologous polypeptide" will be intended to denote the polypeptides exhibiting, compared to the
15 polypeptides of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 and SEQ ID No. 14, certain modifications, such as in particular a deletion, addition or substitution of at least one amino acid, a truncation, an extension and/or
20 a chimeric fusion. Among the homologous polypeptides, preference is given to those in which the amino acid sequence exhibits at least 90% identity, in preference 95%, preferably 97%, and even more preferably 99% identity with the amino acid sequences of the poly-
25 peptides according to the invention. In the case of a substitution, one or more amino acids, which may or may not be consecutive, are replaced with "equivalent amino acids". The expression "equivalent amino acid" is herein aimed at denoting any amino acid which can be
30 substituted for one of the amino acids of the basic structure, without however modifying the essential functional properties or characteristics of the corresponding polypeptides, their biological activities, such as for example the *in vivo* induction of antibodies
35 capable of recognizing the polypeptide, the amino acid sequence of which is included in the amino acid sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 10, SEQ ID No. 12 or SEQ ID No. 14, or a fragment thereof. These equivalent amino

- 5 -

acids may be determined either based on their structural homology with the amino acids for which they substitute, or based on the results of cross biological assays which the various polypeptides may produce. By way of
5 example, mention will be made of the possibilities of substitutions which can be made without their being, as a result of this, an extensive modification of the biological activities of the correspondingly modified polypeptides; for example, replacing leucine with
10 valine or isoleucine, aspartic acid with glutamic acid, glutamine with asparagine, arginine with lysine, etc., it naturally being possible to envision the reverse substitutions under the same conditions. Thus, it is possible to envision introducing certain modifications,
15 such as in particular a deletion, addition or substitution of at least one amino acid, into the alpha-helices of the protein without destroying the calyx formed by the structure composed of the beta-sheets; similarly, it is possible to introduce equivalent amino
20 acids which make it possible to conserve the hydrophobic nature of the beta-sheets. It may also be advantageous to introduce modifications into the sequence of the polypeptides of the invention in order to generate homologous polypeptides lacking protease sites.

25 The term "biologically active fragment" will be intended to denote, in particular, a fragment of amino acid sequence of a polypeptide according to the invention, exhibiting at least one of the functional properties or
30 characteristics of the polypeptides according to the invention, in particular in that: (i) it is capable of being recognized by an antibody specific for a polypeptide according to the invention or by antibodies produced by patients during an immune reaction; (ii) it
35 has at least one of the domains or regions as defined below; (iii) it is capable of binding a hydrophobic ligand and in particular odorous molecules, preferably pheromones; (iv) it is capable of specifically binding a receptor.

- 6 -

The term "polypeptide fragment" is intended to denote a polypeptide comprising a minimum of 15 amino acids, in preference 18 amino acids, preferably 25 amino acids and even more preferably 50 amino acids. The polypeptide fragments according to the invention, obtained by cleavage of said polypeptide with a proteolytic enzyme, or with a chemical reagent, or by placing said polypeptide in a very acid environment, are also part of the invention. When the intention is to use a sequence of 15, 18, 25 or 50 amino acids, this, of course, preferably involves the portions corresponding to functional epitopes of the above polypeptides, which may be integrated into a polypeptide with a longer structure, for example in the form of a fusion protein; this will depend on the intended uses of these polypeptides.

According to a preferred embodiment, the present invention relates to an isolated polypeptide selected from a polypeptide corresponding to the sequence SEQ ID No. 2 and named OBPII_{αα}, to the sequence SEQ ID No. 4 and named OBPII_{αβ}, to the sequence SEQ ID No. 6 and named OBPII_{αγ}, to the sequence SEQ ID No. 10 and named OBPII_{βα}, and to the sequence SEQ ID No. 12 and named OBPII_{ββ}.

The polypeptides according to the invention are characterized in that they preferably comprise the Gly-Thr-Trp-Tyr domain.

The invention also relates to the isolated polynucleotide characterized in that it encodes a polypeptide as described above. The polynucleotide according to the invention is chosen from the polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13.

The invention also relates to an isolated polynucleotide, characterized in that it comprises a polynucleotide chosen from:

- 5 a) a polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13, or the sequence of which is that of the RNA corresponding to the sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7,
10 SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13;
- b) a polynucleotide, the sequence of which is complementary to the sequence of a polynucleotide defined in a),
15 c) a polynucleotide, the sequence of which comprises at least 80% identity, in preference 90%, preferably 95%, and even more preferably 97% identity with a polynucleotide defined in a) or b),
20 d) a polynucleotide which hybridizes, under conditions of high stringency, with a sequence of a polynucleotide defined in a), b) or c),
- 25 e) a fragment of at least 15 consecutive nucleotides, in preference 21 consecutive nucleotides, and preferably 30 consecutive nucleotides, of a polynucleotide defined in a), b), c) or d).
- 30 In the present description, the terms "polynucleotide", "oligonucleotide", "polynucleotide sequence", "nucleotide sequence" or "nucleic acid" will be intended to denote a DNA fragment, both a double-stranded DNA, a single-stranded DNA and products for transcription of
35 said DNAs, and/or an RNA fragment, said synthetic or isolated natural fragments, possibly comprising unnatural nucleotides, denoting a precise chain of nucleotides, which may or may not be modified, making

- 8 -

it possible to define a fragment or a region of a nucleic acid.

The expression "polynucleotide of complementary sequence" is intended to denote any DNA, the nucleotides of which are complementary to those of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13, or a portion of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 or SEQ ID No. 13, and the orientation of which is reversed.

For the purpose of the present invention, the term "percentage identity" is intended to mean a percentage of bases which are identical between the polynucleotides, obtained after the best alignment, this percentage being purely statistical and the differences between the two polynucleotides being distributed randomly and over their entire length.

For the purpose of the present invention, the expression "hybridization under conditions of high stringency" means that the conditions of temperature and ionic strength are chosen such that they allow the hybridization between two complementary DNA fragments to be maintained. By way of illustration, conditions of high stringency for the hybridization step for the purposes of defining the polynucleotide fragments described above are advantageously as follows:

The DNA-DNA or DNA-RNA hybridization is carried out in two steps: (1) prehybridization at 42°C for 3 hours in phosphate buffer (20 mM, pH 7.5) containing 5 × SSC (1 × SSC corresponds to a solution of 0.15 M NaCl + 0.015 M sodium citrate), 50% of formamide, 7% of sodium dodecyl sulfate (SDS), 10 × Denhardt's, 5% of dextran sulfate and 100 µg/ml of salmon sperm DNA; (2) actual hybridization for 20 hours at a temperature which depends on the length of the probe (i.e.: 42°C for a

- 9 -

probe of length > 100 nucleotides), followed by 2 washes for 20 minutes at 20°C in 2 × SSC + 2% SDS, 1 wash for 20 minutes at 20°C in 0.1 × SSC + 0.1% SDS. The final wash is carried out in 0.1 × SSC + 0.1% SDS for 30 minutes at 60°C for a probe of length > 100 nucleotides. The high stringency hybridization conditions described above for a nucleotide of defined length will be adjusted by those skilled in the art for longer or shorter oligonucleotides, according to the teaching of Sambrook et al. (1989).

Advantageously, a nucleotide fragment corresponding to the above definition will have at least 15 consecutive nucleotides, preferably at least 21 nucleotides, and even more preferentially at least 30 consecutive nucleotides, of the sequence from which it is derived.

According to one embodiment of the invention, the polynucleotide according to the invention is characterized in that it is directly or indirectly labeled with a radioactive compound or a nonradioactive compound. The polynucleotide according to the invention is used as a primer for amplifying or polymerizing nucleic acid sequences; the invention also relates to the use of a polynucleotide according to the invention as a probe for detecting nucleic acid sequences. According to the invention, the polynucleotide fragments which may be used as a probe or as a primer in processes for detecting, identifying, titering or amplifying nucleic acid sequence will have a minimum length of 9 bases, preferably 18 bases, and even more preferably 36 bases. Finally, the invention relates to the use of a polynucleotide according to the invention as a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product, in this case a polypeptide according to the invention.

The unlabeled polynucleotide sequences according to the invention may be used directly as a probe, primer or

oligonucleotide; however, the sequences used are generally labeled so as to obtain sequences which can be used for many applications. The primers, probes and oligonucleotides according to the invention are labeled
5 with radioactive elements or with nonradioactive molecules; among the radioactive isotopes used, mention may be made of ^{32}P , ^{33}P , ^{35}S , ^3H or ^{125}I . The nonradioactive entities are selected from ligands, such as biotin, avidin, streptavidin or digoxigenin, haptens,
10 dyes and luminescent agents, such as radioluminescent, chemiluminescent, bioluminescent, fluorescent or phosphorescent agents.

The invention also comprises a method for detecting
15 and/or titering nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following steps: (i) isolating the DNA from the biological sample to be analyzed, or obtaining a cDNA from the RNA of the biological sample; (ii)
20 specifically amplifying the DNA encoding the polypeptide according to the invention using primers; (iii) analyzing the amplification products.

The invention also comprises a kit for detecting and/or
25 titering a nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following elements: (i) a pair of nucleic acid primers according to the invention, (ii) the reagents required to perform a DNA amplification reaction and,
30 optionally, (iii) a component for verifying the sequence of the amplified fragment, more particularly a probe according to the invention.

The invention also comprises a method for detecting
35 and/or titering nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following steps: (i) bringing a probe according to the invention into contact with a biological sample; (ii) detecting and/or titering the

- 11 -

hybrid formed between said probe and the DNA of the biological sample.

The invention also comprises a kit for detecting and/or
 5 titering nucleic acid according to the invention, in a biological sample, characterized in that it comprises the following elements: (i) a probe according to the invention, (ii) the reagents required to carry out a hybridization reaction and, where appropriate, (iii) a
 10 pair of primers according to the invention, and also the reagents required for a DNA amplification reaction.

The invention in particular relates to the methods according to the invention described above, for
 15 detecting and diagnosing cells of cancerous origin, and mainly breast, uterine, ovarian, prostate and lung cancers.

The polynucleotides according to the invention may thus
 20 be used as a primer and/or probe in processes using in particular the PCR (polymerase chain reaction) technique (Erlich, 1989; Innis et al., 1990, and Rolfs et al., 1991). This technique requires choosing pairs of oligo-nucleotide primers which border the fragment which must
 25 be amplified. Reference may, for example, be made to the technique described in American patent U.S. No. 4 683 202. The amplified fragments can be identified, for example after agarose or polyacrylamide gel electrophoresis or after a chromatography technique
 30 such as gel filtration or ion-exchange chromatography. The specificity of the amplification can be controlled by molecular hybridization using, as a probe, the nucleotide sequences polynucleotides of the invention, plasmids containing these sequences or products of
 35 amplification thereof. The amplified nucleotide fragments may be used as reagents in hybridization reactions in order to demonstrate the presence, in a biological sample, of a target nucleic acid of sequence

- 12 -

complementary to that of said amplified nucleotide fragments.

The invention is also directed toward the nucleotide fragments which can be obtained by amplification using primers according to the invention.

Other techniques for amplifying target nucleic acid may advantageously be used as an alternative to PCR (PCR-like), using pairs of primers of nucleotide sequences according to the invention. The term "PCR-like" will be intended to denote all methods using direct or indirect reproductions of nucleic acid sequences, or in which the labeling systems have been amplified; these techniques are of course known; in general, this involves amplifying the DNA with a polymerase; when the sample of origin is an RNA, a reverse transcription should be performed beforehand. There are currently a large number of processes for this amplification, such as for example the SDA (strand displacement amplification) technique (Walker *et al.*, 1992), the TAS (transcription-based amplification system) technique described by Kwoh *et al.* in 1989, the 3SR (self-sustained sequence replication) technique described by Guatelli *et al.* in 1990, the NASBA (nucleic acid sequence based amplification) technique described by Kievitis *et al.* in 1991, the TMA (transcription mediated amplification) technique, the LCR (ligase chain reaction) technique described by Landegren *et al.* in 1988 and improved by Barany *et al.* in 1991, which uses a heat-stable ligase, the RCR (repair chain reaction) technique described by Segev in 1992, the CPR (cycling probe reaction) technique described by Duck *et al.* in 1990, and the Q-beta-replicase amplification technique described by Miele *et al.* in 1983 and improved in particular by Chu *et al.* in 1986 and Lizàrdi *et al.* in 1988, and then by Burg *et al.* (1996) and also by Stone *et al.* (1996).

- 13 -

When the target polynucleotide to be detected is an RNA, for example an mRNA, use will advantageously be made, prior to carrying out an amplification reaction using the primers according to the invention or to carrying out a detection process using the probes of the invention, of an enzyme of the reverse transcriptase type in order to obtain a cDNA from the RNA contained in the biological sample. The cDNA obtained will then be used as a target for the primers or the probes used in the amplification or detection process according to the invention.

The nucleotide probes according to the invention hybridize specifically with a DNA or RNA molecule of a polynucleotide according to the invention, more particularly with the sequences SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 9, SEQ ID No. 11 and SEQ ID No. 13, under high stringency hybridization conditions as given in the form of a previous example.

The hybridization technique may be carried out in diverse ways (Matthews *et al.*, 1988). The most general method consists in immobilizing the nucleic acid extracted from the cells of various tissues or from cells in culture, on a support (such as nitrocellulose, nylon or polystyrene), and in incubating the immobilized target nucleic acid with the probe, under well-defined conditions. After hybridization, the excess probe is removed and the hybrid molecules formed are detected by the suitable method (measurement of the radioactivity, of the fluorescence or of the enzymatic activity linked to the probe).

According to another embodiment of the nucleic acid probes according to the invention, they may be used as a capture probe. In this case, a probe, termed "capture probe", is immobilized on a support and is used to capture, by specific hybridization, the target nucleic

acid obtained from the biological sample to be tested, and the target nucleic acid is then detected using a second probe, termed "detection probe", labeled with an easily detectable element.

In a preferred embodiment, the invention comprises the use of a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product. Among the advantageous nucleic acid fragments, mention should in particular be made of the antisense oligonucleotides the structure of which ensures, by hybridization with the target sequence, inhibition of the expression of the corresponding product. Mention should also be made of the sense oligonucleotides which, by interaction with proteins involved in regulating the expression of the corresponding product, will induce either inhibition or activation of this expression. The oligonucleotides according to the invention have a minimum length of 9 bases, preferably of 18 bases, and even more preferably 36 bases.

The term "expression vector" is intended to mean both autonomously replicating expression vectors of the 35 plasmid type and systems intended to ensure integration in the cells, but these expression vectors may also be expression vectors of the viral type or even, when the intention is to perform, for example, gene therapy, naked DNA. Among the viral vectors, preference is given

to those derived from adenoviruses, from adenovirus-associated viruses (AAVs), from retroviruses, from lentiviruses, and preferably HIV derivatives, from poxviruses and from the herpesvirus, for expression in
5 a eukaryotic system. Among the nonviral vectors, preference is given to naked polynucleotides, such as naked DNA or naked RNA according to the technique developed by the company VICAL, yeast artificial chromosomes (YACs) for expression in yeast, mouse
10 artificial chromosomes (MACs) for expression in murine cells and, preferably, human artificial chromosomes (HACs) for expression in human cells.

According to a particular embodiment, the vector
15 according to the invention comprises elements for controlling the expression of the polypeptides; these control elements are preferably chosen from (i) the promoter sequence of the hOBPIIa gene according to the invention, which corresponds to the sequence SEQ ID
20 No. 15 and/or from the promoter sequence of the hOBPIIb gene according to the invention, which corresponds to the sequence SEQ ID No. 16; (ii) a polynucleotide, the sequence of which is complementary to the sequence SEQ ID No. 15 and SEQ ID No. 16; (iii) a polynucleotide,
25 the sequence of which comprises at least 80% identity with a polynucleotide defined in ((i) or (ii)); (iv) a polynucleotide which hybridizes, under conditions of high stringency, with the polynucleotide sequence defined in (i), (ii) or (iii).

30 The computer tools available to those skilled in the art allow them to easily identify the regulatory promoter boxes required and sufficient to control the gene expression, in particular the TATA, CCAAT and GC
35 boxes, and also the stimulatory (enhancer) or inhibitory (silencer) regulatory sequences which control, in CIS, the expression of the genes according to the invention; among these regulatory sequences, mention should be made of IRE, MRE and CRE.

It is also within the scope of the invention to use the elements defined above and chosen from the sequence SEQ ID No. 15 and SEQ ID No. 16, for controlling the expression of heterologous polypeptides other than those of the invention, and in particular for directing the expression of heterologous polypeptides in the cell types in which the polypeptides according to the invention are normally expressed.

The invention also comprises the host cells, in particular the eukaryotic and prokaryotic cells, characterized in that they are transformed with the vectors according to the invention. The host cells are preferably transformed under conditions which allow the expression of a recombinant polypeptide according to the invention. The host cell may be chosen from bacterial cells, but also from yeast cells and from plant and animal cells; the host cell is preferably a mammalian cell (Edwards and Aruffo, 1993), but also an insect cell in which it is possible to use processes which use baculoviruses for example (Luckow, 1993). These cells may be obtained by introducing into host cells a nucleotide sequence inserted into a vector as defined above, and then culturing said cells under conditions which allow the replication and/or expression of the transfected nucleotide sequence.

According to a particular embodiment, the invention also relates to a transgenic animal or plant which comprises host cells according to the invention.

The invention also relates to a method for preparing a polypeptide, characterized in that it uses a vector according to the invention. More particularly, the invention relates to a method for preparing a recombinant polypeptide, characterized in that transformed cells according to the invention are cultured under conditions which allow the expression of said

- 17 -

recombinant polypeptide, and in that said recombinant polypeptide is recovered.

5 The polypeptide according to the invention can be obtained according to a process of the invention and according to the techniques for producing recombinant polypeptides known to those skilled in the art. The present invention therefore relates to the recombinant polypeptide which can be obtained using the method
10 presented above. In this case, the nucleic acid sequence used is placed under the control of signals which allow its expression in a host cell. An effective system for producing a recombinant polypeptide requires a vector, for example of plasmid or viral origin, and a
15 compatible host cell. The vector must comprise a promoter, translation initiation and termination signals, and also suitable regions for regulating transcription. It must be possible for it to be maintained stably in the cell and it may, optionally,
20 contain particular signals which specify secretion of the translated polypeptide. These various control signals are chosen as a function of the host cell used. To this effect, the nucleic acid sequences according to the invention may be inserted into vectors which
25 replicate autonomously in the host chosen, or vectors which integrate in the host chosen. Such vectors will be prepared according to the methods commonly used by those skilled in the art, and the clones resulting therefrom may be introduced into a suitable host using
30 standard methods, such as for example transfection by calcium phosphate precipitation, lipofection, electroporation or heat shock.

35 The recombinant polypeptides obtained as indicated above may be both in the glycosylated form and nonglycosylated form, and may or may not have the natural tertiary structure.

- 18 -

- The polypeptides obtained by chemical synthesis and possibly comprising unnatural amino acids, corresponding to said recombinant polypeptides, are also included in the invention. The peptides according to the invention
- 5 may also be prepared using techniques which are conventional in the domain of peptide synthesis. This synthesis may be performed in homogeneous solution or in solid phase.
- 10 The recombinant polypeptide purification processes used are known to those skilled in the art. The recombinant polypeptide may be purified from cell lysates and extracts, and/or from the culture medium supernatant, by methods used individually or in combination, such as
- 15 fractionation, chromatography methods, immunoaffinity techniques using specific monoclonal or polyclonal antibodies, etc. A preferred variant consists in producing a recombinant polypeptide fused to a "carrier" protein (chimeric protein). The advantage of
- 20 this system is that it allows stabilization and a decrease in the proteolysis of the recombinant product, an increase in solubility during the *in vitro* renaturation and/or simplification of the purification when the fusion partner has affinity for a specific
- 25 ligand.

The present invention relates to the use of a polypeptide chosen from an hOBPIIa and hOBPIIb polypeptide according to the invention, or a fragment thereof, and

30 from LCN1, retinol-binding protein (RBP) and apolipoprotein D (ApoD), as a protein which binds to a hydrophobic ligand, preferably an odorous molecule. In fact, besides the OBPII polypeptides mentioned above, the OBP function of the lipocalins LCN1, RBP and ApoD

35 has never been suggested. Specifically, while the presence of LCN1 in the nasal mucus has been described (Redl et al., 1992), it was, in fact, attributed another function, namely an antiprotease function, whereas the main function of the LCN1 protein purely

- 19 -

appears to be the transport of hydrophobic ligands; moreover, the tests carried out in the context of the present invention with a recombinant LCN1 protein have not made it possible to demonstrate antiprotease activity. The same is true for retinol-binding protein and apolipoprotein D, which have never been presented as having OBP function.

The present invention also relates to the use of a polypeptide according to the invention or a fragment thereof, LCN1, RBP and apolipoprotein D as a competitive inhibitor, as an agonist or as an antagonist of the cellular receptors for lipocalins. The use of an inhibitor of the binding of lipocalins to their receptor may be employed in an anticancer strategy; specifically, a certain number of tumors are hormone-dependent: thus, breast tumors are sensitive to steroids; since the steroids are transported by lipocalins, it is within the scope of the invention to provide inhibitors of binding to the polypeptides according to the invention and LCN1, OBP or APO-D to avoid the binding of steroid hormones to the receptors of tumor cells.

The invention also relates to a monoclonal or polyclonal antibody and fragments thereof, characterized in that they specifically bind a polypeptide according to the invention. Chimeric antibodies, humanized antibodies and single-chain antibodies are also part of the invention. The antibody fragments according to the invention are preferably Fab or F(ab')₂ fragments.

The polypeptides according to the invention make it possible to prepare monoclonal or polyclonal antibodies. The monoclonal antibodies may advantageously be prepared from hybridomas according to the technique described by Kohler and Milstein in 1975. The polyclonal antibodies may be prepared for example by immunizing an animal, in particular a mouse, with a

- 20 -

polypeptide according to the invention combined with an adjuvant of the immune response, and then purifying the specific antibodies contained in the serum of the immunized animals on an affinity column to which the polypeptide having been used as the antigen has been attached beforehand. The polyclonal antibodies according to the invention may also be prepared by purification on an affinity column on which a polypeptide according to the invention has been immobilized beforehand.

The invention also relates to a monoclonal antibody specific for a polypeptide according to the invention and capable of inhibiting the interaction between said polypeptide and the cellular receptor to which said polypeptide specifically binds. According to another embodiment, the monoclonal antibody according to the invention is capable of inhibiting the interaction between said polypeptide and its hydrophobic ligands, in preference the odorous molecules, and preferably the pheromones, to which said polypeptide binds.

The antibodies of the invention may also be labeled in the same way as described previously for the nucleic acid probes of the invention, and preferably with labeling of the enzymatic, fluorescent or radioactive type. Such labeled antibodies may be used to detect these polypeptides in a biological sample. The biological sample preferably consists of a fluid, for example human biopsies, serum or blood. They thus constitute a means for analyzing the expression of the polypeptide according to the invention, for example by immunofluorescence and/or gold-labeling, and/or with enzymatic immunoconjugates.

More generally, the antibodies of the invention may advantageously be used in any situation in which the expression of a polypeptide according to the invention is to be observed, and more particularly in immunocytochemistry, in immunohistochemistry or in Western

- 21 -

blotting experiments, or in ELISA and RIA techniques. It is thus within the scope of the invention to provide a method for detecting and/or titering a polypeptide according to the invention, in a biological sample, characterized in that it comprises the steps of bringing the biological sample into contact with antibodies according to the invention, and then revealing the antigen-antibody complex formed.

- 10 Also falling within the context of the invention is a kit for detecting and/or titering a polypeptide according to the invention, in a biological sample, characterized in that it comprises the following elements: (i) a monoclonal or polyclonal antibody as described above; (ii) where appropriate, the reagents for constituting the medium suitable for the immunological reaction; (iii) the reagents for detecting the antigen-antibody complexes produced by the immunological reaction. This kit is in particular useful for carrying out Western blotting experiments and for immunoprecipitation experiments.

The hOBPIIs according to the present invention may be used in many applications.

- 25 The first applications of the OBPs lie in the control of odorants; these applications essentially concern personal hygiene (perfumery, cosmetology, pharmacy) or general hygiene.

- 30 They may be used in a process for controlling the volatilization of an odorant; such a process is characterized in that it comprises a step of binding of said odorant with a polypeptide according to the invention or with the LCN1, RBP or apolipoprotein D proteins.

It is also possible to bind the odorant to a solid support using an OBPII according to the invention

The invention also relates to a process for screening a molecule, preferably odorants or flavors, which comprises passing the molecule over a substrate which comprises a polypeptide according to the invention or

5 LCN1, RBP and apolipoprotein D, bound to said substrate, said polypeptide binding said odorant or flavor, and recovering said odorant or flavor from the polypeptide if necessary. The OBPs according to the invention may thus make it possible to isolate odorants

10 or fragrances, by binding them to a support as described above but which, in this case, may be, for example, a chromatography column, by passing over this column the product from which it is desired to capture the odorants. It is, of course, possible, still in this

15 same type of application, to carry out an analysis of a complex fragrance using the differences in retention of the various products by the OBPs.

The isolation process described above may also be used

20 to separate particular "odorants", especially human pheromones.

The hOBPIIs according to the present invention may be used for agrofoods or industrial applications.

25 The OBPs according to the present invention, by virtue of their characteristics, may make it possible to solubilize certain lipophilic molecules by associating them with said OBPs. Thus, the polypeptides according to the invention may be used in combination with

30 dietary fatty acids by way of a food supplement. The present invention relates to a process for solubilizing lipophilic molecules, characterized in that it comprises binding said lipophilic molecule to a

35 polypeptide according to the invention, to LCN1, to RBP or to apoD.

The OBPIIs, like LCN1, RBP and ApoD, may be involved in the transport of fatty acids and in the biological

- 24 -

mechanisms for detecting the fatty acid load of the food intake, in particular in the buccal region. The invention therefore also relates to the use of the polypeptides above, in combination with fatty acids, for decreasing the consumption of fatty acids, in particular in hyperlipidemias or in obesity. The polypeptides above may therefore be used for treating hyperlipidemias and obesity. Specifically, these proteins contribute to the detection of the fatty acid content in the food taken in (Gilbertson, 1998); an excess of these proteins should lead to the physiological system which detects the fatty load of a food intake being deceived. Thus, a food portion which is low in fat but supplemented with OBP, ApoD, RBP or LCN1 pre-loaded with fatty acid will be falsely identified as being rich in fat.

Another application is to supplement a nonmaternal milk with one or more of the polypeptides described above.

The OBPs according to the present invention may be used in preventive and curative therapy.

Thus, a lack of detection of this type of protein in a biological specimen using an antibody, a primer and/or a probe according to the invention may be an element for the diagnosis of anosmia.

Similarly, it is possible to envision the detection of anti-OBPII antibodies in a biological sample of human origin; the presence or the titer of these antibodies may be related to certain types of allergy, in particular in asthmatics. In this case, it may be possible to treat this type of allergy by administering polypeptide fragments as described, which would decrease the immune reactions to the external allergies.

- 25 -

The invention therefore relates to a process for detecting antibodies against human OBPIIs (hOBPIIs) in human serum from an allergic and/or asthmatic patient using an hOBPII polypeptide according to the invention.

5 According to another embodiment, the invention relates to a process for detecting antibodies against human OBPIIs (hOBPIIs) in a biological fluid from a patient suffering from a cancer, and in particular from
10 prostate cancer and/or from breast cancer and/or from uterine cancer and/or from ovarian cancer and/or from lung cancer. Specifically, the proteins according to the invention are overexpressed in tumors, and in particular in prostate cancer (US 5804368, WO 97 10503,
15 CS 84 02898, CS 83 02012, CS 82 08506, CS 82 08215), breast cancer (Stoecz and Gould, 1995; Simard *et al.*, 1992), uterine cancer, ovarian cancer and lung cancer.

The OBPs according to the present invention may also be
20 used in pharmaceutical compositions, this being in particular in order to deliver certain drugs.

In fact, lipocalins are used by mammals to transport hydrophobic molecules in biological fluids. It even
25 appears that they are the natural transporters of xenobiotics *in vivo*. For example, an experimental overload of xenobiotics creates, in male rats, tumors in the proximal convoluted tube (PCT) of the nephron (Borghoff *et al.*, 1990). Specifically, the MUP proteins,
30 only produced in male rats, are reabsorbed by the PCT cells; after lysosomal degradation, the MUP proteins release the xenobiotics which they were transporting. These xenobiotics accumulate in these cells and lead them toward a tumor pathway by mutagenesis. Lipocalins
35 therefore appear to be the ideal structure to trap, in their calyx, a molecule used as a medicinal product, thus avoiding a general distribution thereof. Thus, G. Beste *et al.* (1999) and application WO 99 16873 describe a strategy of mutagenesis and screening

- 26 -

variants of a lipocalin having optimum affinity for a given ligand. It is therefore possible to create a highly specific "medicinal product cage".

5 The present invention therefore relates to a polypeptide according to the invention, as an agent for targeting a pharmaceutical compound. The expression "agent for targeting" is intended to denote the polypeptides of the invention capable of transporting and releasing the
10 ligand to which they are bound, at the level of certain target tissues or cells which have, at their surface, receptors for said polypeptides. Thus, the invention relates to the transport of a medicinal product in the cage of a polypeptide according to the invention, and
15 targeting cells through the ability of the OBPII to bind to a specific receptor.

It is also within the scope of the invention to develop fusion proteins or chimeric proteins comprising the
20 cage corresponding to the lipocalins according to the invention combined with a protein which allows specific cellular addressing, generally different from that which is natural for the OBPIIs. A subject of the present invention is therefore a polypeptide, characterized in that said polypeptide is expressed in the
25 form of a protein from fusion with a protein which allows specific cellular addressing. Among the proteins which allow specific cellular addressing, mention should be made of interleukins, of cytokines, of
30 lymphokines, of chemokines, of growth factors, of hormones, and of monoclonal or polyclonal antibodies. The interleukins, cytokines and lymphokines are chosen from a group preferably composed of the interleukins II-1 to II-20, and the interferons α -IFN, β -IFN and
35 γ -IFN. The growth factors are preferably chosen from the colony stimulating factors G-CSF, GM-CSF, M-CSF, and erythropoietin. The hormones are preferably chosen from steroid hormones.

According to another embodiment, the polypeptide according to the invention, as an agent for targeting a pharmaceutical compound, is combined with a molecule which allows specific cellular addressing. Among the molecules which allow specific cellular addressing, mention should be made of the group of steroids, of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies. The molecule is preferably a steroid. The combination of the polypeptide according to the invention and said molecule is produced either via a noncovalent attachment, using for example the avidin-biotin system, or via a covalent attachment, using for example chemical bridging agents.

Among the pharmaceutical compounds which the polypeptide according to the invention may transport and target, mention should be made of medicinal products, and in particular anticancer agents. The anticancer agents are selected from the group of antiproliferative, antineoplastic or cytotoxic agents, and are used to arrest the development of cancers and to induce regression and/or elimination of the tumor mass. These anticancer agents are preferably radioisotopes, and even more preferably gamma-ray-emitting radioisotopes, such as iodine¹³¹, yttrium⁹⁰, gold¹⁹⁹, palladium¹⁰⁰, copper⁶⁷, bismuth²¹⁷ and antimony²¹¹. Beta- and alpha-ray-emitting radioisotopes may also be used for the therapy. The non-isotopic anticancer agents bound to the polypeptide according to the invention are many and varied; mention may be made of: (i) antimetabolites, such as antifolate agents, methotrexate, (ii) purine and pyrimidine analogs (mercaptapurine, fluorouracil, 5-azacytidine), (iii) antibiotics, (iv) lectins (ricin, abrin) and (v) bacterial toxins (diphtheria toxin); the toxins are preferably chosen from *Pseudomonas* exotoxin A, diphtheria toxin, cholera toxin, *Bacillus anthrax* toxin, Pertussis toxin, *Shigella* Shiga toxin,

Shiga-like toxin, *Escherichia coli* toxins, colicin A, d-endotoxin and *Haemophilus A* hemagglutinin.

5 The invention also relates to a pharmaceutical composition comprising a pharmaceutical compound bound to at least one polypeptide according to the invention, and a pharmaceutically acceptable vehicle. It is also within the scope of the invention to increase the binding capacity by mutagenesis of this same protein. The
10 invention also relates to a pharmaceutical composition as defined above, for treating cancer, and in particular prostate cancer, breast cancer, uterine cancer, ovarian cancer, liver cancer and pulmonary epithelial cell carcinoma. Given that the OBP named
15 hOBPIIb, apolipoprotein D, RBP and α -1-acid glycoprotein are expressed in the prostate, the pharmaceutical composition according to the invention is intended for the treatment of prostate cancer. Similarly, given that it has been demonstrated that the
20 mRNA of the ApoD, RBP and LCN1 proteins is produced in the mammary gland, in addition to the production of hOBPIIb already described in application WO 99 07740, the pharmaceutical composition according to the invention is intended for the treatment of breast
25 cancer.

The invention also relates to a polypeptide according to the invention, as a pharmaceutical compound transporter. The term "transporter" is intended to
30 denote polypeptides according to the invention capable of vehicling a pharmaceutical compound, in the body, without said compound being released at a preferred site in the body. Such a polypeptide constitutes a means for delivering said pharmaceutical compound in
35 the body.

The present invention also relates to a pharmaceutical composition according to the invention, characterized

in that said polypeptide constitutes a delayed form of delivery of said pharmaceutical compound in the body.

According to another aspect, the invention relates to a compound characterized in that it is chosen from an antibody, a polypeptide, a ligand, a polynucleotide, an oligonucleotide and a vector according to the invention, as a medicinal product, and in particular as active principles of a medicinal product; these compounds will preferentially be in soluble form, and combined with a pharmaceutically acceptable vehicle. The term "pharmaceutically acceptable vehicle" is intended to denote any type of vehicle conventionally used in the preparation of injectable compositions, i.e. a diluent and/or a suspending agent, such as an isotonic or buffered saline solution. These compounds will preferably be administered systemically, in particular intravenously, intramuscularly, intradermally or orally. Their optimal methods of administration, doses and pharmaceutical forms may be determined according to the criteria generally taken into account

- 31 -

fetal blood and to the general blood circulation of the fetus.

In addition, the polypeptide according to the invention
 5 may be used to transport a compound from the fetus to the gestating mother. Specifically, the fetus secretes, via the villi of the nasal structures, polypeptides according to the invention which participate in molecule exchanges between the fetus and the mother at
 10 the amniotic membrane. An object of the present invention is therefore also to provide the fetus with polypeptides according to the invention so as to allow the transport of compounds present in the fetus, for example xenobiotics, to the placenta and/or to the
 15 amniotic membrane, in order to allow the detoxification of the fetus.

According to another aspect of the invention, the polypeptide according to the invention may be used as a
 20 pregnancy marker. Specifically, the polypeptide according to the invention is present in various biological liquids of the mother, such as the urine or blood; measuring the concentration thereof and/or the presence thereof constitutes a pregnancy marker. In
 25 this capacity, this marker may be used with, or in place of, or in addition to the pregnancy marker constituted by human chorionadotrophin, hCG; the polypeptide according to the invention and hCG are, in fact, molecules which are secreted by the trophoblastic
 30 placental cells.

Finally, according to another aspect of the invention, the polypeptide may be used as a marker for fetoplacental pathological conditions. It may constitute a
 35 marker for the rupture of the amniotic sack membrane.

Other characteristics and advantages of the invention appear in the remainder of the description with the

examples and the figures, the legends of which are represented below.

5

The top line represents the region of chromosome 9q34. The double-headed arrow indicates the gap between the location of the polymorphic markers D9S1811 and D9S67; the relative position of the markers D9S67 and D9S1826 is uncertain.

The middle level indicates the partial organization of the cosmids at 3 different loci: LCN1c, LCN1b-hOBB_{IIb}, LCN1-hOBB_{IIa}. The cosmids (approximately 40 kb) are represented by horizontal lines with their name and the arms of the T3 and T7 vectors noted below the line. The arrows represent the various genes or pseudogenes with their respective orientation. In the cosmids, the vertical dotted lines represent the EcoRI sites. The symbol ⊗ indicates an uncertain orientation of the locus.

The bottom level shows the intron/exon structures of the LCN1 and hOBPII genes: the black boxes represent the exons; the arrows represent the transcription initiation site; ol1 to ol5 represent the oligonucleotide probes used to screen the cosmids; Alu represents the presence of repeat sequences.

30 **FIGURE 2: Dot Plot Analysis of:**

(A) sequence of the LCN1-hOBPIIa locus (AC000396+ACXXXXX) versus the LCN1b-hOBPIIb locus (AC002098):

(B) sequence of the LCN1-hOBPIIa locus (AC000396+ACXXXXX) versus the sequence of the LCN1c locus:

35 (C) sequence of the LCN1b-hOBPIIb locus (AC002098)
versus the sequence of the LCN1c locus (AC002106).

Genomic sequences were filtered for the repetitive sequences using "Repeatmasker" (REF), and then compared

- 33 -

and dotplotted with the program gcg using a window size of 25, and a criterion of 20 with an 80% homology.

FIGURE 3: Nucleotide sequence of hOBPII genes

5 The upper lines represent the hOBPIIa sequence and the lower lines represent the hOBPIIb sequence for which only the different nucleotides are represented; a dash indicates the absence of corresponding sequences. The shaded capitals are the exon sequences and the lower case letters are the intron sequences. The sizes indicated on the left are indicated in bp. The TATA box is in bold characters and the polyadenylation signal is underlined. The boxes indicate the splice acceptor sites for exons 5, 5b and 5c.

FIGURE 4: Diagrammatic representation of the two hOBPII genes and of their corresponding mRNAs

20 The horizontal lines represent the exon/intron organization with sizes indicated in bp. The shaded boxes numbered from 1 to 7 are the coding exon sequences of the main transcripts; the letters b and c refer to supernumerary exons. The various transcripts are represented using assembled boxes: the first, hOBPIIa α and hOBPIIb α , correspond to the main transcripts, the others correspond to the forms derived from alternate splicing. ↓ indicates a shift in the reading frame resulting from the insertion or from the deletion of an exon and * represents a stop codon. The letter "a" represents an α -helix and "b" β -sheets predicted by the DSC program. The letters in italics are predictions obtained with the "Predator" program.

35 **FIGURE 5: Alignment of the protein sequences derived from the two human genes hOBPIIa and hOBPIIb (hOBPIIa α = OBP2aaHOMS, hOBPIIb α = OBP2baHOMSA, hOBPIIb β = OPB2bbHOMSA, hOBPIIa γ = OBP2agHOMSA, hOBPIIa β = OBP2abHOMSA), of human tear lipocalins (LCN1_HOMSA), of**

- 34 -

rat OBPII (OBP2_RATNO), of bovine lactoglobulin BLG (LACB_BOSTA), of mouse MUP (MUP6_MUSMU), of human RBP (RBP_HOMSA), of bovine OBP (OBP_BOSTA), of rat MUP (MUP_RATNO) and of porcine OBP (OBP_SUSSC).

5

The residues in the dark gray boxes are identical and those in the light gray boxes are similar. The elements of secondary structure predicted with the DSC program are underlined and the amino acid residues are in italics. The β -sheets and the α -helices are numbered for hOBPIIa and b. The anticipated signal peptide cleavage site is indicated with an arrow (AAA↓LS) at position 15. Nonaligned sequences of very divergent forms of spliced genes, hOBPa δ (OPB2adHOMSA) and hOBPb (OBP2bgHOMSA) have been added at the bottom of the alignment after the analysis.

10
15

FIGURE 6: RT-PCR analysis

(A) Detection of the LCN1, LCN1b and LCN1c RT-PCR products with their specific probes, and (B) detection of the hOBPIIa and hOBPIIb RT-PCR products with their specific probes. (C) Control G3PDH RNA. The sizes are indicated in bp.

20
25

FIGURE 7: Tissue location of the hOBP mRNAs

Sections of the middle meatus (A, B), of the conchae (C, D), of the prostate (E, F), of the vas deferens (G, H), and of the mammary glands (I, J) were hybridized with digoxigenin-11-UTP-labeled hOBP riboprobes. The hybridization with a sense hOBP riboprobe did not reveal any signal (B, D, F, H, J). A specific hybridization signal is obtained with an antisense riboprobe (A, C, E, G, I). The arrows indicate different structures: AC: acinar cells, EC: epithelial cells, GC: glandular cells, SD: secretory duct and L: lumen (X200).

30
35

- 35 -

FIGURE 8: Phylogenetic distance tree for vertebrate lipocalins

The usual abbreviations for lipocalins were used. Indicated after the symbol "_" are the first three letters of the genus followed by the first two letters of the species.

FIGURE 9: Scheme of the evolution of the LCN1-OBPII gene subfamily during evolution

The boxes indicate the exons arranged on a line representing the genomic DNA. The "/" between the lines indicate that the loci are not consecutive, without it being possible to determine the order. The large cross under the symbol "?" illustrates a partial duplication or complete duplication event with a subsequent genomic deletion for the LCN1c locus (choice indicated by the symbol "*"). The smallest cross indicates the removal of the seventh exon which appears to be specific for humans because of the numerous repeat sequences Alu present in this genomic region and because the rat has two VEGP genes. The symbol "***" marks the exon recruitment step based on the data present and those of the literature; this step may have appeared at any time after the duplications of the loci and may have been sequential.

FIGURE 10: RT-PCR analysis, in the oral sphere and the genital sphere, of the expression of the other known human lipocalins

Definition of novel OBP and VEGP functions for the RBP (retinol-binding protein) and ApoD (apolipoprotein D) proteins.

FIGURE 11: Study of the polyclonal antibody against the hOBPII proteins

FIGURE 12: Immunohistochemistry on the tissues of the olfactory apparatus

FIGURE 13: Immunohistochemistry on tissues of the oral sphere

FIGURE 14: Immunohistochemistry on the mammary glands and lung

- 37 -

control (C) prepared using pre-immune serum. Strong immunoreactivity is also observed on the sections of lung (E and F), again compared to the negative control (D). Each observation is made at a magnification of X 100 for A and C and at a magnification of X 200 for B, D, E and F.

FIGURE 15: Demonstration of the hOBPII proteins in various nasal structures: concha (A: 200x, B: 400x), septum (C: 300x, D: 600x), middle meatus (E: 400x, F: 600x)

Detection of the hOBPII proteins with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. AC: secretory acinar cell, P: DAB precipitate (hOBPII detection).

FIGURE 16: Demonstration of the LCN1 protein in various nasal structures: concha (A: 200x, B: 500x), septum (C: 100x, D: 500x), middle meatus (E: 200x, F: 600x)

Detection of the LCN1 protein with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. AC: secretory acinar cells, P: DAB precipitate (LCN1 detection).

FIGURE 17: Demonstration of the ApoD protein in various nasal structures: concha (A: 500x, B: 700x), septum (C: 300x), middle meatus (D: 400x)

Detection of the ApoD protein with a mouse monoclonal antibody revealed by peroxidase activity detected by DAB. AC: secretory acinar cell, P: DAB precipitate (ApoD detection).

FIGURE 18: Demonstration of the hOBPII protein in various structures of the oral sphere: lacrymal gland (A: 200x, B: 600x), von Ebner's glands (C: 100x, D: 400x), lung (E: 200x, 800x)

Detection of the hOBPII protein with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. AC: secretory acinar cell, P: DAB precipitate (hOBPII detection).

FIGURE 19: Demonstration of the hOBPII proteins in various placental structures: chorionic villi (A: 300x, B: 800x), amniotic membrane (C: 800x), cord (D: 600x)

Detection of the hOBPII proteins with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. L: lacuna (contains maternal blood), C: fetal capillary, Am: amniotic membrane, E: epithelial cells derived from the extra-embryonic ectoblast, MB: basement membrane, M: mesenchymal layer, P: DAB precipitate (hOBPII detection).

FIGURE 20: Demonstration of the LCN1 protein in various placental structures: chorionic villi (A: 200x, B: 800x), amniotic membrane (C: 600x), cord (D: 500x)

Detection of the LCN1 protein with a rabbit polyclonal serum revealed by peroxidase activity detected by DAB. L: lacuna (contains maternal blood), C: fetal capillary, Am: amniotic membrane, E: epithelial cells derived from the extra-embryonic ectoblast, MB: basement membrane, M: mesenchymal layer, P: DAB precipitate (LCN1 detection).

FIGURE 21: Demonstration of the ApoD protein in various placental structures: chorionic villi (A: 100x, B: 500x), amniotic membrane (C: 400x), cord (D: 400x)

- 5 Detection of the ApoD protein with a mouse monoclonal antibody revealed by peroxidase activity detected by DAB. L: lacuna (contains maternal blood), C: fetal capillary, Am: amniotic membrane, E: epithelial cells derived from the extra-embryonic ectoblast, MB: basement
10 membrane, M: mesenchymal layer, P: DAB precipitate (ApoD detection).

EXAMPLES

15 **EXAMPLE 1: MATERIALS AND METHODS**

1.A. Human chromosome 9 cosmid library

- A copy of the library of cosmids specific for human
20 chromosome 9, LL09NC01P, constructed by Dr. J. Allmaman (Biochemical Sciences Division, Lawrence Livermore National Library, Livermore, CA USA) under the aegis of the National Gene Library Project, supported financially by the American Department of Energy, was used. The
25 library was screened and the clones analyzed as previously described (Lacazette et al., 1997).

1.B. Cloning and sequence analysis

- 30 A Lambda gt11 human testes cDNA library (Clontech) (10^7 p.f.u.) was amplified by 30 polymerase chain reaction (PCR) cycles (94°C 45 sec, 54°C 45 sec, 72°C 1 min 30 sec) with the primer oliEST58 CCTGCAGGTACATGAGCTTCC and 5' or 3' screening amplimers for inserts located on
35 the arms of the lambda gt11 vectors. A nested PCR was then carried out with oliEST26 CGCTGTATTGCGCAGGCTCC and oligonucleotides specific for the arm of the vector. The PCR products were subcloned into the pGEM-T(r)

vector, which made it possible to obtain the 5' end of the hOBPII gene cDNAs.

- The sequences obtained using the standard oligonucleotide pGEM-T(r) and a dye terminator-based sequencing ready reaction mix (Applied Biosystems) were separated by electrophoresis using an ABI PRISM 377 automatic sequencer (Perkin Elmer) and were then analyzed with the sequence navigator 1.0.1. software (Perkin Elmer).
- Full length cDNA clones of hOBPIIa (hOBPIIa α , hOBPIIa β , hOBPIIa δ , hOBPIIa γ) and hOBPIIb (hOBPIIb α , hOBPIIb β , hOBPIIb γ) were obtained from the RT-PCR by purifying the bands of interest according to the manufacturer's instructions (Qiagen gel extraction kit) or, for the weakly expressed alternative forms, by subcloning the nested PCR products into a pGEM-T(r) vector.

1.C. RT-PCR analysis

- Tissue samples were collected from 45 to 55 year old Caucasian individuals, in agreement with the French regulations in force. The total RNA is extracted according to a single-step method using the RNA NOW[®] reagent, according to the manufacturer's (Biogentex) instructions. 5 μ g of total RNA were reverse-transcribed in a final volume of 20 μ l using 0.5 ng of oligonucleotide GACTCGAGTCGACATCGATTTTTTTTTTTTTTTT with the Superscript[®] preamplification system (Gibco BRL). Three μ l of these reactions were then used for the following PCRs. The expression of the specific mRNAs was determined by PCR using: the primers TL: CCTCTCCCAGCCCCAGCAAG and AP: GACTCGAGTCGACATCG for the LCN1-type genes (LCN1, LCN1b, LCN1c) and, for the hOBPII-type genes, the primers DE: CGCCCAGTGACCTGCCGAGGTC, and FI: CTTTATTTGGAGTCAGGTGGGTG. As a quality control for the RNAs the primers G3PDH1: CTCTGCCCCCTCTGCTGATG and G3PDH2: CCTGCTTACCACCTTCTTG for the G3PDH gene were used; the G3PDH gene is considered to be constitutively

- 41 -

expressed in all cell types. 32 PCR cycles (94°C 45 sec, 54°C 45 sec, 72°C 2 min 30 sec) were performed and the amplification products were separated on 1% agarose gel. The DNA was transferred onto a Hybond N⁺® membrane.

For the detection of the expression of the various genes, several oligonucleotides specific for the respective genes were synthesized:

- o1LCN1: GACTCAGACTCCGGAGATGA,
- o1LCN1b: AACTCAGACACCAGAGATGA,
- o1LCN1c: GACTCAGATCCCGGAGATGA,
- o15: CCAGGAGGGACCACTACA specific for the hOBPIIb gene,
- o14: CCGGGACGGACGACTACG specific for the hOBPIIa gene,
- G3PDH3: CTCATGACCACAGTCCATGC.

The oligonucleotides are labeled with γ^{32} P-ATP using T4 kinase (Applied Biosystem); the labeled oligonucleotide hybridizations are performed at 42°C. The final wash is performed in a solution of 0.1 X SSC, 0.1% SDS at 48°C for 20 min. The specificity of the oligonucleotide hybridization reactions is controlled using samples of digested cosmid DNA (p233G2 for LCN1 and hOBPIIa, P19E7 for LCN1b and hOBPIIb, and P181A9 for LCN1c) loaded onto the gel with RT-PCR products.

1.D. Genotyping and linkage analysis

The genotyping is carried out with PCR reactions using 100 ng of genomic DNA originating from 8 CEPH reference families, and using the oligonucleotides oli9 TGTTCCGGGAACGCAGCTT and oli10a TGCCGCTGTCCCCACGTCGG. The thermocycler parameters consist of an initial cycle at 94°C for 10 min followed by 30 cycles at 94°C for 30 sec, 55°C for 30 sec and 70°C for 45 sec, and then a final elongation step of 10 min at 70°C. The PCR products are then analyzed on a 3% agarose gel. The information regarding the markers for chromosome 9 may

be obtained at the following internet address ([HTTP://galton.ucl.ac.uk](http://galton.ucl.ac.uk)); the analyses were carried out using the linkage study tools previously described in Lacazette et al. (1997). The haplotypes are reconstructed manually according to the recombination events previously described in family 1362 (Attwood et al., 1994).

1.E. Secondary structure predictions

A multiple alignment of the lipocalin proteins for which the crystallographic structures have already been described (Monaco et al., 1992; Spinelli et al., 1998), with the hOBPIIa and hOBPIIb proteins, was obtained using the Clustalx software (<ftp://ftp.infobiogen.fr>). The putative secondary structures were determined with the DSC (Discrimination of protein Secondary structure Class) program developed by R.D. King and M.J.E. Sternberg (<http://bioweb.pasteur.fr/sequal/interfaces/dsc-simple.html>). The secondary structures of the proteins corresponding to the alternatively spliced forms are presumed to be identical to the conventional forms before the reading frame shift; after the shift, the structural prediction is made with a single sequence and is performed using the Predator software (<http://pbil.ibcp.fr/cgi-bin>).

1.F. Phylogenetic analysis

The lipocalin proteins, the sequences of which are entirely known, were aligned three times consecutively using the Clustalx software (<ftp://ftp.infobiogen.fr>). Distances in the phylogenetic tree were calculated with Clustalx and plotted with Njplot.

1.G. In situ hybridization

Serial sections cut on a cryostat (8 μ m thick) are collected on SuperFrost® Plus slides (Menzel Glazer)

and stored at -80°C. Antisense and sense RNA probes are obtained according to standard techniques using T7 or SP6 polymerase, from a matrix obtained by digestion of the phOBPIIaP2 cDNA clone with NcoI or PstI restriction enzymes, and using DIG-11-UTP (Boehringer Mannheim) (the probe is approximately 150 nucleotides long). The matrices digested with PstI and transcribed with T7 RNA polymerase correspond to the antisense probe and the matrices digested with NcoI and transcribed with the SP6 RNA polymerase correspond to the sense probe. Tissue sections are fixed in 4% paraformaldehyde for 15 min and then rinsed for 5 min in 2 X PBS. After acetylation (2 x 5 min in a triethanolamine (TEA) buffer, pH 8, containing 0.25%, v/v, of acetic anhydride), the tissue sections are prehybridized at 60°C for 15 min in 50% formamide/1 X SSC. The labeled probes are applied to each of the sections in 50 µl of hybridization buffer (50% formamide, 1 X Denhardt's, 500 µg/ml total tRNA, 10% Dextran sulfate, 10 mM dithiothreitol). The sections are covered and then incubated in humid chambers at 50°C overnight. After hybridization, the slides are immersed at 55°C in a washing buffer (50% formamide, 1 X SSC) for 2 hours. Each slide is then rinsed twice 5 min in 2 X SSC at ambient temperature, and then treated for 30 min with 10 mg/ml of RNase at 37°C and, finally, immersed in a washing solution (50% formamide, 2 X SSC) for 2 hours at 55°C. The slides are then placed in 0.1 X SSC for 15 min at 55°C. The immunodetection is performed using an alkaline phosphatase-conjugated anti-DIG antibody (Fab fragments) according to the Boehringer Mannheim protocol. The sections are examined at different magnifications using an Axiophot microscope (Zeiss).

1.H. Production of a monoclonal antibody against the hOBPII proteins

Two hundred and fifty µl of fusion proteins were given to the company Agro-Bio for the production of

antibodies. Rabbits (New Zealand White SPF) are injected on days 0, 14, 28 and 42. The sera are taken on days 0, 35, 49 and 63. In order to test the antibody, the fusion protein is loaded in lanes 1 and 3 (figure 11), while human nasal mucus is loaded in lanes 2 and 4. Lanes 1 and 2, and also the lane corresponding to the molecular weight ladder, correspond to revelation with Coomassie blue. Lanes 3 and 4 correspond to detection of the proteins recognized by the antibody using the Western blot technique. Lanes 1 and 3 show the presence of a series of truncated recombinant proteins between 30 and 42 kDa derived from a relatively inefficient synthesis due to the presence of many codons which are rare in the bacterium, within the hOBPIIB sequence. However, this production of recombinant protein was sufficient to produce a polyclonal antibody of good quality, as indicated by the revelation, in lane 4 corresponding to the nasal mucus, of an 18 kDa band specific for the hOBPII proteins.

20

1.I. Immunohistochemistry

1.I.1. 8 μ m serial sections of various tissues are fixed with paraformaldehyde (5 min) and rinsed three times with 1 X PBS (15 min) then incubated for 30 min in a 3% solution of BSA in 1 X PBS, before being incubated overnight in the presence of the anti-fusion protein antibody in a 1 X PBS solution. After three rinses in 1 X PBS (15 min), a rabbit anti-IgG antibody coupled to FITC (green staining by fluorescence) in a 1 X PBS solution is placed in contact with the slides for 3 hours. After rinsing in 1 X PBS, a solution of DAPI (100 ng/ μ l in 1 X PBS) is applied for 10 min (counterstaining of the cell nuclei in blue). After three rinses in 1 X PBS (15 min) the slides are mounted in water-glycerol (50/50). The analysis is carried out in the presence of DAPI and FITC filters with the aid of a CDD camera using an integration time of between 4 and 32 ms.

- 45 -

1.I.2. The tissues are frozen at -80°C in the presence of OCT. 7 micrometer serial sections are cut using a microtome. The tissues are then fixed with 4% paraformaldehyde in PBS. The slides are incubated for 10 min in a solution of methanol in the presence of 4.5% of H_2O_2 , and then rinsed three times in PBS for 5 min. After incubation for 30 min in a 3% bovine serum albumin solution, the first antibody (diluted to 1/350) is incubated overnight at ambient temperature (rabbit polyclonal antibodies for hOBPII and LCN1, and mouse monoclonal antibody for ApoD). Then, after three 15 min rinses in PBS, the second antibody (diluted to 1/300) (anti-rabbit for hOBPII and LCN1, and anti-mouse for ApoD) is incubated for 3 h at ambient temperature. After three rinses in PBS for 15 min, peroxidase revelation with DAB is carried out for 2 to 10 min, using the "Vector" kit. The slides are then rinsed with water and counterstained with Mayer's hematoxylin for 2 min. After two rinses with water, the slides are dehydrated by passing them successively through baths containing 70%, 95%, 100% and 100% ethanol solutions and, finally, two baths of toluene. The slides are then mounted in Canada balsam and observed using a Zeiss microscope.

EXAMPLE 2: IDENTIFICATION OF A GENE HOMOLOGOUS TO LCN1 LOCATED ON HUMAN CHROMOSOME 9

The identification of the LCN1 complementary DNA encoding the lipocalin from human tears (Lassagne and Gachon, 1993) has previously been reported, as has the location of the gene on chromosome 9q34 (Lassagne et al, 1993; Lacazette et al, 1997). The two genes encoding the von Ebner's gland proteins 1 and 2 (Kock et al, 1994) correspond to the proteins homologous to LCN1 in rats; this poses the question of whether other genes encoding an LCN1 protein exist in the human genome. *In situ* hybridization experiments (Lassagne et

al, 1997); the sequencing of the corresponding clones was performed by a group from the Massachusetts Institute of Technology (Boston, USA).

- 5 Analyses comparing sequences in the database, for LCN1, LCN1b and LCN1c, revealed strong homologies between the previously described LCN1 gene (accession number L14927) and the three cosmid sequences: P161A1 having the accession number AC002098, P203H12 with the
10 accession number AC000396 and P161G2 with the accession number AC002106.

- A very fine analysis, in particular of the 3' region of the LCN1 genes, revealed that the LCN1c sequence
15 corresponded to the clone having the accession number AC002106, LCN1b to the number AC002098 and LCN1 to the number AC000396; there is, however, an insertion of 60 base pairs at position 12360 of the clone having the accession number AC000396 compared to that having the
20 number L14927. Additional analyses revealed that these sequences are homologous over a region which is much larger than the LCN1 genes. As illustrated by the dot plot analyses (figure 2), these three cosmids correspond to duplicated genomic regions; the cosmids P161A1
25 (AC002098) and P203H12 (AC000396) are homologous over their entire sequences; the cosmid P161G2 (AC002106) is homologous to the sequence only for sequences located upstream of intron 3 of the LCN1 gene.

- 30 The relative positions of these duplicated regions of human chromosome 9 were analyzed. The results were compared with the physical map established in the context of the physical mapping project by restriction analyses of the cosmids (Hornigold et al, 1997) using
35 the same library LLN09NC01P. Approximately the same cosmids were found in the two searches for the LCN1c locus; the sequence comparison for the cosmid P181A9 reveals that its T3 end contains the Surf 5 gene (figure 1). In addition, AC002106 is located in a

- 48 -

sequence contig between ABO and the Surfeit locus, confirming the location of LCN1c. P161A1 and P203H12 have less precise locations using the data from Hornigold and from his collaborators because of the limit of the restriction mapping strategy for the duplicated regions. P203H12 (AC000396) appears to correspond to the LCN1 gene which was previously located close to the D9S1826 marker (Lacazette et al., 1997), with the exception of a 60 base pair insertion.

In order to test whether P203H12 may correspond to a 4th duplicated region, the region was tested by PCR on genomic DNA from 150 unrelated individuals using primers specific for AC000396 and L14927. A single band corresponding to the length of the AC000396 sequence was detected (data not shown), thus proving that P203H12 contains the previously described LCN1 gene. The LCN1b locus was not positioned precisely in the region, as demonstrated by the fact that the AC002098 ends and also the ends of the cosmids containing LCN1b detect no homologous sequence in the databanks.

The sequence analysis made it possible to identify a putative minisatellite at position 3177-3724 of the cosmid corresponding to AC002098 (figure 1); a rare polymorphism was thus demonstrated in a population of 20 unrelated individuals (PIC = 0.05). This new polymorphic marker is informative only in family 1362 of the 8 CEPH reference families tested.

The linkage analysis revealed two-point lod scores greater than 3 at theta = 0 for the D9S275 and D9S1818 markers. The reconstruction of the haplotype confirmed the location of the LCN1b gene between the D9S1811 and D9S67 markers in chromosome 9q34 (figure 1).

EXAMPLE 4: IDENTIFICATION OF TWO NEW LIPOCALIN GENES

The sequence analyses revealed new data.

The comparison of AC002098 to the databank revealed similarities between this sequence and the lipocalin genes. In addition to the region 21000 to 27000, which
5 contains the LCN1b gene, the region around position 2150 contains sequences which exhibit similarities with the sequences encoding the rat type II odorant-binding proteins, lipocalins from tears and also the EST AA460385.

10 In parallel, the comparison of the AC000396 sequence to the databank revealed, in addition to the region 11100 to 17100 containing the LCN1 gene, similarities for the same group of sequences in the region 36600 to 37800.

15 The EST AA460385 expressed in human testes corresponds to 4 exons of the new lipocalin gene present in the clone P161A1 (AC002098). A putative 50 base pair exon similar to the EST sequence is also present at the end
20 of the clone P203H12 (AC000396).

The inventors have therefore concluded that a new lipocalin gene exists at a position distal to LCN1b. The inventors have put forward the hypothesis that,
25 subsequent to a genomic duplication, a second gene orthologous to the gene encoding the EST is present in the 3' region of LCN1.

The sequencing of the cosmid P233G2 containing this
30 region (figure 1) with oligonucleotides defined from the EST in fact revealed the presence of another lipocalin gene at a locus 20 kb distal to the LCN1 gene. In order to identify the first exons of the two new genes, nested PCRs on cDNA clones originating from a testes
35 library were carried out between the oligonucleotides located in the 5' region of the EST and the arms of the vector. The PCR products were cloned and their sequence revealed three additional exons going by the genomic sequence (figure 1). A TATA box is present upstream of

- 50 -

the first exon in both cases (figure 3). The two mRNAs, hOBPIIa corresponding to the gene located downstream of LCN1 and hOBPIIb located downstream of LCN1b (figures 3 and 4), are 97.5% and 63% identical to those corresponding to the LCN1 gene. The intron/exon organizations of these two genes are consistent with the lipocalin family.

In addition, the deduced protein sequences (170 amino acids) confirm that they belong to the lipocalin family. The two putative mature proteins hOBPIIa (MW = 17.8 kDa) and hOBPIIb (MW = 18.0 kDa) are 89% identical. These two novel proteins contain a putative signal peptide of 15 amino acids (figure 5), the conserved residues GXWY at position 27 to 30, and two cysteines which may be involved in a disulfide bridge (position 74 to 166).

However, the paired sequence comparisons with the other lipocalins indicate weak conservation of the amino acid residues (15 to 25%), with the exception of human TL/VEG encoded by the LCN1 gene (mean value 43% over 155 amino acids) and rat OBPII (mean value 45.5%). Moreover, the calculated isoelectric points of hOBPIIa and of hOBPIIb are 7.85 and 8.72, respectively, whereas those of the lipocalins are acid (in the region of 4.5), with the exception of rat OBPII (PI = 9.01). The prediction for the secondary structures of the hOBPIIa and hOBPIIb proteins with the DSC program, by carrying out multiple alignments with the sequences of lipocalins of known structures, indicates the presence of 8 strands of antiparallel β -sheets which may allow the formation of a calyx, followed by an α -helix and a final β -sheet, in agreement with the known data for the structures of the lipocalins (figure 5).

**EXAMPLE 5: STUDY OF THE EXPRESSION OF THE LIPOCALIN
GENES IDENTIFIED**

In order to specify whether LCN1b, LCN1c, hOBPIIa and
5 hOBPIIb are expressed genes, RT-PCR analyses were
carried out on 18 different human tissues known to
produce lipocalins (figure 6).

Two pairs of primers were synthesized; one recognizes
10 the LCN1-type mRNAs and the other the hOBPII-type
mRNAs. The hybridization of the oligonucleotides
specific for the genes, on membranes on which the RT-
PCR products are immobilized after transfer via the
Southern technique, and then the subcloning of the
15 hybridized products revealed that LCN1b and LCN1c are
not expressed in any of the products tested, whereas
the LCN1 mRNAs are detected in the lacrymal gland, the
sweat gland, the von Ebner's glands, the nasal septum,
the epithelium of the nasal concha, as well as the
20 placenta and mammary glands (figure 6A). These data and
the sequence information, which indicates that the TATA
box and the last exon have been lost, make it possible
to affirm that LCN1b and LCN1c are pseudogenes which do
not contribute to the formation of the human LCN1
25 proteins.

On the other hand, the hOBPIIa and hOBPIIb genes are
expressed, which confirms the previous detection
thereof in the cDNA libraries. Surprisingly, although
30 both proteins hOBPIIa and hOBPIIb are very similar over
their entire sequence, including in the 1.5 kb promoter
region, their expression profiles are different
(figure 6B). The hOBPIIa protein is strongly expressed
in the nasal septum, the middle meatus, the nasal
35 concha, the testes and the placenta, and more weakly in
the mammary glands, the lacrymal glands, the sweat
glands, the von Ebner's glands and the lung. On the
other hand, the hOBPIIb protein is expressed
predominantly in the prostate, the testes and the

mammary glands, and more weakly in the submaxillary glands, the nasal septum and the middle meatus.

In addition, the RT-PCR analyses revealed the existence of alternative splicing of the product of transcription of the hOBPIIa gene and of the hOBPIIb gene, which generates, respectively, four and three mRNAs (figures 3, 4, 5 and 6).

The transcription of the hOBPIIa gene generates at least four mRNAs which encode four different proteins; the first mRNA encodes the hOBPIIa α protein which corresponds to the hOBPIIa protein described above. In the hOBPIIa gene, three different splice acceptor sites have been identified for exon 5 (figures 3 and 4), thus forming two other splice variants. A first splice variant has an acceptor site for exon 5 located 49 bp before the previous one (exon 5b); this generates a 725 nucleotide mRNA which encodes the 146 amino acid protein hOBPIIa β . This protein is identical up to the 8th putative β -sheet and then different with only 16 additional amino acids. A second splice variant has an acceptor site for exon 5 located 65 bp before the previous one (exon 5c); this generates a 741 nucleotide mRNA which encodes a 228 amino acid protein hOBPIIa γ . This protein has the first eight putative β -sheets identical to those of hOBPIIa α , and is then different in the C-terminal region (figure 5) due to a reading frame shift generated by this alternative splicing event; the structure of this C-terminal region predicted by the Predator program is a long bent region containing a 9th β -sheet.

In the case of the hOBPIIb gene, in addition to the hOBPIIb α mRNA previously described, a 106 bp supernumerary exon (exon 3b) between the previous exons 3 and 4 was identified (figure 3). This longer mRNA (782 nucleotides) encodes a 165 amino acid protein hOBPIIb β . From a protein structure point of view,

- 53 -

hOBPIIb β is identical to hOBPIIb α up to the 5th putative β -sheet and then differs due to a reading frame shift. The predictions from the computer programs indicate that the motif ALWEALAIIDTRLK is an α -helix which is just behind the fifth β -sheet. Two additional β -sheets may be present in the long C-terminal portion.

None of the alternative splicing variants for one gene is detected symmetrically for the other gene, although the putative splice acceptor and donor sites may be present (figure 3). In addition to these protein motifs which conserve the conventional structure of a lipocalin, we have demonstrated, for the two genes hOBPIIa and hOBPIIb, the existence of a small amount of mRNA which has undergone alternative splicing and encodes proteins, the sequence of which is not directly related to the lipocalins. mRNAs encoding hOBPIIa δ and hOBPIIb γ , which lack the sequence encoding exon 2 and which have, respectively, exon 5b and exon 5, encode putative secreted proteins of 147 and 85 amino acids, respectively (figures 4 and 5); these proteins diverge from the previous proteins from the 24th amino acid.

In order to identify the cells expressing the hOBPII genes, the inventors hybridized digoxigenin-labeled sense and antisense ribonucleic acid probes on tissue sections (figure 7). The hOBPII mRNAs are detected in the acinar cells of the middle meatus and of the nasal conchae, and also epithelial cells of the conchae; this supports the idea that the hOBPII proteins are involved in olfactory function. In addition to the production in the oral sphere, mRNAs encoding hOBPII were detected in the genital sphere, in particular in the glandular cells of the prostate, and in the secretory epithelial cells of the vas deferens. No signal was detected in the male gonads, which suggests that the expression of the hOBPII genes detected in the RT-PCR experiments corresponded to the presence of additional ducts in the tissue preparation (rete testis and lobuli

epididymidis). In combining these results from the detection of all of the mRNAs encoding hOBPII with those of the RT-PCR approach, it appeared that five hOBPII proteins (hOBPIIa α , hOBPIIa β , hOBPIIa γ , hOBPIIb α , hOBPIIb β) are secreted by the epithelial cells of the ducts of the male gonads, and also acinar cells of the middle meatus and of the nasal conchae; in these cells, the mRNAs encoding hOBPIIa are highly predominant. Only the two hOBPIIb proteins (hOBPIIb α and hOBPIIb β) are secreted by the epithelio-glandular cells of the prostate and of the mammary glands.

EXAMPLE 6: PHYLOGENETIC ANALYSIS AND CLASSIFICATION OF THE LIPOCALINS

The dotplot analysis (figure 2) and also the genomic duplications which we revealed indicate a common origin for the LCN1 and hOBPII genes. To clarify the relationships between the members of the lipocalin family and to verify that we identified the human gene orthologous to rat OBPII (Dear *et al.*, 1991), we constructed a phylogenetic distance tree with the vertebrate lipocalins (figure 8).

The inventors demonstrated nine main groups of lipocalins derived from a common precursor:

- the apolipoprotein and retinol binding protein (RBP) family (group 1);
- the prostaglandin D synthase and neutrophil gelatinase-associated lipocalin precursor group (group 2);
- the alpha-1-microglobulin/bikunin (protein HC) subfamily (group 3);
- the orosomucoid subfamily (A1AG, A1AH, A1AI) (group 4);
- the oral sphere subfamily 1 (OBPII-type-LCN1/VEGP, VNSP I and II, LALP, CanF1) (group 5);
- the lactoglobulin subfamily (group 6);

- the subfamily of proteins secreted by the lizard epididymis (group 7);
- the oral sphere subfamily 2 (mouse major urinary proteins (MUP)) (group 8);
- 5 - the oral sphere subfamily 3 (OBPI, mouse OBPII, aphrodisin, probasin, BD20) (group 9).

10

Group 9 corresponds to the oral sphere family 3 and contains OBPs which have already been described. The aphrodisin protein has already been described as a

- 56 -

- pheromone transporter (Henzel et al., 1988) and appears to be orthologous to the rat and mouse OBPI protein, with two paralogous OBPI genes. Finally, the olfactory lipocalins produced by the Bowman's glands of *rana pipiens* (OLFA RANPI), which are considered to be potential odorant transporters in frog mucus, are not related to any putative OBP group (groups 5, 8 and 9), thus suggesting the existence of other OBP categories.
- 10 Some lipocalins have been described as being allergens. The major allergen of dogs, the CanF1 protein, mainly expressed in the von Ebner's glands (Konieczny et al., 1997), appears in the tree to be the dog VEG protein. This result, which shows that LCN1 may be allergenic,
- 15 prompts the inventors to propose that the OBPII proteins are involved in allergic processes. Similarly, the major allergen of horses, EquC1, expressed in the liver and the salivary glands (Grégoire et al., 1996), appears to be orthologous to an MUP protein member
- 20 (group 3). The major allergen of cows (BD20 BOSTA), which is present in the oral sphere family 2 (group 4) is more closely related to probasin. CanF2, which is mainly expressed in the parotid gland (Konieczny et al., 1997), does not appear to be orthologous to a
- 25 previously described lipocalin.

The present invention has made it possible to reveal the existence of a genomic duplication at the q34 locus of human chromosome 9, which harbors a gene family of

30 the LCN1 type; this family comprises, besides the LCN1 gene, which has been previously described, two pseudo-genes and also two hOBPII genes which are paralogous to LCN1. The inventors have revealed that the hOBPII-LCN1 family results from consecutive genomic duplication

35 events. The sequences and also the genomic organization revealed that the LCN1 and hOBPII genes derive from a common ancestor and were generated by means of tandem duplication. The sequence comparisons demonstrated that the hOBPIIa α and hOBPIIb α proteins are the hOBPII

protein forms closest to LCN1; this is corroborated by the fact that the size of exon 5 of LCN1 is 121 bp, which corresponds to the size of exon 5a of the hOBPII protein, and by the fact that no exon 3b was found in the LCN1 protein. Similar results are obtained when this comparison is carried out with the other seven exons of the lipocalins. These data are in favor of the diversity of the hOBPII proteins being acquired through the integration of surrounding additional genomic DNA at the upstream splice acceptor site for exon 5 of hOBPIIa or through the recruitment of a supernumerary exon (exon 3b) for the hOBPIIb protein. The hypothesis of a recruitment of exons rather than a decrease in the size of the exons or than a loss of exons is more probable.

The inventors showed that the hOBPII and LCN1 genes encode proteins involved in various functions, as shown by the expression of these genes in both the oral sphere and the genital sphere. In addition, the inventors showed, by the phylogenetic analysis (example 6), that several different proteins could contribute to the same odorant-binding protein function; thus, three lipocalin subfamilies (groups 5, 8 and 9) corresponding to several proteins are found expressed in the oral sphere, and in particular in the nasal and buccal glands.

This analysis, showing that several lipocalins contribute to the same physiological function and that the same protein could contribute to various functions, led the inventors to analyze the expression of the other human lipocalins in all of the tissues studied (figure 10). This led to the demonstration that the gene encoding apolipoprotein D is expressed in the glands of the nasal concha and of the middle meatus, thus making it a potential odorant-binding protein. Similarly, retinol binding protein (RBP) is expressed

- 58 -

by the nasal epithelium and may also contribute to this function.

5 The inventors therefore propose the inclusion of the ApoD and RBP proteins in the human OBP family and include them in all the claims relating to these human OBPs.

10 The inventors have demonstrated that the transcription of the two hOBPII genes generates many alternative transcripts which encode different proteins, the structure of which is compatible with that of a hydrophobic ligand transporter.

15 The inventors have demonstrated the expression of the two hOBPII genes in the oral sphere (nasal glands, von Ebner's glands, submaxillary glands, lacrymal glands, lung). The inventors have also demonstrated that the hOBPII proteins according to the invention are produced
20 by the cells of the genital sphere; the hOBPII gene is mainly expressed in the prostate, the vas deferens and the mammary glands, while the expression of the hOBPIIa gene is restricted to the vas deferens. The in situ analyses have revealed that the mRNA is produced by the
25 glandular cells of the prostate and epithelial secretory cells of the vas deferens, supporting the idea that the corresponding proteins are secreted into the seminal fluid. The proteins according to the invention may therefore be involved in the reproductive
30 function, but also in all the other functions usually attributed to lipocalins.

EXAMPLE 7: PRODUCTION OF A RECOMBINANT HOBPIIb α PROTEIN IN A PROKARYOTIC SYSTEM

35

A PCR on the plasmid DNA of an hOBPIIb α clone using the primers BIIa/b (5' GTC GGA TCC CTG TCC TTC ACC CTG GAG G 3'), a sense oligonucleotide beginning 45 bases after the protein-initiating ATG, and XIIb (5' GTC CTC GAG

- 59 -

GTG TTC GGG AAC GCA GCT TC 3'), an antisense oligo-nucleotide preceding the stop codon of the hOBPIIb α protein, made it possible to amplify all of the DNA encoding the secreted hOBPIIb α protein. The BamH I and Xho I enzymatic restriction sites located at the ends of the two oligonucleotides (bases underlined) were used for directional cloning into a plasmid expression vector pGEX-6P1, followed by transformation by electroporation (1800 V, 200 Ω , 25 μ F) into a bacterial strain BL21. Synthesis of the recombinant protein is obtained by adding IPTG, at 5 mM final for 3 h, to 250 ml of culture of the strain in LB medium containing 100 μ g/ml of ampicillin pre-incubated at 37°C for 2 h. The centrifuged cultures are taken up in 25 ml of TENG buffer. The lysate is sonicated and recentrifuged. The fusion protein is then purified using 4 ml of beads bearing covalently attached insoluble glutathione (Sigma) per 25 ml of supernatant. After incubation for 4 h, they are washed with 3 volumes of 1M NaCl and then with 10 volumes of 1 X PBS. The elution is obtained by bringing the beads into contact with a glutathione solution (10 mM reduced glutathione, 50 mM Tris-HCl, pH 8.0) for 10 min.

The amount of recombinant protein produced is estimated by migration on polyacrylamide gel and staining with Coomassie blue (figure 11). The specificity of induction of a recombinant protein is tested by Western blot using a goat anti-GST antibody (figure 11), revealed with a peroxidase-coupled goat anti-IgG antibody, using an ECL+plus kit (Amersham). The separation of the fusion protein into two proteins is obtained by proteolysis of 100 μ g of pre-dialyzed recombinant protein with 2U of preScissionTM protease (Pharmacia Biotech) in 10 μ l final containing 1 X enzyme buffer, for 4 h at 5°C.

**EXAMPLE 8: DETECTION OF THE hOBPIIs IN VARIOUS TISSUES
BY IMMUNOHISTOCHEMISTRY**

5 The location of the hOBPII proteins in the nasal structures (figures 12 and 15), the buccal structures and the lacrymal glands (figures 13 and 18), the mammary glands and the lungs (figures 14 and 18) is revealed by immunohistochemistry.

10 **EXAMPLE 9: DETECTION OF THE hOBPIIs, LCN1 and ApoD IN THE NASAL STRUCTURES BY RT-PCR AND BY IMMUNOHISTOCHEMISTRY**

15 The RT-PCRs carried out using the sets of primers for the hOBPIIs and for LCN1 reveal the presence of the corresponding mRNAs in at least one of the nasal structures. The techniques of immunohistochemical detection both by fluorescence detection and by revelation using peroxidase and DAB reveal the presence
20 of the hOBPII (figure 15) and LCN1 (figure 16) proteins in the epithelial cells of the acini of the nasal glands, and also in the lumina of the secretory ducts. Some can also be detected on mucus attached to the tissues.

25 The RT-PCRs carried out using the sets of primers for apolipoprotein D reveal the presence of the corresponding mRNAs in at least one of the nasal structures. The techniques of immunohistochemical detection by
30 revelation using peroxidase and DAB reveal the presence of the ApoD protein (figure 17) in the epithelial cells of the acini of the nasal glands, and also in the lumina of the secretory ducts, although the expression appears to be weaker and in fewer acini than for the
35 hOBPIIs.

**EXAMPLE 10: DETECTION OF THE hOBPIIs, LCN1 and ApoD IN
THE PLACENTA BY RT-PCR AND BY IMMUNOHISTO-
CHEMISTRY**

5 The RT-PCRs carried out using the sets of primers for
the hOBPIIs and for LCN1 reveal the presence of the
corresponding mRNAs in the placenta. The techniques of
immunohistochemical detection by revelation using
peroxidase and DAB reveal the presence of the hOBPII
10 (figure 19) and LCN1 (figure 20) proteins very strongly
in the lacunae of the placental villi and much more
weakly, and very diffusely, in the epithelial cells of
the amniotic membrane and in subjacent cells, both for
the amniotic membrane and for the cord. The expression
15 of the mRNAs detected by RT-PCR in the placental villi
indicates that these hOBPII proteins are produced by
the placenta in order to transfer lipophilic molecules
(hormones, fatty acids, vitamins, etc.) to the fetus
via the fetal blood circulation. The proteins detected
20 in the amniotic membrane may correspond to the
absorption of these proteins from the amniotic fluid,
since it is known that the nasal structures of the
fetus are bathed in this amniotic fluid. The hOBPII and
LCN1 proteins would thus contribute to the transport of
25 lipophilic substances which are small in size from the
mother to the fetus in the chorionic villi via the
fetal blood, and from the fetus to the mother via the
amniotic fluid.

30 The RT-PCRs carried out using the sets of primers for
the ApoD protein reveal the presence of the
corresponding mRNAs in the placenta. The techniques of
immunohistochemical detection by revelation using
peroxidase and DAB reveal the presence of the ApoD
35 protein very strongly in the lacunae of the placental
villi (figure 21). The ApoD protein is not detected in
the cells of the amniotic membrane nor in subjacent
cells, both for the amniotic membrane and for the
cordon. The expression of the mRNAs detected by RT-PCR

- 62 -

in the placenta indicates that the ApoD protein is produced by the placenta in order to transfer lipophilic molecules (hormones, fatty acids, vitamins, etc.) to the fetus via the fetal blood circulation. The ApoD protein may also be produced by the fetal liver. The ApoD protein would thus contribute to the transport of lipophilic substances which are small in size from the mother to the fetus in the chorionic villi via the fetal blood.

More generally, the expression of lipocalins by the placenta, such as alpha-1-acid glycoprotein (A1AG), prostaglandin D synthase (PGDS), PP14 and RBP, as revealed by the RT-PCR techniques, indicates that these proteins, which have hydrophobic molecule-transporting properties, are recruited in massive amounts for mother-child connections, for transporting these molecules which may be steroid hormones, fatty acids, vitamins or xenobiotics, and more generally metabolism-derived detoxification products.

- 63 -
REFERENCES

- Attwood, J. *et al.* (1994) *Genomics* **19**, 203-214.
- 5 Barany, F., (1991), *Proc. Natl. Acad. Sci. USA*, **88**,
189-193.
- Beste *et al.* (1999), *Proc. Natl. Acad. Sci. USA*, **96**,
1898-1903.
- 10 Bocskei, Z. *et al.* (1992) *Nature* **360**, 186-188.
- Borghoff S.J. *et al.* (1990) *Annu. Rev. pharmacol. Toxicol.* **30**, 349-367
- 15 Burg, J.L. *et al.* (1996), *Mol. and Cell. Probes*, **10**,
257-271.
- Chu, B.C.F. *et al.* (1986), *Nucleic Acids Res.*, **14**,
20 5591-5603.
- Dear, T.N. *et al.* (1991) *Biochemistry* **30**, 10376-10382.
- Dewald, G. *et al.* (1996) *Ann Hum Genet* **60**, 281-291.
- 25 Duck, P. *et al.* (1990), *Biotechniques*, **9**, 142-147.
- Edwards, C.P., and Aruffo, A., (1993), *Curr. Op. Biotechnology* **4**, 558-563.
- 30 Erlich, H.A., (1989), New York: Stockton Press.
- Flower, D.R. (1995) *J Mol Recognit* **8**, 185-195.
- 35 Flower, D.R. (1996) *Biochem J* **318**, 1-14.
- Gilbertson T.A. (1998) *Cur. Op. Neurobiology* **8**, 447-452.

- 64 -

- Gregoire, C. et al. (1996) J Biol Chem 271, 32951-32959.
- Guatelli J.C. et al. (1990), Proc. Natl. Acad. Sci. USA, 87, 1874-1878.
- Henzel, W.J. et al. (1988) J Biol Chem 263, 16682-16687.
- Holzfeind, P. and Redl, B. (1994) Gene 139, 177-183.
- Hornigold, N. et al. (1997) Genomics 41, 385-389.
- Innis, M.A. et al. (1990), Academic Press.
- Igarashi, M. et al. (1992) Proc Natl Acad Sci USA 89, 5376-2380.
- Kievitis, T. et al. (1991), J. Virol. Methods, 35, 273-286.
- Kock, K. et al. (1994) Eur J Biochem 221, 905-916.
- Kohler, G. et al. (1975), Nature, 256 (5517), 495-497.
- Konieczny, A. et al. (1997) Immunology 92, 577-586.
- Kwoh, D.Y. et al. (1989), Proc. Natl. Acad. Sci. USA, 86, 1173-1177.
- Lacazette, E. et al. (1997) Ann Hum Genet 61, 449-455.
- Landegren, U. et al. (1988), Science, 241, 1077-1080.
- Lassagne, H. and Gachon, A.M. (1993) Exp Eye Res 56, 605-609.
- Lassagne, H. et al. (1993) Genomics 18, 160-161.
- Lassagne, H. et al. (1995) Cytogenet Cell Genet 71, 104.

- Lizardi, P.M. et al. (1988) *Biotechnology* 6, 1197-1202.
- Luckow, V.A. (1993) *Curr. Op. Biotechnology* 4, 564-572.
- 5 Matthews, J.A. et al. (1988), *Anal. Biochem.* 169: 1-25.
- Miele, E.A. et al. (1983) *J. Mol. Biol.* 171: 281-295.
- 10 Miller, W.L. (1998) *Clin Perinatol* 25, 799-817, v.
- Monaco, H.L. and Zanotti, G. (1992) *Biopolymers* 32, 457-465.
- 15 Nagata, A. et al. (1991) *Proc Natl Acad Sci USA* 88, 4020-4024.
- Nahmias, J. et al. (1995) *Eur J Hum Genet* 3, 65-77.
- 20 Pelosi, P. (1996) *J Neurobiol* 30, 3-19.
- Pervaiz, S. and Brew, K. (1987) *Faseb J* 1, 209-214.
- Redl, B. et al. (1992) *J Biol Chem* 267, 20282-20287.
- 25 Rolfs, A. et al. (1991), Berlin: Springer-Verlag.
- Sambrook, J. et al. (1989), T. Sec. Ed. Cold Spring Harbor Lab., Cold Spring Harbor, New York.
- 30 Segev, D., (1992), Kessler C. Springer Verlag, Berlin, New York, 197-205.
- Senoo, H. et al. (1990) *J Lipid Res* 31, 1229-1239.
- 35 Shaw, P.H. et al. (1983) *Cell* 32, 755-761.
- Simard et al. (1992) *Endocrinology* 30, 1115-1121.

- Spinelli, S. et al. (1998) Biochemistry 37, 7913-7918.
- Stoesz S.P. and Gould M.N. (1995) Oncogene 11: 2233-2241.
- Stone, B.B. et al. (1996) Mol. and Cell. Probes 10: 359-370.
- van Slegtenhorst, M. et al. (1995) Eur J Hum Genet 3, 78-86.
- Walker, G.T. et al. (1992) Nucleic Acids Res. 20: 1691-1696.
- Zeng, C. et al. (1996) Proc Natl Acad Sci USA 93, 6626-6630.

CLAIMS

1. An isolated polypeptide comprising an amino acid sequence having at least 90% identity with the amino acid sequences SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14.
2. An isolated polypeptide, characterized in that it comprises a polypeptide chosen from:
 - a) a polypeptide of sequence SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6, SEQ ID No. 8, SEQ ID No. 12 or SEQ ID No. 14;
 - b) a polypeptide which is a variant of a polypeptide of amino acid sequences defined in a);
 - c) a polypeptide homologous to the polypeptide defined in a) or b) and comprising at least 90% identity with said polypeptide of a);
 - d) a fragment of at least 15 consecutive amino acids of a polypeptide defined in a), b) or c);
 - e) a biologically active fragment of a polypeptide defined in a), b) or c).
3. An isolated polypeptide selected from a polypeptide corresponding to the sequence SEQ ID No. 2 and named OBPII_{aa}, to the sequence SEQ ID No. 4 and named OBPII_{ab}, to the sequence SEQ ID No. 6 and named OBPII_{ay}, and to the sequence SEQ ID No. 12 and named OBPII_{bb}.
4. The polypeptide as claimed in any one of claims 1 to 3, characterized in that it comprises at least the Gly-Thr-Trp-Tyr domain.

- 68 -

5. An isolated polynucleotide, characterized in that it encodes a polypeptide as claimed in any one of claims 1 to 4.

6. The polynucleotide as claimed in claim 5, of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13.

7. An isolated polynucleotide, characterized in that it comprises a polynucleotide chosen from:

a) a polynucleotide of sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13, or the sequence of which is that of the RNA corresponding to the sequence SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5, SEQ ID No. 7, SEQ ID No. 11 or SEQ ID No. 13;

b) a polynucleotide, the sequence of which is complementary to the sequence of a polynucleotide defined in a),

c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or b),

d) a fragment of at least 15 consecutive nucleotides, in preference 21 consecutive nucleotides, and preferably 30 consecutive nucleotides, of a polynucleotide defined in a), b), c) or d).

8. The polynucleotide as claimed in claim 7, characterized in that it is labeled directly or indirectly with a radioactive compound or a nonradioactive compound.

9. The use of a polynucleotide as claimed in claim 8, as a probe for detecting nucleic acid sequences.

10. The use of a polynucleotide as claimed in any one of claims 5 to 8, as a primer for amplifying or polymerizing nucleic acid sequences.

5

11. The use of a polynucleotide as claimed in claim 8, as a sense or antisense oligonucleotide for controlling the expression of the corresponding protein product.

10 12. A recombinant vector for cloning a polynucleotide as claimed in one of claims 5 to 8 and/or for expressing a polypeptide as claimed in one of claims 1 to 4, characterized in that it contains a polynucleotide as claimed in any one of claims 5 to 8.

15

13. The vector as claimed in claim 12, characterized in that it comprises the elements which allow the expression, optionally the secretion, of said polypeptide in a host cell.

20

14. The vector as claimed in any one of claims 12 to 13, characterized in that the elements which allow the expression of said polypeptide are chosen from:

25 a) the isolated polynucleotide of sequence SEQ ID No. 15 and SEQ ID No. 16;

b) a polynucleotide, the sequence of which is complementary to the sequence of the polynucleotide defined in a);

30

c) a polynucleotide, the sequence of which comprises at least 80% identity with a polynucleotide defined in a) or in b);

35

d) a polynucleotide which hybridizes, under conditions of high stringency, with a sequence of the polynucleotide defined in a), b) or c).

15. The vector as claimed in claims 13 and 14, for expression in eukaryotic cells, selected from viral DNA and naked DNA.
- 5 16. A host cell, characterized in that it is transformed with a vector as claimed in one of claims 12 to 15.
- 10 17. A process for preparing a recombinant polypeptide, characterized in that a host cell as claimed in claim 16 is cultured under conditions which allow the expression and, optionally, the secretion of said recombinant polypeptide, and in that said recombinant
15 polypeptide is recovered.
18. A recombinant polypeptide which can be obtained using a process as claimed in claim 17.
- 20 19. The use of a polypeptide chosen from a polypeptide as claimed in any one of claims 1 to 4 and 18, or a fragment thereof, as a protein which binds to a hydrophobic ligand, preferably an odorous molecule.
- 25 20. The use of a polypeptide as claimed in any one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}, a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at
30 least 90% identity with said polypeptide hOBPII_{ba} or a fragment thereof, as a competitive inhibitor, as an agonist or as an antagonist of the cellular receptors for lipocalins.
- 35 21. A monoclonal or polyclonal antibody, and fragments thereof, characterized in that it is specifically against an isolated polypeptide as claimed in one of claims 1 to 4 and 18.

22. The use of an antibody as claimed in claim 21, for demonstrating the presence of a polypeptide as claimed in one of claims 1 to 4 and 18 in a biological sample.

5

23. A process for detecting an antibody against hOBPII in human serum from an allergic and/or asthmatic patient, using an hOBPII polypeptide.

10 24. A process for controlling the volatilization of an odorant, characterized in that it comprises a step of binding of said odorant with a polypeptide as claimed in any one of claims 1 to 4 and 18, or with the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}
15 or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.

20 25. The process as claimed in claim 24, characterized in that the polypeptide is bound to a solid support.

26. The process as claimed in claim 24, characterized in that the polypeptide is in a liquid composition.

25

27. The process as claimed in claim 26, characterized in that said composition is a fragranced composition for the skin.

30 28. A process for screening a molecule, preferably odorants or flavors, which comprises passing the molecule over a substrate which comprises a polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}
35 or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, bound to said substrate, said polypeptide

- 72 -

binding said odorant or flavor, and recovering said odorant or flavor from the polypeptide if necessary.

29. The process as claimed in claim 28, characterized in that the molecules are human pheromones.

30. A process for solubilizing lipophilic molecules, characterized in that it comprises binding said molecule to a polypeptide as claimed in any one of claims 1 to 4 and 18, or to the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}.

31. The application of the polypeptides as claimed in one of claims 1 to 4 and 18, or of the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, of a polypeptide which is a variant of said polypeptide hOBPII_{ba} or of a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, in combination with dietary fatty acids, as a food supplement.

32. The application as claimed in claim 31, for preparing a medicinal product intended for the treatment of hyperlipidemias and obesity.

33. The application as claimed in claim 31, for supplementing nonmaternal milks.

34. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as an agent for targeting a pharmaceutical compound.

- 73 -

35. The polypeptide as claimed in claim 34, characterized in that said polypeptide is expressed in the form of a protein from fusion with a protein which
5 allows specific cellular addressing.

36. The polypeptide as claimed in claim 35, characterized in that said protein which allows specific cellular addressing is chosen from the group composed
10 of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

37. The polypeptide as claimed in claim 34, characterized in that said polypeptide is combined with a
15 molecule which allows specific cellular addressing.

38. The polypeptide as claimed in claim 37, characterized in that said molecule which allows specific
20 cellular addressing is chosen from the group composed of steroids, of interleukins, of cytokines, of lymphokines, of interferons, of growth factors, of hormones and of antibodies.

39. The polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said
25 polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity
30 with said polypeptide hOBPII_{ba}, as a pharmaceutical compound transporter.

40. A pharmaceutical composition comprising a pharmaceutical compound bound at least to a polypeptide as
35 claimed in one of claims 34 to 39, and a pharmaceutically acceptable vehicle.

- 74 -

41. The pharmaceutical composition as claimed in claim 40, characterized in that the pharmaceutical compound is chosen from the group of anticancer agents.
- 5 42. The pharmaceutical composition as claimed in claim 41, characterized in that said anticancer agent is a radioactive isotope chosen from the group: iodine¹³¹, yttrium⁹⁰, gold¹⁹⁹, palladium¹⁰⁰, copper⁶⁷, bismuth²¹⁷ and antimony²¹¹.
- 10 43. The pharmaceutical composition as claimed in any one of claims 40 to 42, characterized in that said polypeptide as claimed in any one of claims 34 to 39 constitutes a delayed form of delivery of said
15 pharmaceutical compound in the body.
44. A pharmaceutical composition comprising an expression vector as claimed in claim 12 or 13, and a pharmaceutically acceptable vehicle.
- 20 45. The pharmaceutical composition as claimed in any one of claims 40 to 44, for treating cancer preferably chosen from breast cancer, uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell
25 carcinoma.
46. The use of a polypeptide chosen from the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba}
30 and a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the treatment of uterine cancer, prostate cancer, liver cancer and pulmonary epithelial cell
35 cancer.
47. The use of the polypeptide as claimed in any one of claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of

- 75 -

sequence SEQ ID No. 10, or a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, for preparing a medicinal product intended for the transport of a compound across the placental barrier.

48. The use as claimed in claim 47, characterized in that said transport is carried out from the gestating mother to the fetus, and in that said compound is chosen from hormones, essential fatty acids, lipophilic medicinal products and vitamins.

49. The use as claimed in claim 47, characterized in that said transport is carried out from the fetus to the mother and is intended for the detoxification of the fetus.

50. The polypeptide as claimed in claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a pregnancy marker.

51. The polypeptide as claimed in claims 1 to 4 and 18, or the polypeptide hOBPII_{ba} of sequence SEQ ID No. 10, a polypeptide which is a variant of said polypeptide hOBPII_{ba} or a polypeptide homologous to said polypeptide hOBPII_{ba} comprising at least 90% identity with said polypeptide hOBPII_{ba}, as a marker for a fetoplacental pathological condition.

(12) DEMANDE INTERNATIONALE PUBLIÉE EN VERTU DU TRAITÉ DE COOPÉRATION
EN MATIÈRE DE BREVETS (PCT)

(19) Organisation Mondiale de la Propriété
Intellectuelle
Bureau international



(43) Date de la publication internationale
22 février 2001 (22.02.2001)

PCT

(10) Numéro de publication internationale
WO 01/12806 A2

(51) Classification internationale des brevets: C12N 15/12,
C07K 14/47, C12Q 1/68, C12N 15/11, 5/10, C07K 16/18,
G01N 33/68, A61K 7/32, 7/46, A23C 9/152, C07K 19/00
// A61P 3/04, 3/06, 35/00

GACHON, Françoise (FR/FR); 11, rue des Paillards,
F-63340 Romagnat (FR).

(21) Numéro de la demande internationale:

PCT/FR00/02319

(22) Date de dépôt internationale: 11 août 2000 (11.08.2000)

(25) Langue de dépôt: français

(26) Langue de publication: français

(30) Données relatives à la priorité:

99/10439 12 août 1999 (12.08.1999) FR

(71) Déposant (pour tous les États désignés sauf US): UNI-
VERSITÉ D'Auvergne (FR/FR); 49, boulevard
François-Mitterrand, F-63000 Clermont-Ferrand (FR).

(72) Inventeurs:

(72) Inventeur: PITIOT, Gilles (FR/FR); 151, rue du
Chevalereau, F-75013 Paris (FR).

(72) Inventeurs: et

(75) Inventeurs/Déposants (pour US seulement): LA-
CAZETTE, Eric (FR/FR); Appartement 311, 66,
boulevard La Fayette, F-63000 Clermont-Ferrand (FR).

(81) États désignés (national): AT, AG, AL, AM, AY, AU, AZ,
BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GR, GU, HK, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NO,
NZ, PL, PT, RO, RU, SD, SI, SG, SK, SL, TJ, TM, TR,
TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) États désignés (régional): brevets ARIPO (GI, GM, KE,
LS, MW, MZ, SD, SI, SZ, TZ, UG, ZW), brevet eurasien
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), brevets européens
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, JI,
MC, NL, PT, SD), brevet OAPI (BF, BJ, CF, CG, CI, CM,
GA, GN, GW, ML, MR, NE, SN, TD, TG).

Publiée:

— Sans rapport de recherche internationale, sera republiée
dès réception de ce rapport

En ce qui concerne les codes à deux lettres et autres abrévia-
tions, se référer aux "Notes explicatives relatives aux codes et
abréviations" figurant au début de chaque numéro ordinaire de
la Gazette du PCT

(54) Title: ODORANT BINDING HUMAN PROTEINS FIXING HYDROPHOBIC LIGANDS: POLYPEPTIDES AND
POLYNUCLEOTIDES CODING FOR SAID POLYPEPTIDES AND USES THEREOF

(54) Titre: "ODORANT BINDING" PROTÉINES HUMAINES FIXANT DES LIGANDS HYDROPHOBES: POLYPEPTIDES
ET POLYNUCLEOTIDES CODANT LESDITS POLYPEPTIDES ET LEURS APPLICATIONS

(57) Abstract: The invention concerns novel polypeptides fixing hydrophobic ligands and in particular odours, called OBPII (Odor
ant Binding Protein), the polynucleotides coding for said polypeptides and specific antibodies directed against said polypeptides.
The invention also concerns the uses of said molecules for personal hygiene, uses in agri-food system and nutritional and therapeutic
uses

(57) Abrégé: L'invention concerne de nouveaux polypeptides fixant des ligands hydrophobes et notamment des odeurs, dénommés
OBPII (Odorant Binding Protein), les polynucleotides codant pour lesdits polypeptides et des anticorps spécifiques dirigés contre
lesdits polypeptides. L'invention concerne également les applications de ces molécules notamment pour l'hygiène corporelle. Les
applications agro-alimentaires, nutritionnelles et thérapeutiques.

WO 01/12806 A2

1 / 21




Fig. 1




FIG. 2

[illegible]

FIG. 3

4/21




FIG. 4

6 / 21

FIG. 6




FIG. 7

8 / 21




FIG. 8

9/21




FIG. 9

10 / 21





FIG. 10

11 / 21



12/21




FIGURE 12

WO 01/12806

PCT/FR00/02319

13 / 21




FIGURE 13

WO 01/12806

PCT/FR00/02319

14 / 21




FIGURE 14

15/21




FIG. 15

WO 01/12806

PCT/FR00/02319

16 / 21




FIG. 16




FIG. 17

WO 01/12806

PCT/FR00/02319

18/21




FIG. 18

19/21




FIG. 19

WO 01/12806

PCT/FR00/02319

20/21




FIG. 20

WO 01/12806

PCT/FR00/02319

21 / 21




FIG. 21

DECLARATION AND POWER OF ATTORNEY

As a below named inventor, I HEREBY DECLARE:

THAT my residence, post office address, and citizenship are as stated below next to my name;

THAT I believe I am the original, first, and sole inventor (if only one inventor is named below) or an original, first, and joint inventor (if plural inventors are named below or in an attached Declaration) of the subject matter which is claimed and for which a patent is sought on the invention entitled **ODORANT-BINDING HUMAN PROTEINS HYDROPHOBIC LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES CODING FOR SAID POLYPEPTIDES AND USES THEREOF**

(Attorney Docket No. 065691-0260)

the specification of which (check one)

_____ is attached hereto.

XX was filed on Aug. 11, 2000 as ~~United States Application Number~~ of PCT International Application Number PCT/FR00/02319 and was amended on _____ (if applicable).

THAT I do not know and do not believe that the same invention was ever known or used by others in the United States of America, or was patented or described in any printed publication in any country, before I (we) invented it;

THAT I do not know and do not believe that the same invention was patented or described in any printed publication in any country, or in public use or on sale in the United States of America, for more than one year prior to the filing date of this United States application;

THAT I do not know and do not believe that the same invention was first patented or made the subject of an inventor's certificate that issued in any country foreign to the United States of America before the filing date of this United States application if the foreign application was filed by me (us), or by my (our) legal representatives or assigns, more than twelve months (six months for design patents) prior to the filing date of this United States application;

THAT I have reviewed and understand the contents of the above-identified specification, including the claim(s), as amended by any amendment specifically referred to above;

THAT I believe that the above-identified specification contains a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the invention, and sets forth the best mode contemplated by me of carrying out the invention; and

THAT I acknowledge the duty to disclose to the U.S. Patent and Trademark Office all information known to me to be material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I HEREBY CLAIM foreign priority benefits under Title 35, United States Code § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number	Country	Foreign Filing Date	Priority Claimed?	Certified Copy Attached?
99 10439	France	Aug. 12, 1999	yes	

I HEREBY CLAIM the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

U.S. Provisional Application Number	Filing Date

I HEREBY CLAIM the benefit under Title 35, United States Code, § 120 of any United States application(s), or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application Number	PCT Parent Application Number	Parent Filing Date	Parent Patent Number
	PCT/FR00/02319	August 11, 2000	

I HEREBY APPOINT the registered attorneys and agents at Customer Number 22428



22428

PATENT TRADEMARK OFFICE

to have full power to prosecute this application and any continuations, divisions, reissues, and reexaminations thereof, to receive the patent, and to transact all business in the United States Patent and Trademark Office connected therewith.

I request that all correspondence be directed to:

Stephen B. Maebius
FOLEY & LARDNER
Customer Number: 22428



22428

PATENT TRADEMARK OFFICE

Telephone: (202) 672-5569
Facsimile: (202) 672-5399

I UNDERSTAND AND AGREE THAT the foregoing attorneys and agents appointed by me to prosecute this application do not personally represent me or my legal interests, but instead represent the interests of the legal owner(s) of the invention described in this application.

I FURTHER DECLARE THAT all statements made herein of my own knowledge are true, and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Name of first inventor

PITOT Gilles

Residence

151 rue du Chevaleret, 75013 Paris / France

Citizenship

French

Post Office Address

The same as residence

Inventor's signature

[Signature]

Date

June 13, 2002

Name of second inventor

LACAZETTE Eric

Residence

Appartement 221, 66 boulevard La Fayette, 63000 Clermont-

Citizenship

French

Ferrand / France

Post Office Address

The same as residence

Inventor's signature

[Signature]

Date

June 13, 2002

Name of third inventor

300

GACHON Francoise

Residence

11 rue des Paillards, 63540 Romagnat / France


Citizenship

French

Post Office Address

The same as residence

Inventor's signature



Date

June 13, 2002

Name of fourth inventor

Residence

Citizenship

Post Office Address

Inventor's signature

Date

Att'ny's Docket No. _____

SMALL ENTITY DECLARATION
[37 CFR 1.9(c-f)]

Each undersigned declares that:

- (1) ☐ the application attached hereto
(2) ☐ U.S. Application Serial No. _____ filed _____
(3) ☐ U.S. Patent No. _____ Issued _____

is entitled to the benefits of "small entity" status for paying reduced fees under 35 USC 41(a) and (b) to the Patent and Trademark Office by virtue of the following:

(4) ☒ Each undersigned declares that he/she qualifies as an independent inventor, or would qualify had he/she made the invention, as defined in 37 CFR 1.9(c).

(5) ☐ The undersigned declares that he/she is an official empowered to act on behalf of the concern identified below; that this concern qualifies as a small business concern as defined in 37 CFR 1.9(d).

(6) ☐ The undersigned declares the he/she is an official empowered to act on behalf of the organization identified below; that this organization qualifies as a nonprofit organization as defined in

- (a) ☐ 37 CFR 1.9(e)(1)
(b) ☐ 37 CFR 1.9(e)(2)
(c) ☐ 37 CFR 1.9(e)(3)
(d) ☐ 37 CFR 1.9(e)(4)

State law of France

(7) Each person, concern or organization to which I/we have assigned, granted, conveyed or licensed, or am under an obligation under contract or law to assign, grant, convey, or license any rights in the invention is listed below:

- (a) ☐ no such person, concern or organization
(b) ☐ persons, concerns or organizations listed below

[a separate declaration is required from each named person, concern or organization having rights to this invention averring to their status as "small entities."]

Full Name PITOT Gilles

Address 151 rue du Chevaleret, 75013 Paris / France

- ☒ Individual ☐ Small Business Concern ☐ Nonprofit Organization

I/we acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement of small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

I/we hereby declare all statements made herein of his/her own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application, any patent issued thereon or any patent to which this declaration is directed.

(8) PITOT Gilles June 13, 2002
Typed Name of Inventor Signature Date
PITOT Gilles [Signature]
Typed Name of Inventor Signature Date

(9) _____
Name of Small Business Concern or Nonprofit Organization

By _____
Typed Name Signature Date

Title of Signatory

SEQUENCE LISTING

<110> UNIVERSITE D'Auvergne Clermont I

<120> HUMAN ODORANT-BINDING PROTEINS WHICH BIND HYDROPHOBIC LIGANDS: POLYPEPTIDES AND POLYNUCLEOTIDES ENCODING SAID POLYPEPTIDES, AND USES THEREOF

<130> D15947

<160> 16

<170> PatentIn Vers. 2.0

<210> 1

<211> 676

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (43)..(552)

<223> cDNA396 (676) /g1 (hOBPIIa-alpha)

<400> 1

cgcccagtgga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
Met Lys Thr Leu
1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg 102
Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
5 10 15 20

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val
25 30 35

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val
40 45 50

aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe
55 60 65

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr
70 75 80

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctc ata tac 342
Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr
85 90 95 100

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp
105 110 115

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg ggt agg aat 438
 Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Gly Arg Asn
 120 125 130

cct aat acc aac ctg gag gcc ctg gaa gaa ttt aag aaa ttg gtg cag 486
 Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln
 135 140 145

cac aag gga ctc tgc gag gag gac att ttc atg ccc ctg cag acg gga 534
 His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly
 150 155 160

agc tgc gtt ctc gaa cac taggcagccc ccgggtctgc acctccagag 582
 Ser Cys Val Leu Glu His
 165 170

cccaccctac caccagacac agagcccga ccacctggac ctacctcca gccatgacc 642
 ttcctgctc ccacccaact gactccaaat aaag 676

<210> 2
 <211> 170
 <212> PRT
 <213> Homo sapiens

<400> 2
 Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1 5 10 15

Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
 20 25 30

Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
 35 40 45

Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala
 50 55 60

Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
 65 70 75 80

Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
 85 90 95

Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
 100 105 110

Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
 115 120 125

Val Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala Leu Glu Glu Phe Lys
 130 135 140

Lys Leu Val Gln His Lys Gly Leu Ser Glu Glu Asp Ile Phe Met Pro
 145 150 155 160

Leu Gln Thr Gly Ser Cys Val Leu Glu His

WO 01/12806

PCT/FR00/02319

4

ctaggcagcc cccgggtctg cacctccaga gccacccta ccaaccagaca cagagcccgg 660
accacctgga cctaccctcc agccatgacc ctccctgct cccaccacc tgaactccaa 720
taaag 725

<210> 4
<211> 146
<212> PRT
<213> Homo sapiens

<400> 4
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu
1 5 10 15
Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
20 25 30
Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
35 40 45
Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala
50 55 60
Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
65 70 75 80
Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
85 90 95
Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
100 105 110
Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
115 120 125
Val Gly Pro Cys Arg Cys Pro His Val Gly Ser Pro Gly His Leu Thr
130 135 140
Cys Arg
145

<210> 5
<211> 741
<212> DNA
<213> Homo sapiens

<220>
<221> CDS
<222> (43)..(726)
<223> cDNA396 (741) /SM4 (hOBPIIa-gamma)

<400> 5
cgccacagtga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg 54
Met Lys Thr Leu
1

WO 01/12806

PCT/FR00/02319

5

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc 150
Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met Val Val 35
25 30

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg 198
Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val 50
40 45

aag gtg aca gcc ctg ggc ggt ggg aac ttg gaa gcc acg ttc acc ttc 246
Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala Thr Phe Thr Phe 65
55 60

atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg aag acg 294
Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg Lys Thr 80
70 75

gag gag cct ggc aaa ttc agc gcc tat ggg ggc agg aag ctg ata tac 342
Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg Lys Leu Ile Tyr 100
85 90 95

ctg cag gag ctg ccc ggg acg gac gac tac gtc ttt tac tgc aaa gac 390
Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe Tyr Cys Lys Asp 115
105 110

cag cgc cgt ggg ggc ctg cgc tac atg gga aag ctt gtg gca tct gct 438
Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu Val Ala Ser Ala 130
120 125

ccc tgc agg gcc gtg ccg ctg tcc cca cgt cgg ctg acc tgg cca cct 486
Pro Cys Arg Ala Val Pro Leu Ser Pro Arg Arg Lys Thr Trp Pro Pro 145
135 140

cac ctg cag gta gga atc cta ata cca acc tgg agg ccc tgg aag aat 534
His Leu Gln Val Gly Ile Leu Ile Pro Thr Arg Pro Thr Lys Asn 160
150 155

tta aga aat tgg tgc agc aca agg gac tct cgg agg agg aca ttt tca 582
Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg Arg Thr Phe Ser 180
165 170 175

tgc ccc tgc aga cgg gaa gct gcg ttc tcg aac act agg cag ccc ccg 630
Cys Pro Cys Arg Arg Glu Ala Ala Phe Ser Asn Thr Arg Gln Pro Pro 195
185 190

ggt ctg cac ctg cag agc cca ccc tac cac cag aca cag agc ccg gac 678
Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr Gln Ser Pro Asp 210
200 205

cac ctg gac cta ccc tcc agc cat gac cct tcc ctg ctg cca ccc acc 726
His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu Leu Pro Pro Thr 225
215 220

tgactccaaa taaag 741

WO 01/12806

PCT/FR00/02319

6

<210> 6
<211> 228
<212> PRT
<213> Homo sapiens

<400> 6
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
1 5 10 15
Ser Phe Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys
20 25 30
Ala Met Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys
35 40 45
Val Ser Pro Val Lys Val Thr Ala Leu Gly Gly Gly Asn Leu Glu Ala
50 55 60
Thr Phe Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu
65 70 75
Met Arg Lys Thr Glu Glu Pro Gly Lys Phe Ser Ala Tyr Gly Gly Arg
85 90 95
Lys Leu Ile Tyr Leu Gln Glu Leu Pro Gly Thr Asp Asp Tyr Val Phe
100 105 110
Tyr Cys Lys Asp Gln Arg Arg Gly Gly Leu Arg Tyr Met Gly Lys Leu
115 120 125
Val Ala Ser Ala Pro Cys Arg Ala Val Pro Leu Ser Pro Arg Arg Leu
130 135 140
Thr Trp Pro Pro His Leu Gln Val Gly Ile Leu Ile Pro Thr Trp Arg
145 150 155 160
Pro Trp Lys Asn Leu Arg Asn Trp Cys Ser Thr Arg Asp Ser Arg Arg
165 170 175
Arg Thr Phe Ser Cys Pro Cys Arg Arg Glu Ala Ala Phe Ser Asn Thr
180 185 190
Arg Gln Pro Pro Gly Leu His Leu Gln Ser Pro Pro Tyr His Gln Thr
195 200 205
Gln Ser Pro Asp His Leu Asp Leu Pro Ser Ser His Asp Pro Ser Leu
210 215 220
Leu Pro Pro Thr
225

<210> 7
<211> 607
<212> DNA
<213> Homo sapiens

WO 01/12806

PCT/FR00/02319

7

<220>

<221> CDS

<222> (43)..[483]

<223> cDNA396 (607) - short form (hOBPIIa-delta)

<400> 7

```

cgccacagtga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg      54
                                     Met Lys Thr Leu
                                     1

ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc acc ctg      102
Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Leu Ser Phe Thr Leu
5          10          15          20

gag gag gag gat gag gga gaa tgc gtg cat cca gaa gaa aat cct gat      150
Glu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu Glu Asn Pro Asp
25          30          35

gcg gaa gac gga gga gcc tgg caa att cag cgc cta tgg ggg cag gaa      198
Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu Trp Gly Gln Glu
40          45          50

gct cat ata cct gca gga gct gcc cgg gac gga cga cta cgt ctt tta      246
Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg Leu Arg Leu Leu
55          60          65

ctg caa aga cca gcg ccg tgg ggg cct gcg cta cat ggg aaa gct tgt      294
Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His Gly Lys Ala Cys
70          75          80

ggc atc tgc tcc ctg cag ggc cgt gcc gct gtc ccc acc ttg gct cac      342
Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro Thr Leu Ala His
85          90          95

ctg gcc acc tca cct gca ggt agg aat cct aat acc aac ctg gag gcc      390
Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr Asn Leu Glu Ala
105          110          115

ctg gaa gaa ttt aag aaa ttg gtg cag cgc aag gga ctc tgc gag gag      438
Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly Leu Ser Glu Glu
120          125          130

gac att ttc atg ccc ctg cag acg gga agc tgc gtt ctc gaa cac      483
Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val Leu Glu His
135          140          145

taggcagccc ccgggtctgc acctccagag cccaccctac caccagacac agagcccgga 543

ccacctggac ctaccctcca gccatgaccc ttccctgtcc ccaccaccc gactccaaat 603

aaag                                              607

```

<210> 8

<211> 147

<212> PRT

<213> Homo sapiens

<400> 8

```

Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
 1             5             10             15

Ser Phe Thr Leu Glu Glu Glu Asp Glu Gly Glu Ser Val His Pro Glu
          20             25             30

Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
          35             40             45

Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Arg Asp Gly Arg
 50             55             60

Leu Arg Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Leu His
 65             70             75             80

Gly Lys Ala Cys Gly Ile Cys Ser Leu Gln Gly Arg Ala Ala Val Pro
          85             90             95

Thr Leu Ala His Leu Ala Thr Ser Pro Ala Gly Arg Asn Pro Asn Thr
100             105             110

Asn Leu Glu Ala Leu Glu Glu Phe Lys Lys Leu Val Gln Arg Lys Gly
115             120             125

Leu Ser Glu Glu Asp Ile Phe Met Pro Leu Gln Thr Gly Ser Cys Val
130             135             140

Leu Glu His
145

```

<210> 9

<211> 676

<212> DNA

<213> Homo sapiens

<220>

<221> CDS

<222> (43)..(552)

<223> cDNA2098 (676) - conventional form (hOBPIIb-alpha)

<400> 9

```

cgcccgatga cctgccgagg tcggcagcac agagctctgg ag atg aag acc ctg      54
                                     Met Lys Thr Leu
                                     1

ttc ctg ggt gtc acg ctc gcc ctg gcc gct gcc ctg tcc ttc acc ctg      102
Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe Thr Leu
 5             10             15             20

gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg gtg gtc      150
Glu Glu Glu Asp Ile Thr Gly Thr Trp Val Lys Ala Met Val Val
          25             30             35

gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc cca gtg      198
Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser Pro Val

```


<400> 11	cgc cga ctg acc tgc cga ggt cgg cag cac aga gct ctg gag atg aag	48
Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys	1 5 10 15	
acc ctg ttc ctg ggt gtc acg ctc ggc ctg gcc gct gcc ctg tcc ttc	96	
Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe	20 25 30	
acc ctg gag gag gag gat atc aca ggg acc tgg tac gtg aag gcc atg	144	
Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met	35 40 45	
gtg gtc gat aag gac ttt ccg gag gac agg agg ccc agg aag gtg tcc	192	
Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser	50 55 60	
cca gtg aag gtg aca gcc ctg ggc ggt ggg aag ttg gaa gcc acg ttc	240	
Pro Val Lys Val Thr Ala Leu Gly Gly Lys Leu Glu Ala Thr Phe	65 70 75 80	
acc ttc atg agg gag gat cgg tgc atc cag aag aaa atc ctg atg cgg	288	
Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg	85 90 95	
aag acg gag gag cct ggc aaa tac arg gcc tgc ttg tcc gca atc gag	336	
Lys Thr Glu Glu Pro Gly Lys Thr Ser Ala Lys Ser Ala Val Glu		

WO 01/12806

PCT/FR00/02319

11

100	105	110	
atg gac cag atc acg cct gcc ctc tgg gag gcc cta gcc att gat aca 384			
Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr			
115	120	125	
ttg agg aag ctg agg att ggg aca agg agg cca agg att aga tgg ggg 432			
Leu Arg Lys Leu Arg Ile Gly Thr Arg Arg Pro Arg ile Arg Trp Gly			
130	135	140	
cag gaa gct cat gta cct gca gga gct gcc cag gag gga cca cta cat 480			
Gln Glu Ala His Val Pro Ala Gly Ala Ala Gln Glu Gly Pro Leu His			
145	150	155	160
ctt tta ctg caa aga cca gca cca tgg ggg cct gct cca cat ggg aaa 528			
Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His Gly Lys			
165	170	175	
gct tgt ggg taggaattct gataccaacc gggaggccct ggaagaattt 577			
Ala Cys Gly			
aagaatttgg tgcagcgcaa gggactctcg gaggaggaca ttttcacgcc cctgcagacg 637			
ggaagctgag ttcccgaaaca ctaggcagcc cccgggtctg caectccaga gccacccta 697			
ccaccagaca cagagcccgagg accacctgga cctaccctcc agccatgacc ctccctgat 757			
cccaccaccc tgactccaaa taaag 782			
 <210> 12			
<211> 179			
<212> PRT			
<213> Homo sapiens			
 <400> 12			
Arg Pro Val Thr Cys Arg Gly Arg Gln His Arg Ala Leu Glu Met Lys			
1	5	10	15
Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu Ser Phe			
20	25	30	
Thr Leu Glu Glu Glu Asp Ile Thr Gly Thr Trp Tyr Val Lys Ala Met			
35	40	45	
Val Val Asp Lys Asp Phe Pro Glu Asp Arg Arg Pro Arg Lys Val Ser			
50	55	60	
Pro Val Lys Val Thr Ala Leu Gly Gly Gly Lys Leu Glu Ala Thr Phe			
65	70	75	80
Thr Phe Met Arg Glu Asp Arg Cys Ile Gln Lys Lys Ile Leu Met Arg			
85	90	95	
Lys Thr Glu Glu Pro Gly Lys Tyr Ser Ala Cys Leu Ser Ala Val Glu			
100	105	110	
Met Asp Gln Ile Thr Pro Ala Leu Trp Glu Ala Leu Ala Ile Asp Thr			

WO 01/12806

PCT/FR00/02319

13

cagagccgg accacctgga cctacctcc agccatgacc ctccctgct cccaccacc 527
tgactccaaa taaag 542

<210> 14
<211> 85
<212> PRT
<213> Homo sapiens

<400> 14
Met Lys Thr Leu Phe Leu Gly Val Thr Leu Gly Leu Ala Ala Ala Leu
1 5 10 15
Ser Phe Thr Leu Glu Glu Glu Asp Glu Gly Gly Ser Val His Pro Glu
20 25 30
Glu Asn Pro Asp Ala Glu Asp Gly Gly Ala Trp Gln Ile Gln Arg Leu
35 40 45
Trp Gly Gln Glu Ala His Ile Pro Ala Gly Ala Ala Gln Glu Gly Pro
50 55 60
Leu His Leu Leu Leu Gln Arg Pro Ala Pro Trp Gly Pro Ala Pro His
65 70 75 80
Gly Lys Ala Cys Gly
85

<210> 15
<211> 10664
<212> DNA
<213> Homo sapiens

<220>
<223> hOBP1a Gene

<400> 15
ctctgcttct atattcgcc tccaaatctg tgctcaatgc agcaactgga gtgacccctt 60
aaatcagtaa gtcacagctt gcctttgtca gagctatcca gggcttttca ctacagacag 120
aagctgaagt cctcgtggtg gtcttcaatc cctacatggc cgttccacc actcccagc 180
ctcatgtgtg gccggtctcc ctggatcatt tgctgtggct gctctgcgt gtgttcccg 240
aaactgccag cgttctccca cctctgggct ggcaactggat gctcctgcca cctggactcc 300
tcttcagct gacgagctca tggcttgctt ccttcatgct ttaaattcgg tgttgaatg 360
ccaccttggc gagctgttc ctcatcaatt catgtaaagg acaataaacc cctgtctgg 420
ccactctgt ccaactgttc cactttgctt ttccatagc actgatcacc atttaaaata 480
atgtatgaac cagtgaacca tcagtgaacca gagacagtag attgaacagg tattgtctgc 540
acagtgaaca atcagctcta gaggtttaaa gagaaccaca aagaatggct caggattgca 600

WO 01/12806

PCT/FR00/02319

14

cgagggcagt taaggaagaa ataaacaggg gtggggatcc ttccacaag tgtgggttca 660
 gaccgcctgg gagaaggtgt ggttctccca agggaagctg gagaagttt ctgggttgtc 720
 ccagccacag ctggcccacg gtcagggcag aggccagcag cgagggaat gttagctggg 780
 tctggcaagc aggaagcctc tcttccccg caaggcaggt gggctggggc tgggaagcct 840
 acaagatga ctgggaaccc acagggtgcag atgccactga atctcaatag gaagccatct 900
 ggggggttcc cctgaattca atgtggtgtg tgccgcaga cgtcccaca ttgtgccact 960
 gccatttata cagggaagaga aagaaaaagg aagaatgga agcatctgga accagtcac 1020
 ctggagccat gctaggaggt gcttccccct acgctcaac caacaaagct tagcattgca 1080
 ccagggtgac aagagaagcg cctgctggct ccagctccat tgctcgga ccagccatga 1140
 aggggtgcgt tggagctgga ggcagaacat tgatagctgg cactgcaat caettattta 1200
 ttttgttcat ttttaagtc ctgcacctag aatataagcc ccccaagcag aggacatttg 1260
 ttttattgat cgatgtatc ctgtgtcccc aaagaatgag aggcactgag aaagtctgca 1320
 aaatcaaac ataaaaatga acctttatc agtcattgtt attttgatgg atatttgagg 1380
 catttccaag attgttaagt aacaattgaa ccttctcct ggttcctgtg tgggagtgtg 1440
 tctgttcaaa tgatgctctt gagggtgagt gctgagtcct tggctctagg ttttttttt 1500
 ttaagcattt atgctcattg tggtttttaa attaaacatt taacctgag acactgtaga 1560
 ttccccatga attgtaaaaa gccacacaga gctatcatgt gtatcttcac ctggtcttgc 1620
 ccagccccaa cccagcaat gacagacctg ttctccactc ctgcaatctg ctcatgcaa 1680
 gaatgtctgc tattgcaatc ataaaattgt gggattggct ttttttttcc tgtgcagcat 1740
 cattctctgg agattcatcc tattgttgca ttatcaata gttatttcca tttacttct 1800
 gagtgtgct ctatggtatg gatgtaccac agtctgttta accattcacc tgttggagga 1860
 agtctgtgtt tatagatttg ggctatgaca catgtatagg tttttgcatg gacatcagtt 1920
 ttcatttccc tgggacaag gccaggggt tctattgctg gattctatgc ttgttacagg 1980
 gctcattttg tttgttttg cttgtttta tttgtttt aacctgtcaa gccatttcc 2040
 agatccagtt tcatgcac ctcaccagc ttcagtatga tcatatgat ctatctcag 2100
 ccaccttaat aggtatgtac tgatatatca tggcttttat ttgcatttca ctgagtaca 2160
 atggtgttga gcatttttc atgtgtttat ttgccatctg tatatctct ctagtcaagt 2220
 gtcccttcac gtcttttgtt tacgttctat tttgaaact gttgagttt gaaaaattct 2280
 ttataaagta tagaaactaa ttctttgttg aatagttagt ttgtcaatat tttcttcag 2340

WO 01/12806

PCT/FR00/02319

15

tctttggcct gtctttttat tctgttaaca gggctcttta cagagcaaaa ggtttttatt 2400
 ttgatgaagt ctatttttaac aatttttccct tttatggatc atattttttgg caacaaatct 2460
 aaaacctcct gaccagctc catatgtcaa agattttcct gttttctaaa agttttatag 2520
 ttttaagttt tatgttgaag tctatgatcc attttgagtt aattttcata cagggtgtga 2580
 gaccaagggt gtggttcttc tttttctttg gtggttttgt ctgtggatgt ccagttgctc 2640
 cagcccatth gctacaaaag ctatctttcc tccactgaat tacttttgca tctttgtaaa 2700
 aatgtaattg ggtgtatttg tacagggtctg tttagaggatt ctttattgtc tgtccattg 2760
 atctatgcac ctgtccatgt gctagctata taagtcttga aagggtagcc ttagctggg 2820
 tgtgttgccg agagcctgta atcccagcta ttcgggaagt ggaggcagga gaatcgattg 2880
 aaccaggag gtggagggtg cagtgaagta agatcgtgcc actgcactcc agcctgggtg 2940
 acagagtga ctccatata aaaaaataa acaaaaaata agtagcgtga ttttccca 3000
 ctattctttt tttaaaaaag ttttagctat tccagttcct ttgcctttcc atataaatt 3060
 tagaataatc ttgtctatct ctaccacat tctttctgga attttgatat aaattttgtt 3120
 acatctttat attattttgag agaaatgata tttttactat gttgagctct ctaatccatg 3180
 gatataacgt ctctccattt gtttagatct tctttgattt attttataat cattgcattg 3240
 ttttcagcat acaaatccag catatgggtt gtttagacta tgcctaggga tctcattttt 3300
 tttagccatta taaatagtac tgtgttttta agtttagggt ccattactag tatgtagaca 3360
 cacaattgat ctttgtatat ttatctttgt tcttgcaacc ttgctgaact cacttactag 3420
 ttctaggagg tgtattgttt tcttttgttt tgtttttcaa tttcttgga ttttctacag 3480
 agataataat gtcatctgca gatgcagttt tcttcttcc ttccaattt gtatgtcttt 3540
 aatttcttt ttaaaaaacc tatattactc tgactagaac tttctgtact atgttaataa 3600
 caagtgttag agtggacatc ctgacctgt cctgatgtt aaagagaaa catttgtaac 3660
 tgaatatccc agctcaaaa tgtgcttaaa aactttttc ctttcttgtc ttgagccttg 3720
 aacatactt cgaaactctt tatttctccc ttcccaacca ggcacttccg tgagcagtg 3780
 tgccttatct aattatgtgc ttacttagaa attccagggg ccaattttga acaaaaccag 3840
 gcagagagac ccagctgcag aatctctcc cttaggggga gttacaggta gcttaccat 3900
 tcccggtgta aatcaggatg acgcaaacca gacctccga cagacgattg atgactca 3960
 ataaccatga gaacaagatg cagaccaaca tcttctgca ccattccac atatttcca 4020
 caccttttcc tctttaaacc ccttctgctc gtccagaaaa tctgaatggt cttttaaagg 4080

catgggtctg gccattcccc aactgccagt atttgaataa agctgcttct cttttaccac 4140
acctcacttc tcatgecttg acttctgagc agcgagcagc tggacttgag ccagttacac 4200
atcagttctt caccattaga aataatgtag ccataggttt tttttctgta gatgttcttt 4260
ttcaagttaa agaagtcttc ttctattcct atttttctga gaggtgttat cccgaatgag 4320
tggtgaattt tgtaaatac ttttaacaac ccaacaggaa ccaccatcag aagccatcca 4380
gagaaacgca ccaggccaca aagcactggg ggccagggat cttgcccttg ctgtctgccca 4440
tggttggaac ccagcctcc aacctacca tccccgacg gtgtctgcag cagttgaacc 4500
caaccagcat ctaaaagaac acagttgggt aacgagactg ggacacaggg caagatgggt 4560
ggacaatggg aggcctcttg agagcaccgg taccagcgag catagaattc atgggggtga 4620
cctgttccct gaagcatctg cgcgtgttgt tccagcattt tcttcaagga ttgagccagc 4680
agcaccagtg tcatacgggt cttaaataca tgattcacag ccaaccaatg aaatacaagg 4740
tgccggctgg cgcgggtggc tcacgcctgt aatccagca ctttgggagg ccgaggcggg 4800
cggatcacga ggtcaggaga tcgagacctt cccggctaaa acggtgaaac ccgctctcta 4860
ctaaaaatac aaaaaaaatt agcggggcgt agtggcgggc gcctgtagtc ccagctactt 4920
gggaggctga ggcaggagaa tggcgtgaac ccgggaggcg gagcttgagc tgagccaaga 4980
tcccgccact gcactccagc ctgggcgaca gagcgagact cegttcaca aaaaaaaaaa 5040
aaaaaaaaaa aaagaataa caaggtgcct ggggtacagg caacaaaaat ggggaacgga 5100
gaaatcttcc cgttgaggta gagactccag cctgtttgct catctctggt cctgaagagc 5160
ccagtccccg cctaaggat ggggtttctg ctgcgcgaca cttgccgtga gaggggtgag 5220
gcactgggtc acgccagccc tttctttata gcccccaggg ttattatagag tgtcatttag 5280
tattatttag caagcacttg aggggtgtctg atcttgggcc agagaggcac aaagatttgt 5340
tgggcccagc acctgectgc agagcgtggg tcagccttgg gtcccagggc agatgacgca 5400
ggcccgggaa ctacagggtc caggaggagg aaggcaaaagt tctggctcag gttggtggg 5460
gatgaggcca gcgagccag gtgccaaagg gagctcagcc acaactctg agcacaggct 5520
ggcaggtggc tcttgatgct catgccccc atttatctaa aggyatgaga ttcaaggcct 5580
gtcctgttgg ctggggccg tcgaagctga cgagagaggg gatgtagagt gaatgtatat 5640
tccactctac cacttgatt taacagggag atggatgatg aacacgtgca ggaggaacca 5700
ggcaggacaa tcagagaga tcacgtgttc tgaggacagc acagccaagg tccggtacgg 5760
agtgaagcgg ggtggggcag gcggcggggt cctcatatg gcccgaggag gccgtatata 5820

WO 01/12806

PCT/FR00/02319

17

tactgacctt gagccacaca atagtgccct tctctgcccc taggaagctc gaggtcaggg 5880
 tccagggtggg gaaatcaat gcagagtggtg tccagagtg ggcggaagct tgggtcttag 5940
 ggcgtgcggg actcagctgg cagcagcccc acatctctat ggttctaaag cccagtcctat 6000
 ttctgctcag caggagagat gccagttccc cagaggactt gcccagggtc ccagccgttg 6060
 cctcggggagg gctcaggggt gaggggaggga gaattccgag ccgtggggccc tccctctgtg 6120
 gctcgggggtg cagacgtgca ctaccctgcc ctgtcctctg gagtctcccg ggctcatcca 6180
 agtggggcaca ttgggtgca aacctcgac agcatcgtgt gtcttttctt ctctggcttg 6240
 cactgaattg ctgttcacca gatgccagca atgaggacac tccccctccc ggatcgagga 6300
 ctggttgcca ccatggggag ggggtgcacc tgccacgtgc tcccaggaca ctggccaggg 6360
 ggctataaag aacatctcga gaggagccag cacagccttg ttcagacgcc cagtgcacctg 6420
 ccgaggtcgg cagcacagag ctctggagat gaagaccctg ttccctgggtg tccgctctgg 6480
 cctggccgct gccctgtcct tcaccctgga gaggaggat gtgagctggg ttggcgtggg 6540
 cggatggagg agccaggtag actcctgggc agggggcagt gccaggggcc ctgcttttag 6600
 aggtgtcact taagcctggg gtggtgggtg aggggtccta ttgttccttc agcagacaat 6660
 gtctcccatg aggccaggg ccggagcagg ctcggtcctg gggttcctgc tgcactgacg 6720
 cctgaagccc gaaggtctcg cagggttggt cctgtggag ggagggtca cctggtgctg 6780
 gggcccgggg gtccatgggg tgcagacatg cctcctctcc actgggggct gggagccctg 6840
 agcagggggc tggtcttaac tcactccagc tgagctctaa ctaagggtca ggaaccacgc 6900
 ctgcctttag ggggtggcag cgggcaacct ggggtgtctg ttatagctgc aggcctgagt 6960
 gccagggtca gagtagaatc tgggccaccc atggtgggct caccgacctg gectgtcca 7020
 gatcacaggg acctggtacg tgaagcccat ggtggtcgat aaggacttcc cggaggacag 7080
 gaggcccagg aaggtgtccc cagtgaaggt gacagccctg ggcggtggga acttggaagc 7140
 cactgtcacc ttcattgtgag tgttgcacc tgcaggggcc ctacggccac ttctgctccc 7200
 cgccccagac ccacctggg cccattgccc caccacatt tcgggtgttg ggaagagtca 7260
 cccctgctt tgaggggaaa cagccagggc atcctgaagc tcggtgggtg gggggggcag 7320
 tggaaatttc aggttgcggg gtcagggcca tgcaccaggt gactgagga tgggccaggt 7380
 gtgtcctggg agccctgccc cgcgtgtctc ctgttttcca ggaggaggga tcggtgcact 7440
 cagaagaaaa tctgatgag gaagacggag gacctggca aatacagcgc ctgtgagccc 7500
 ctccccgacc cccactccc catgccaac ccggatgca ccagccccc tgcagggtga 7560

WO 01/12806

PCT/FR00/02319

18

gagtgccac gccacaattc tgccagggtc ccagccctgc ccacctccaa ggaggggctg 7620
 gectctcett cctggggggc tggtagccct gacatcagac accaggtgtg acaggcttgt 7680
 ccacagtaga gatggaccag atcaagcctg cctctcggga ggccctagcc attgacacat 7740
 tgaggaaatc gagtgttagg gaccaggagg ccgagggtta gggatgggaa gccaaagctg 7800
 aggggtttggg atcaggaatc cgagggttag ggacagggaa gtggggcagg agcagctgct 7860
 ggagctggga aggccggact ctagtccctg acgtgctctg gccttgctgg tccattactt 7920
 gcattgggac ctccgagag gaggtcctg cctccgtgtc cgggtccatg ctgtgcggag 7980
 cagccaggcc tggctcaggc tgtccagggc acctgggtga ccaactgaac attctcagt 8040
 gttctctcgt gtggtcctga gtgctctctc cgggaatgag ggcactgaag acccatcttc 8100
 tctgtcatct acagatgggg gcaggaagct catatacctg caggagctgc ccgggacgga 8160
 cgactacgtc ttttactgca aagaccagcg ccgtgggggc ctgcgtctaca tgggaagaact 8220
 tgtgggtgag gggcccgctg gggcctgcac gtctgcccc atggtctctg cctccagaag 8280
 ccagtgaac caccatcacc acgccctggc acggggggaa aaggaaagccc cctgcgcggg 8340
 ccttcgtgtg ctaggcacca agcgtgccc tggatggctg gtccaagttc ctgaagtggg 8400
 agtggggtgg gccaggcagg gacagacacg gccctcggtg acgtgaacct gccaaaggcc 8460
 gcttgtgggg tctcaggtgt agggggcctc ccttaagggg gaggtancat cttaacagag 8520
 ctcttcctgg ggcagggaact ctccaggcgg gcagggcagc cagtgcctct gggacacaag 8580
 gtccctccag gtgagggttg tgacctgca gagtggcttt gggagctgcc caggtccccc 8640
 tggggttgct gagtggcttg gaacctgcca ctgtccctt tccctgggac ctctcactg 8700
 ggcggtggcc gtctcctctg tcccagtc caccctgag ctcttgacca ttctcaggcc 8760
 tctctctccc ctgctcgtt gctggacagt tgccatctct tctgtcccca gcccccacc 8820
 tgagctctga tccactctcg ggccctctcc ccgtcctgat gctggccgt ggtcgtctcc 8880
 ttttagcacc tgtccctcgc agggccgtgc cgctgtcccc acgtcggtc acctggccac 8940
 ctacactgca ggttaggaatc ctaataccaa cctggaggcc ctggaagaat ttaagaatt 9000
 ggtgcagcac aagggaactc cggaaggagg cattttcacg cccctgcaga cgggtgagga 9060
 cggctgtgcc cagtaacccc tgttcccttg tgtctctgtg tgatctccag tgtcccatga 9120
 cctcgtgtc ctcccatgct ccccgcatte cccatgtgcc ccgagctcc tcgcaggggc 9180
 tctgggacct gcttagcacc ctgcgtgttg gaggtctgc actctgggct gcgatgggt 9240
 ctggggctcc gcgctctggg ctgcgatcgc gtctggggct ccgcgtctg ggctgcgatg 9300

WO 01/12806

PCT/FR00/02319

19

gggtctgggg ctcgcgcctc tgggctgcga tggggctctgg ggctccgcgc tctgggctgc 9360
gatggggtctc ggggctccgc gctctgggct gcgatggggt ctggggctcc gcgctctggg 9420
ctgcgatggg gctctggggt ccgcgcctctg gctgcgatg ggtctgggg ctcgcgcctc 9480
tgggctgcga tggggtctctg ggctccgcgc tctgggctgc gatggggtct ggggctctga 9540
gctctggggt gcgatggggt ctgggcccctg gtctagggct ccttctaate cctgggtttt 9600
tcttggtctc tgcagggaagc tgcgttctcg aacactaggg tgagttaggc tttaggaggg 9660
cactggacaa gccagagagc ctgggttccc ggggttcgag ggtacatctg ctctggccct 9720
tcccatccca cacagccagg gagaccccc cagggtcagg cacgaggttg gcacctcaga 9780
gtctgcccac ccaaaattcc tgggacattc ggaagtcct ttgttttacc attctcgcac 9840
ctgcagagccc gagtgggggt cctcctcggc ctttccacag cgaggcctcc ctcgggtctc 9900
ctcagggtgct agctcgcccc atcgcccct gcacctgtcc ccactcggtc taectccccc 9960
caccaactca ccaaggatgc tcagaggcct gccagtcac tgaggagctc gaggctgctc 10020
tggagccccg aggetgccca gcagtggccg atgtggaagc tgcagagctc ggggagggag 10080
ctctgggctc ggctctctgc ctacctgca gcctccctg cctctgctcc tcttcccagc 10140
acagcagccc ccgggtctgc acctccagag cccacctac caccagacac agagcccgga 10200
ccactggac ctaccttca gccatgacct ttccctgctc ccacctacct gactccaat 10260
aaagagcttc tccccagct ctgggcaggc ctatctgtgg ggacggaggg gctcgcaccg 10320
gtccctctgg aggcctgctg ggagggggag ccacaaggga agctggggag atgttgagcc 10380
tagcaagggc caaacacaa gaggcacgat gtccaacagg ctgtggggct gcgtgatgtc 10440
ctggaggggc ctcggaaga gccgcccctg gatctcaggc tcagcttggg acgggcaggg 10500
ctctgggcag gagcacttg gaagccactg ggaggggcgg agtggggaca cggcgctaga 10560
cctgcacag tgggtccacc acagggctcc cgcgccgggg gtctcagtlg gatcctccga 10620
gcgggtccac tttaactcc tgnctcagt ggcactactg gata 10664

<210> 16
<211> 13591
<212> DNA
<213> Homo sapiens
<220>
<223> hOBPIIb Gene
<400> 16
tctctgcttc tatattcggc ctccaaatct gtgctcaatg cagcaactgg agtgaccct 60

WO 01/12806

PCT/FR00/02319

20

taaatacgt a gtcacagct tgcctttgtc agagctctcc agggctcttc actcagagca 120
gaagctgaag tcctcgtggt ggtccttaat cctacatgg cagttccacc cactccccag 180
ctcatgtgt gcccggtctc cctggatcat ttgctgtggc tgcctgtctg tgtgttcccg 240
gaaactgcca gcattctccc acctccagge tggcactgga tgctctgccc acctggactc 300
ctctccagc tgacgagctc atggcttgc tcttcatgt cttaaattcg gtgtttgaat 360
gccaccttg cggggctggt cctcatcaat tcatttaag gacaaataac ccttgtctc 420
gacactcctg tccaacttgt ccactttgct tttccatag cactgatcac catttaaaa 480
aacgtatgaa ccagtgaacc atcaggatcc agagacaata gattgaacag ggattgcttg 540
caccaatgaa aatcagctct agaggtttaa agagaaccac aaagaatggc tcaggattgc 600
acgaggcgca ttaaggaa gaataaacagg ggtggggatc ctttccacaa gctcgggttc 660
agacctatg ggagaagggt tggttctccc aagggaagct ggagaagttt gctgggtgtg 720
cccagccaca gctggccac ggtcaggcca gagggccagca ggcagggaaa tgtaggctgg 780
gtctggcaag caggaaagct ctctccccc ccaaggcagg tgggctgggg ctgggaagcc 840
tgcaagagtc actgagaacc cacagggtga gatgccactg aatctcaata ggaagccatc 900
tgggggcggt cccctgaatt caatgtgggt tgtgccgcca gacgtccccg acttgtgcca 960
ctgccatttg cataggaaga gaaagaaaaa ggaagaaatg gaagcatctg gaaccagtc 1020
tcttggaacc atgtaggag gcgcttctcc ctacgcctca accaacaag cttagcattg 1080
caccagggtc acaagagaag cgctgtcttg ctccagctcc attgcctcgg aaccggccat 1140
gaagggtacg tgtggagctg gaggaagac atgatagct ggcactgcaa ttcacttatt 1200
tattgtgttc attttaagtc ccctgcacct agaataaag cccccgagc acaggacatt 1260
tgtttcattg atcgatgtat tccttgtgccc ccaaagaatg agaggcatct agaaagtctg 1320
caaaaatcaa acataaaaat gaacctttat tcagtcattg ttattttgat ggaatttga 1380
ggcatttcca agatttga gtaacaattg aaccttctg ctggttcag tgtgggagtg 1440
tatctgttga aatgatgct ctgagtgagg ttgctgagtc ttggctcta ggttttttt 1500
tttaagcat ttatgcttat tgtggttttt aaattaaaca tttaacctg agacattgta 1560
gattcccatg cagttgtaaa aagccacaca gagctatcat gtgtatctc acctggcttg 1620
ctccagcccc aaccccgaca atgacagacc tgttctccc tctgaaatc tgcatttgc 1680
aagaatgtcg tctattgcaa tcaataaatt gtgggattgg ctttttttt tctgtgcag 1740
catcattctc tggagattca tccattgtt gcatttatca atagtttatt ccattttact 1800

WO 01/12806

PCT/FR00/02319

22

ttttaatttcc tttttaaaaa acctttattg ctctgactag aactttctgt actatgttaa 3600
 atacaagtgg tgaaagtggg catccttgcc ttgtccctga tgttaaggag aaagcgtttg 3660
 taactgagta tcccgagctc aaaatgtgct taaaaacttt ttccctttct tgctttcagc 3720
 ctgaaacat acttcgaaac tctttatttc tccctttccc accaggcact tctgtgagca 3780
 gtgctgcgtt atctaattat gtgcttactt agaaattcca ggggccaatt ttgaaacaaa 3840
 ccaggcgag agaccagct gcagaatcct ccctcttagg gggagttaca ggtagcctac 3900
 cacttcccg ctgaaatcag gatgactcaa accagacctc tggacagacg attaatgact 3960
 catgataacc attggaacaa gatgcagacc aacatctccc tgcaccatc ccacatattt 4020
 cccacacctt ttctctcta aaccctctcg ctacgtccag aaagtgtgaa tggctcttta 4080
 aaggcatggg gctctggcat tctctactg ctacatttg aataatgtg ctttcttttc 4140
 accacacttc acttctcatg ccttgacttc tgacagcga gcagctggac ttgagccagt 4200
 tacacatcag tctttcacca tgagaaatga tgttagccat aggttttttg tagatgctct 4260
 ttgtcaagtt aaggaggttc tcttctattc ctactttct gagagtgtgt ttctgaatg 4320
 ctgtgatgaat ttagtcaagt actttttctg cattgatcga tatgatcatg taatttttct 4380
 tcttaacata ttaatatggt tgatttttga gtattgtacc aggtttccat ccttgaata 4440
 aactgctttt ggtcatgggt tagaattaat ttatatatt attatttctg aatattttgt 4500
 aaaggatttc tgatctata ttcatgaggt atattgttct gcagctttcc tttttgtgtt 4560
 gtcaggtttt ggttgggaga tattctctca tcttctgaga ttatgcagag ttggtgttat 4620
 ttatttttta aatggttgg agaattttct aatgaacca tatggacatg aagaattatt 4680
 ttggaagct tttaaaatta aaatgttaac ttaattgtc atagagctat taaagtattc 4740
 tatcttatat tggcattgtg tttttgaga aattggttca ttccacctat gttgtcaaat 4800
 atatgtggga aggtctcttc gtagtatttc ctattatcc ttgatgtct gcagggctctg 4860
 tagtgatagt ctctgttttg ttccagatgt tgggtatttg tgtcttctt tcttttttg 4920
 ttgtcagtc ttctagaac tgcctcaatt ttattaatt ttccagagaa ctaaccttg 4980
 ttctaattgt ttctctgtt gtcttctgc ttctgatttt ttctgcttcc tgcttttgat 5040
 ttattaattg ctgctcttat ctgtgttatt tctttcttc ttgctttggg tttaatttgc 5100
 tcttctttt ctaggttctt gaagtgggag cttagatagt tgattttgga ctctctcttt 5160
 ctaatatatg catttaatgc ctctcagcac tgatttagct gtgtctcaca aattttgata 5220
 tgtttttgtt tgtttgttt tgaggtagag tctcgtctg tatccagc tggagtgcag 5280

tggcactatc ttggetcact gcaacctcca cctcctgggt tgaagtaatt ctectgcttc 5340
agccccctaa gtactgtgga ttacagggtat acgccaccat gccagcaat ttattttatt 5400
attttatttt gtatttttag tagagatgag gttttgtcat gctgtccagg ctggctctga 5460
actcctgacc tcaagtgatc tgccccagtg gggctccaaa gcactgagat tataggcata 5520
agccactgtg cccagcctgt ttttgttttt ttgagatgg agtcttgctc tgtcaccagg 5580
gctggagtg cagtgcctga tagccactg caacctccgc ctcccgggt caagtgttc 5640
tctgacctca gctcccgat tagctgggat tacaggcgtg caccaccaca ctacagtagt 5700
ttttgcattt ttggtagaga tgggttttgc ccatgttggc caggctggte tcgaattctc 5760
gatgcgaagt gatccaccg cctgggcctc ccaaagtgtc ggaattatag gcacnagcca 5820
tcacgcccag ctgatatgtt gtattttcat ttcatccag cctagtatat ttttaatttt 5880
accttcagge ttctctttg acctgtggat tattcacagg tgtgttgttt ccaagcatct 5940
gaagaaagat ttccattat ctttctggca ttgattata gttagattcc atgtggtcag 6000
agactacct ctatatcatt taaattttta aaaatttctt gaggtcatt ttctcatcca 6060
ggatatggc tatcttgga tatattctgg tgcacttgaa aagaatgtgt gtagtgtctg 6120
tgccagggtg tgtgttctac aaatgtcaat tcgattatgt taattgatgg gtggccagat 6180
tctttgatgt cctgctgggt tttctgtcta gttgctctga gagaagggta ttgaagtctc 6240
caactataat tgtggctttt taaatttctc ctttcagttc tgttttgctt cacatattgt 6300
gcagctaagt ttggtgcac acacgtttag gattactatg tcttctttgc agaattggcc 6360
acttattatt gtataatttc cctctctgtt aattagtctt tgttctaaag tctattttac 6420
ctgtttattg aataatgctt ctgctttctt ttgattaatg tttatatac tttttctcat 6480
tttttacttt caacctgtct ctattgttac attgaagta agtttcttgt agacggcata 6540
tagttgtata atggctttta attcacttg ccaatcactg tcatttaata tttaaacct 6600
ttacatttaa tataattatt aacatgctag agtttgtatt attttatag ggttgctata 6660
acaaaatact accaactggg tggtctagaa caaaaattta ttcttcaca ttctgggtgc 6720
cagaagtctg agatcaagt agatttggaa ggtagaaaaa ccaacaaaat atgttaatga 6780
tgttaccatt gtgggcaact gggactcagt ccttctgagg gccatctgag aaatagggtg 6840
gaacctatatt tgattgttcc acttagaagg aagagtcag accatttate ccatcagtta 6900
ctatccctac agactgagga tgcgtattca cttgcacatc tgggtttcat cagtgtcagg 6960
ggaagcacag aagaaaaggt gcaggcactt aaggttggaa gctgtgaata cgtccgtgca 7020

WO 01/12806

PCT/FR00/02319

25

gggctctagg gcgtcgsga ctcagctggc agcagcccca cgtctctctg gttctaaagc 8820
 ccagtcacat tctgctcagc agggagatgg ccagtcaccc agaggactg cccagggtcc 8880
 cagccgtggc cctggggggg tgcaggsggt ggtgaggagg tatcccgagg cttggggccc 8940
 tgcctctctg gcttggggg cagatggaca ccacctgcc cgtctctctc gagtctctctg 9000
 ggcctcatctg agtgggcgcg ttcgggtggt gcaaactctg gatggcatcg tgtgtctttt 9060
 cttctctggc tggcactgac ttgctgtcca ccagatgcca gcaatgagga cactccccct 9120
 cccggatgca ggactggtt cccacatggg gagggggtgca ccgtgccacg tgtctccagg 9180
 acactggcca gggggctata aagaacatct cgagaggagc cagcacagcc ttgttcagac 9240
 gccagtgac ctgccagggt cggcagcaca gagctctgga gatgaagacc ctgttctctg 9300
 gtgtcacgct cggcctggcc gctgacctgt ccttcacctt ggaggaggag gatgtgagct 9360
 ggggttgcgt gggcgatgg agggagccagg cggactcctg ggcagggggc agtgccaggg 9420
 gccctgcttt aggaggtgct actgaaggct ggcttctgac ccctgctcc cagcctgggg 9480
 tgggtgtgga ggggtcctat tgttcttcca gcagacacgg ccccccagg cccaggggcg 9540
 gagcaggctc gtctcagggg ttctctgtgc actgacgctt gaagcccgaa ggtctcgag 9600
 ggttggggcc tgtgagggga gggctcactt ggtgctgggg cccgggggtc catgggtgct 9660
 agacatgccc tcttccactt gggggctggg agccctgagc agggggctgg ctctaaetca 9720
 ctccagctga gctctaacta aggtgcagga acacagcctg cctttaaggg cagcagccgg 9780
 gcacatggg tgtctgttta tagctgcagg cctgagtgcc agggtcagag tagaatctgg 9840
 gccacccatg gtgggtcac ggccttgccc tgcctccagat cacagggacc tggtaegtga 9900
 aggccatggt ggtcgttaag gactttccgg aggacaggag gccagggaag gtgtccccag 9960
 tgaagtgac agccctgggc ggtgggaagt tggaaagcac gttcaccttc atgtgagtg 10020
 tgcccactgc agggcccctc aggccacttt cgtccccctc cccagaccca cctggtgccc 10080
 attgcccact ccaggtttcg ggtgttggga agagtcaacc cctgctcttg agggaaacag 10140
 cctgggcatc ctgaagctcg gtgggtggg ggacagtgga attttcaggt tgccgggtca 10200
 ggccatgca ccagtgagc tgaggatggg ccatgggtgt cctgggagcc gctgcccggc 10260
 tgtctcctgt ttccaggag gaggatcgg tgcattcaga agaaaatcct gatgccaag 10320
 acggaggagc ctggcaataa cagcgctgtg gaggccctcc cccactccca cccccacct 10380
 cccccaccgc caacccagct gcaccagcct ccacaggtag agagtgcaca ggctgcccct 10440
 ttgccagggc cccagctctg cccacctcca agggggggct ggcctctctt tcttgggggg 10500

WO 01/12806

PCT/FR00/02319

26

ctggtggccc tgacatcaga caccgggtgt gacaggcttg tccgcagtcg agatggacca 10560
gatcacgcct gccctctggg aggcctcagc cattgacaca ttgaggaagc tgaggattgg 10620
gacaaggagg ccaaggatta ggtacgggga ggctgagggt tagggatggg gaagctgagg 10680
gtlaaggatg gggaaagctga gggtaagga tggggaggct gagggttagg gacgggggcc 10740
aagggttagg gatcgggaag ctgagggtta gggatgagga ggcgagggtt tagggatggg 10800
gaggccgagg gttagtgctg cggaaagctga ggattagaga tggggaggct gagggggaag 10860
atgagggtta gggacaggga agtggggcag gacgagctgc tggagctggg aaggccggac 10920
tctagtctct gacgtgctct ggccttgtgg ctccattact tgcattggga ccttcctgag 10980
aggaggctcc tgcctccgtg tccgggtcca cactgtcggg agcagccagg cctgtctcag 11040
gctgtccagg gcacctgggt gaccgctgaa acattccga gtgtttcttc atgtggcccc 11100
gagtgttctc tctgggaatg acccattttc tctgtcatct acagatgggg gcaggaagct 11160
catgtacctg caggagctgc ccaggaggga ccactacatc ttttactgca aagaccagca 11220
ccatgggggc ctgtccaca tgggaaagct tgtgggtgag gggcttctg ggtctgctg 11280
gtcctgcccc acggtctctg cctctggaag ccggtgggaa cagcaccacc atgccctggc 11340
atgggggaaa aggaagcccc ctgtgccggc ttcatgtgc cgggcaccgc tgggcagccg 11400
gtccaagtac ctgaagtggg aatgggatgg gccaggcagg gacagacatg gccctcagtg 11460
acatgaacct gccaaaggcc acttctgggg tctcgggtgt aggagggtca cctaaagggg 11520
gagggtcacc ttaagcgtcc taagagagct ctcatgggg cagggaacct ccagggcagg 11580
aggggtggcg gtgcctctgg gagacaaagt cctccagggt gagggtctgt accctgcagg 11640
gtggcattgg gagctgccca ggctccctgg ggttgccgag tggcttgag agtccccgcc 11700
actgtcccc tctctgggga cctctcatct gggcagtgac tgtctctct gtccccagtc 11760
ccaccctga gctctcatcc attctcaagt ctctctctct gcttgcagg tgcctgggcta 11820
tgcccatctc tctgtcccc gggccacccc cagagctctg gtccactctt gggctctctc 11880
ccttgtctg gtgctgggga gtggccatct cctctgtccc cagcccccac ccgagctct 11940
gatccactct caggctctct cccctgtcct ggtgctgggc cgtggtcgtc tcttttcggc 12000
atctgtctcc tgcagggcgg tgccgctgtc ccacgctgg ctcacctggc caectcaect 12060
gcaggtagga attctgatac caaccgggag gccctggaag aatttaagaa attgtgcag 12120
cgcaagggac tctcggagga ggacattttc acgcccctgc agcgggtga ggtgtgctgt 12180
gcccagtcct ctgtgtcct ctgctgtgtc tgtctgtat ctccagtgc ccatgacccc 12240


WO 01/12806

PCT/FR00/02319

27

catgtctctc	catgtceccc	gcattcccaca	tgtgcccega	gtctctctgc	aggggctccc	12300
gggcccctgt	tagegtctctc	ctcattggag	gctctgtgct	ctgggctcgc	atggggtctg	12360
gggctcccg	ctctgggctg	cgatggggct	tggggctcgc	cactctgggc	tgcgatggg	12420
tctggggctc	cgcgctctg	gctcgcatg	gctctggggc	tctgagctct	gggctgtgat	12480
ggggctctgg	ccctggtcta	gggcgccttc	taatccctgg	gtttttcttg	gtctctgcag	12540
gaagctgcgt	tcccgaacac	tagggfagat	gagcctttag	gaggggcactg	gacaagccca	12600
gagtcctggg	ttcccggggt	tcgagggtae	atctgctctg	gccctcccac	teccacacag	12660
ccaggggagac	ccccccagg	tcagggcaga	ggttggcacc	tcagagtctg	ccccaccaca	12720
gtctctggga	cattcgggaa	gtccttggtt	ttatctatcc	tgcacctgcc	agcccgaagt	12780
agggctctcc	tcggcctttc	cacagcagag	cttccctccg	ctctccctcag	gtgtgcagtc	12840
agccccatgc	cccctgcacc	tgtecccacg	cggtccactc	cccaccatcc	accacccaag	12900
gatgtctaga	ggcctgcccc	gtcattggag	gagctgaggt	cgctctggag	ccccgaggtt	12960
gccccagcag	ggccgatgtg	ggggctcgag	agcctgggga	gggagctctg	gccctggcct	13020
ctgcccctac	ctgcagcctc	cttgacctct	gctctcttcc	ccagcacacg	agccccccgg	13080
tctgcacctc	cagagcccac	cttaccacca	gacacagagc	ccggaccacc	tggacctacc	13140
ctccagccat	gaccttctcc	tgtcccacac	cacctgactc	caataaagat	ccttctcccc	13200
cagctctggg	caggcctatc	tgtggggaca	gaggggcttg	cacccgctcc	ctgggaggtc	13260
tgctgggagg	gggagccaca	agggaaagct	gggagatgtt	ggacctagca	agggccaacac	13320
cacaagaggc	acgatgtcca	acaggcctga	ggggctcgct	gatgtctcgg	aggggcctcc	13380
ggaagagcgc	ccctcagggtc	tcaggttcag	cttagggacag	gcagggccct	gggcaggagc	13440
gttttggaag	ccaactgggc	ggacacagag	gggggacacg	cgtcaggggt	gcagcagttg	13500
ggccaccgca	gggtctccgc	ctcaggggct	tcagagggat	cttccaagct	ccccattttt	13560
agcagctcgg	gctcaqtqgc	agcactaaqa	a			13599

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☒ Scanned copy is best available. Some of the drawings are
very dark & some are
faded